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La identificación de la función génica se ha logrado en gran medida mediante la 
introducción de mutaciones en el gen de interés en células y organismos. Históricamente, el uso 
de algunos organismos, como levaduras o insectos sociales, que solo tienen un único conjunto de 
cromosomas idénticos (organismos haploides) ha sido fundamental para identificar mecanismos 
moleculares específicos y vías de señalización esenciales en la célula mediante la realización de 
rastreos (screenings) genéticos globales. En estos rastreos, la recuperación de mutantes se basa 
en la selección de una característica fenotípica necesaria para identificar posteriormente los genes 
alterados que producen el fenotipo observado. Los organismos haploides poseen una sola copia 
de cada gen y, por lo tanto, su genoma proporciona un marco genético ideal para asignar una 
función o un fenotipo a un gen. Debido a la ausencia de un segundo alelo que pudiera compensar 
la ausencia del primero, todas las mutaciones son dominantes. La realización de este tipo de 
rastreos genéticos han sido más complicados en células de mamífero debido a sus genomas 
diploides, y dichos experimentos se han hecho mediante la aplicación de tecnologías propensas a 
efectos indirectos tales como la interferencia de ARN. Recientemente, el establecimiento de líneas 
celulares de mamíferos haploides ha permitido la implementación de tecnologías de rastreos 
similares a las que se realizan en levaduras. No obstante, el trabajo en el laboratorio con células 
haploides de mamífero confronta un desafío técnico importante conocido como "diploidización", y 
que se refiere a la pérdida de las células haploides en el cultivo, que son progresivamente 
reemplazadas por células diploides. Este fenómeno plantea importantes preguntas biológicas: 
¿por qué el estado haploide es genéticamente inestable en células de mamífero? ¿Es posible 
estabilizarlo genética o químicamente? ¿Es factible generar tejido haploide en un organismo? La 
presente tesis trata de abordar estas preguntas. 
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Gene function identification has been to a large extent achieved by the disruption of the 
gene of interest in cells or organisms. Historically, the use of some organisms such as yeast or 
social insects, which only carry a single set of chromosomes (haploid organisms), has been critical 
to identify essential pathways and molecular mechanisms in biology through forward genetic 
screens. In these experiments, the recovery of mutants is based on the selection of a phenotype to 
subsequently identify the gene(s) disrupted that produce the observed phenotype. Due to the 
absence of a second allele, all mutations in haploid cells are dominant since no compensation by 
the second allele can take place. Forward genetic screenings have been more challenging in 
mammalian cells due to their diploid genomes, and these experiments were carried by 
technologies such as RNA interference that are prone to indirect effects. Recently, the 
development of haploid mammalian cell lines has now enabled the implementation of similar 
forward genetic screens as the ones performed in yeast. Yet, work with mammalian haploid cells 
faces a severe technical challenge known as “diploidization”, which refers to the progressive loss 
of haploid cells from the culture that are replaced by diploids. This phenomenon raises several 
important biological questions: Why is the haploid state genetically unstable in mammals? Is it 
possible to stabilize haploidy in mammals either genetically or chemically? Is it possible to make 
mammalian haploid tissue? Addressing these questions was the aim of this thesis. 
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 ACA  Anti-centromere antibodies 
 AD-CRE Cre Recombinase Adenovirus 
 APC  Anaphase-promoting complex 
 BFP  Blue fluorescent protein 
 BSA  Bovine serum albumin 
 BUB1  Budding uninhibited by benzimidazoles 1 
 BUB3  Budding uninhibited by benzimidazoles 3 
 BUBR1 Budding uninhibited by benzimidazoles-related 1 
CDC20 Cell division cycle 20 
CDK  Cyclin dependent kinase 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
DAB  10-Deacetylbaccatin III 
DAPI  4',6-diamidino-2-phenylindole 
DNA  Deoxyribonucleic acid 
DMSO  Dimethyl sulfoxide 
EdU  5-Ethynyl 2’-deoxyuridin 
EGFP  Enhanced green fluorescent protein 
EGTA  Ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
ESCs  Embryonic stem cells 
FACS  Fluorescence-activated cell sorting 
FAH  Fumarylacetoacetate hydrolase 
FSC  Forward scatter 
Q-FISH Quantitative fluorescence in situ hybridization 
H2AX  Histone H2A.X 
H2B  Histone H2B 
HMG-CoA Hydroxymethyl glutaryl coenzyme A 
Il2rg  Interleukin 2 Receptor Subunit Gamma 
iPSCs  Induced pluripotent stem cells 
KFP  Katushka fluorescent protein 
KO  Knockout 
LATS2  Large tumor suppressor kinase 2 
LIF  Leukemia inhibitory factor 
MAD1  Mitotic arrest deficient 1 
MAD2  mitotic arrest deficient 2 
 MEFs  Mouse embryonic fibroblasts 
 mhaESCs Mouse haploid embryonic stem cells 
 mESCs Mouse embryonic stem cells 
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 MMC  Mitotic checkpoint complex 
 MPS1  Monopolar spindle 1 
 MTAs  Microtubule-targeting agents 
 n  Number 
 NEBD  Nuclear envelope breakdown 
 NTBC  2-(2-nitro-4-trifluoro-methyl-benzoyl)-1,3 cyclohexanedione 
 p21  Cyclin-dependent kinase inhibitor 1 
 p53  Tumor suppressor protein 53 
 pH2AX  Phosphorylated form of histone H2A.X at serine 139 
 PBS  Phosphate buffer saline 
 PCR  Polymerase chain reaction 
 pH3  Phosphorylated form of histone H3 at serine 10 
 PI  Propidium iodide 
 PIPES  Piperazine-N,N′-bis(2-ethanesulfonic acid) 
 PFA  Paraformaldehyde 
 PNA  Peptide nucleic acid 
 RAG  Recombination-activating gene 
 RFP  Red fluorescent protein 
 SAC  Spindle assembly checkpoint 
 sgRNA  small guide RNA 
 shRNA  short hairpin RNA 
 SKY  Spectral karyotype 
 SSC  Side scatter 
 TOM  tdTomato fluorescent protein 
 UDP  Uridine 5'-diphospho 
 USP28  Ubiquitin carboxyl-terminal hydrolase 28 
 WEE1  WEE1 G2 checkpoint kinase 
 WT  Wild type 
 53BP1  Tumor suppressor p53-binding protein 1 
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1. The cell cycle 
The mammalian cell cycle is a highly organized and tightly regulated series of events that 
lead to genome duplication and cell division. It is regulated through a complex network of growth-
regulatory signals and controlled by proteins surveying genome integrity to ensure the progression 
of the cell cycle without any DNA damage transmission to daughter cells (T. Otto & Sicinski, 2017). 
The cell cycle is divided into four major phases: G0/G1-S-G2-M (Figure 1) and each transition is 
regulated by cyclin-dependent kinases (CDKs). The activity of CDKs requires the binding of their 
regulatory subunits known as cyclins (Marcos Malumbres & Barbacid, 2009). Cyclins are proteins 
synthesized and degraded at specific time points of the cell cycle hereby tightly regulating CDK 
activity. CDKs driving the cell cycle during interphase are CDK2, CDK4 and CDK6, while CDK1 is 
the major kinase regulating entry into mitosis (Marcos Malumbres & Barbacid, 2009). In the G1 
phase, cyclin D expression is induced by mitogenic signals and binds CDK4 and CDK6. Active 
CDK4/6-CyclinD complexes drive the expression of cyclin E, which subsequently activates CDK2 
in early S-phase. In late S-phase, CDK2 is next activated by cyclin A allowing the transition from S-
phase to G2/M. At this point, cyclin A activates CDK1 initiating the mitotic program. Following 
nuclear envelope breakdown, cyclin A is degraded facilitating the binding of cyclin B to CDK1, 
which becomes the major complex driving the cells through mitosis (Marcos Malumbres & 
Barbacid, 2009). 
 
 
 
 
 
 
 
 
 
 
2. An overview of mitosis 
In order to divide, a cell has to replicate its genome, pack it into chromosomes and split 
them into two identical daughter cells. The pioneer and first descriptor of the chromosome 
separation associated to cell division was Walther Flemming in the late 19th century (Paweletz, 
2001). He called this process “mitosis”, a greek word that literally means thread, reminding hereby 
of the shape of mitotic chromosomes observed under a microscope (Mitchison & Salmon, 2001). 
Figure 1: The cell cycle. The cell cycle 
consists of four consecutive, tightly 
regulated phases. The regulation is 
accomplished by cell cycle kinases that are 
activated at different time points by their 
specific subunit proteins, the cyclins. 
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We now know that mitosis is divided into five consecutive and morphologically distinct phases: 
prophase, prometaphase, metaphase, anaphase and telophase (Figure 2) (Musacchio & Salmon, 
2007). Before entering mitosis, cells must complete an entire copy of their DNA during S-phase. 
Additionally, mitotic entry requires the activation of cyclin-dependent kinase-1 (CDK1), the master 
mitotic kinase, through its binding to cyclin B (Peters, 2006; Santamaría et al., 2007). Interestingly, 
how cells sense that the genome is successfully duplicated and whether or if this is directly 
involved in the activation of the mitotic machinery remains poorly understood (O’Connor, 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
During prophase, DNA undergoes a massive process of condensation that gradually 
increases until metaphase. Simultaneously, the mitotic spindle, a cytoskeletal structure that will 
separate sister chromatids into the daughter cells, begins to form by moving the two pairs of 
centrioles to the opposite poles as microtubules polymerize from duplicated centrosomes 
Figure 2: Overview of Mitosis. Mitosis is divided into 5 consecutive phases. Prophase is the first 
phase of mitosis, where chromosomes start to condensate and cyclin B levels starts to accumulate 
activating CDK1. Prometaphase is initiated by the nuclear envelope breakdown. In this phase 
chromosomes are getting attached to microtubules. Once all chromosomes are attached and properly 
aligned to the metaphase plate, metaphase starts followed by the activation of the anaphase-
promoting complex (APC). Activated APC allows the cell to separate the sister chromatids by the 
enzyme separase in anaphase. In the last phase, the telophase, the chromosomes decondensate and 
the nucleus is reformed. 
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(O’Connor, 2008). Prometaphase starts with nuclear envelope breakdown. At this point, 
microtubules have access to chromosomes and, by rapid assembling and disassembling, engage 
with kinetochores, the attachment sites of chromosomes. Prometaphase ends when all 
chromosomes are bi-orientated, meaning that the kinetochores of all sister chromatids are 
connected with microtubules to the opposite poles of the spindle (O’Connor, 2008). This 
arrangement ensures that both daughter cells receive exactly one copy of each chromosome. At 
metaphase all chromosomes align in the middle of the division plane to form the metaphase plate. 
Metaphase is followed by anaphase, where sister chromatids are abruptly separated and moved 
towards spindle poles by the progressive shortening of microtubules. Once spindle poles are 
reached, telophase begins. During telophase the nuclear membrane is reformed and 
chromosomes decondensate. Finally, and after the completion of mitosis, cytokinesis initiates, 
leading to the partition of the cytoplasm and its content so that two daughter cells with identical 
genomic information are generated (O’Connor, 2008). 
 
 
3. When mitosis needs extra time: The spindle assembly checkpoint 
The major safeguard mechanism to ensure proper chromosome segregation in mitosis is 
the spindle assembly checkpoint (SAC). The SAC, active during late prophase and prometaphase, 
prevents anaphase onset as long as both kinetochores from each chromosome are improperly 
attached or non-attached to the spindle (Musacchio, 2015). Once all the kinetochores from each 
individual sister chromatid are properly attached to the mitotic spindle microtubules in a bi-
orientated manner, the SAC becomes inactive and the cell can progress into anaphase (Figure 3) 
(Vitale, Galluzzi, Castedo, & Kroemer, 2011). Essential components of the SAC, including MAD1, 
MAD2, BUBR1, BUB1 and BUB3, were identified in the early 90s in genetic screens performed in 
yeast (Hoyt, Totis, & Roberts, 1991; R. Li & Murray, 1991). From a molecular point of view, current 
models suggest that unattached kinetochores or those lacking tension strength lead to the 
activation of MAD2, BUBR1 and BUB3 kinases, which cluster at the kinetochore and organize the 
mitotic checkpoint complex (MMC). Additional components of the SAC include MAD1, BUB1, 
MPS1 and Aurora-B, which catalyze the MCC formation and amplify its signal (Musacchio & 
Salmon, 2007). An active SAC leads to the MMC-dependent sequestration of CDC20, an activating 
factor of the anaphase-promoting complex (APC), which in turn is a multi-subunit E3 ubiquitin 
ligase complex (Vitale et al., 2011). Once the last chromosome has properly aligned with the 
spindle, the SAC is properly inactivated, allowing the release of CDC20, the activation of APC and 
the initiation of anaphase. Two APC targets are known to play central roles during mitotic 
progression: cyclin B and securin. Degradation of cyclin B is necessary to eliminate the high levels 
of CDK activity (CDK1, specifically) that raise upon entry into mitosis. In fact, cyclin B degradation 
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is initiated just after the SAC is inactivated and mostly depleted prior to anaphase, so that its 
presence is often used to measure the duration of the SAC (Clute & Pines, 1999). In addition, APC 
also degrades securin, an inhibitor of a protease called separase, which cleaves the cohesin rings 
that entrap both sister chromatids in eukaryotic chromosomes (Musacchio & Salmon, 2007). 
Hence, APC activation restores basal CDK levels and promotes the dissolution of sister chromatid 
linkage to enable their physical separation. When chromosome segregation is hampered, the 
persistent activation of the SAC can lead to a prolonged mitosis and, eventually, cell death, a 
property that has been exploited pharmacologically through the design of SAC-activating drugs as 
anticancer agents (see below). In summary, the SAC is a central checkpoint pathway that 
facilitates proper chromosome segregation during mitosis thereby limiting genomic instability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. The SAC as a target in cancer therapy 
As mentioned above, targeting mitosis by chemical activation of the SAC has been 
exploited to attack highly proliferative cancer cells. Since cancer cells often show alterations in 
their ploidy such as aneuploidy or polyploidy, which complicate cell division, further impairing 
chromosome segregation has been used as a strategy to efficiently kill these cells. In addition, 
Figure 3: The spindle assembly checkpoint (SAC) is active until the metaphase-anaphase 
transition. The SAC is the safeguard mechanism of proper chromosome segregation in mitosis. It is 
active until all microtubules are properly attached to the kinetochores and thus, chromosomes are bi-
orientated. Unattached kinetochores recruit proteins from the MCC, a cluster of SAC-core-proteins, 
leading to the inhibition of the APC complex and the anaphase onset. 
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many cancer cells present mutations in SAC components, consequently weakening checkpoint 
integrity (Dominguez-Brauer et al., 2015; Geert J P L Kops, Weaver, & Cleveland, 2005; Lapenna 
& Giordano, 2009; M. Malumbres, 2011; Pérez de Castro, de Cárcer, & Malumbres, 2007; Weaver 
& Cleveland, 2006). Until recently it was thought that, in contrast to what occurs in flies and yeast, 
the SAC was essential for cellular viability in mammals (G. J. P. L. Kops, Foltz, & Cleveland, 2004; 
Michel et al., 2004). Surprisingly, Raaijmakers and colleagues recently revealed that MAD1 and 
MAD2 are dispensable in the human haploid HAP1 cell line, both in its haploid or diploid state 
(Raaijmakers et al., 2018). In any case, and regardless of this specific observation, drugs that 
activate the SAC are a well-established therapeutic strategy. 
 
A successful SAC-activating strategy has been the use of microtubule-targeting agents 
(MTAs) (Figure 4), which lead to mitotic arrest and are highly toxic for many cancer cells 
(Dominguez-Brauer et al., 2015). For instance, Paclitaxel and Docetaxol are well-established and 
clinically approved representatives of MTAs that act by inhibiting microtubule de-polymerization 
(Dominguez-Brauer et al., 2015). Although MTAs are indicated for the treatment of leukemia, lung, 
breast and ovarian cancers, their continuous application is often limited due to severe side effects, 
including neurotoxicity and myelosuppression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Chemical-
induced activation of 
the SAC. The SAC is 
physiologically activated 
in mitosis to secure the 
correct and complete 
alignment of all 
chromosomes at the 
metaphase plate. 
Chemical-induced 
activation of the SAC 
can be achieved by 
reagents that impair the 
alignment of the 
chromosomes. MTAs, 
such as Paclitaxel, 
stabilize the 
microtubules imparing 
the cell to enter into 
anaphase, which 
subsequently will lead to 
its death. 
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Another well-established compound that activates the SAC by reversibly inhibiting 
microtubule polymerization is Nocodazol, a drug identified in a screen for antihelminthic 
compounds (De Brabander et al., 1975; Peterson & Mitchison, 2002). While this compound could 
not hold its anti-cancer drug potential in early clinical studies, it is a frequently used drug in 
biomedical research. 
Finally, a different strategy to activate the SAC is through the inhibition of the mitotic kinesin 
Eg5 with Monastrol, a compound found in a phenotypic screening approach (Mayer et al., 1999). 
Inhibition of Eg5, a motor protein essential for the spindle bipolarity, induces a mono-astral 
phenotype and mitotic arrest (Mayer et al., 1999; Myers & Collins, 2016). Unfortunately, and 
despite Eg5 inhibitors reached clinical trials, the clinical data so far has also been disappointing 
(Myers & Collins, 2016). 
Of note, it is important to bear in mind that the SAC can be activated to different degrees 
depending on the compound or dose used. This is due to the fact that the SAC has been shown to 
work as a rheostat rather than an all-or-nothing checkpoint (Collin, Nashchekina, Walker, & Pines, 
2013). For instance, Nocodazol activates the SAC for longer times than Paclitaxel, although the 
duration of the SAC does not always correlate with the toxicity of the drugs. 
 
 
5. Polyploidy in physiological and pathological conditions 
Most animals possess two sets of chromosomes, thus carrying a diploid genome (Wutz, 
2014). However, there are certainly examples of species with a different ploidy. For instance, there 
are several insects, where males are haploid and reproduce parthenogenetically whereas females 
are diploid and reproduce sexually – popular examples being bees, wasps or ants (Normark, 2003; 
S. P. Otto & Gerstein, 2008). As for polyploidy, while this is much rarer in animals than in plants, 
we can also find animals carrying a polyploid genome in several species of insects, fish, 
amphibians and reptiles (Mable, Alexandrou, & Taylor, 2011; S. P. Otto & Whitton, 2000; Van De 
Peer, Mizrachi, & Marchal, 2017). 
In addition to ploidy differences between species, it is also possible to identify different 
levels of ploidy within a unique individual. For instance, polyploidy is a normal developmental 
pathway used to increase total organ size, when most or all of the cells in the organ are polyploid 
such as in Drosophila embryos (Edgar, 2006; Orr-Weaver, 2015). A similar example is found in the 
tomato as its size depends on the ploidy of the pericarp cells (Chevalier et al., 2014). Polyploid 
cells often derive from non-canonical cell cycles (endocycle and endomitosis) and/or cell fusions 
(Figure 5). A cell undergoing endocycles switches between G- and S-phase without entering 
mitosis, whereas in the endomitosis a mitotic failure leads to polyploidy (Orr-Weaver, 2015). In 
mammals, few organs are formed physiologically of polyploid cells, most often through 
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endomitosis. For instance, up to three quarters of all cardiomyocytes carry a polyploid genome 
(Anatskaya & Vinogradov, 2004). During early postnatal development and in response to 
myocardial stress, such as myocardial infarction, cardiomyocytes grow and increase in size. In 
most cases this hypertrophy is due to endomitosis, which has been suggested to may facilitate the 
contraction of the heart under stress conditions due to the bigger cell sizes (Orr-Weaver, 2015; 
Pandit, Westendorp, & De Bruin, 2013). Mammalian megakaryocytes are another example of 
polyploidy achieved by endomitosis, which are cells deriving from the hematopoietic lineage that 
harbor a dramatically high chromosome number. Their gigantic cell size is essential to bud off 
sufficient numbers of platelets from their cytoplasm (Orr-Weaver, 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From all organs, the liver contains the biggest amount of polyploid cells. Up to 50% of all 
hepatocytes in humans and 90% in rodents become progressively polyploid through endomitosis 
(Duncan, 2013; Gentric & Desdouets, 2014; Orr-Weaver, 2015; Zhang et al., 2018). As in other 
organs, the ploidy status in the liver is dynamic and may increase after surgical manipulation or in 
disease conditions such as in nonalcoholic fatty liver disease (Gentric et al., 2015; Tamura et al., 
1992). Besides the well-known gradual accumulation of polyploid cells in the liver, it is surprising 
that little is known about the functional advantage, if any, of the high prevalence of polyploid 
hepatocytes in our organism. One hypothesis states that polyploid cells are transcriptionally more 
active and thus, potentially better detoxifiers (Gentric & Desdouets, 2014). Alternatively, it could 
also be that hepatocytes have a high resistance to DNA damage- or chromosomal instability-
induced apoptosis, to avoid the premature loss of an excessive number of cells in an organ that is 
frequently exposed to toxins. 
Figure 5: The road to 
polyploidy. Polyploid cells 
arise from cell fusion or 
aberrant cell cycles. Cell 
fusion leads initially to two 
nuclei with a final 4n DNA 
content. Similarly, a cell 
entering endocycles or 
endoreplication, which lack a 
complete mitosis after DNA 
replication, will also lead to a 
single nucleus with a 4n 
DNA content. Finally, 
endomitosis occurs due to 
defects in mitosis. If the 
defect happens before 
anaphase, the polyploidy cell 
will end up with one nuclei 
with 4n. Defects occurring in 
anaphase or later will lead to 
a cell with two nuclei with the 
same 4n DNA content. 
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As mentioned above, and besides endomitosis, mammalian polyploid cells can also be 
generated by cell fusion. This is the case of myoblasts, involved in the formation of the skeletal 
muscle fibers, multinucleated osteoclasts, involved in bone metabolism and trophoblast cells, 
which fuse into a multinucleated syncytiotrophoblast to originate the human placenta (Pandit et al., 
2013; Vignery, 2000; Xing, 2012; Zybina et al., 2002). Once again, the functional advantage of cell 
fusion in these tissues is currently unknown (Pandit et al., 2013). 
 
Even if polyploidy occurs physiologically, it has also been linked to cellular transformation 
since it can lead to aneuploidy and subsequent genomic instability, one of the hallmarks of cancer 
(Hanahan & Weinberg, 2011; reviewed in (Coward & Harding, 2014)). In fact, cancer cells rarely 
contain exact multiples of its original genome and instead, often present complex aneuploid 
karyotypes (Davidson et al., 2000; Ferti, Stamouli, Panani, Raptis, & Young, 2004; Ganem, 
Storchova, & Pellman, 2007; Griffin et al., 2007; Pfau & Amon, 2012). Considering the high 
prevalence of aneuploidy in cancer, compounds that specifically target aneuploid, or genomically 
unstable cells in general, are in great need. However, a deep understanding of how aneuploidy 
perturbs the cellular machinery, and the discovery of chemical agents that can exploit these 
perturbations remains challenging. In this regard, a recently published chemical screen revealed 
that inhibition of the UDP-glucose ceramide glucosyltransferase, an enzyme involved in the 
sphingolipid homeostasis, is preferentially toxic for aneuploid cells in vitro (Tang et al., 2017). 
However, to what extent drugs targeting aneuploid or polyploid cells can show efficacy as an 
anticancer therapy remains to be tested. Finally, it should be mentioned that while some degree of 
aneuploidy might facilitate carcinogenesis, genomic instability is intrinsically toxic to mammalian 
cells and thus also in certain contexts be detrimental for cancer cells. Along these lines, a recent 
study has suggested that polyploidy might be tumor-suppressive in the liver (Zhang et al., 2018). 
 
 
6. Haploidy in mammalian cells 
Forward genetic screens have largely relied on yeast as a model organism, due to the 
availability of haploid individuals that facilitates these approaches. As a consequence, the isolation 
of animal haploid cell lines has long been sought by biomedical researchers. Initial reports on the 
successful isolation of haploid cell lines in frogs date back to the 1960s. Interestingly, this early 
work already reported that haploid cell cultures rapidly become diploid upon prolonged culture, 
which they suggested occurs through “diploidization"; namely the gain of a second chromosomal 
set. Haploid cell lines were later isolated from insects like cockroaches and flies (Debec, 1978), 
which faced the same limitation. The first attempt to generate primary haploid mammalian 
embryonic stem cells (ESCs) came in the 1980s. To do so, parthenogenesis was induced by 
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ethanol and, although unfertilized oocytes entered early embryonic development, all generated cell 
clones carried a diploid set of chromosomes (Ulrich Elling & Penninger, 2014; Kaufman, 
Robertson, Handyside, & Evans, 1983). Thirty years later, the establishment of the first vertebrate 
haploid ESC lines was finally achieved in zebrafish (Yi, Hong, & Hong, 2009). This pioneering work 
was followed by two other groups that succeeded in generating parthenogenetic mouse haploid 
ESCs (mhaESCs), modifying the original ethanol-based protocol (U Elling et al., 2011; Martin Leeb 
& Wutz, 2012) (Figure 6). However, once again, mhaESCs were rapidly lost in culture due to 
“diploidization” and thus, frequent and continuous cell sorting was essential to prevent the loss of 
the haploid cell population. In addition, while the aggregation of mhaESCs with diploid mESC led to 
chimeric mice with contribution from the haploid cells, there was no evidence of haploidy in 
differentiated tissues, further illustrating the rapid loss of ploidy observed in these lines (Martin 
Leeb & Wutz, 2012). Along these lines, subsequent work showed that differentiation of mhaESCs 
into embryonic cell lineages correlated with the loss of haploidy as early as the post implantation 
state (M. Leeb et al., 2012). Androgenetic mhaESCs have also been established, where the 
haploid genome derives from sperm rather than oocytes (W. Li et al., 2012; Yang et al., 2012). To 
date, haploid ESCs have also been generated from rat, monkey and human (W. Li et al., 2014; 
Sagi et al., 2016; Yang et al., 2013; Yi et al., 2009). Interestingly, human haploid ESC could be 
differentiated into haploid cells in vitro (Sagi et al., 2016), although nobody has succeeded in 
generating a proliferating and differentiated primary mammalian cell line to date. In addition, to 
what extent mammalian haploid tissue can be generated remains unknown. 
 
 
 
 
 
 
 
 
Besides the interest of primary haploid mammalian cell lines for developmental studies, the 
isolation of a near-haploid cell line (KBM7) from a human patient of chronic myeloid leukemia 
heralded the era of haploid mammalian forward genetic screens. This human cancer cell line was 
initially isolated in 1995 and consisted of a mixed population of cells with different ploidy. It 
displayed several genomic alterations including the characteristic Philadelphia chromosome, which 
carries a fusion between chromosome 9 and 22 giving rise to the BCR-ABL fusion protein 
(Andersson et al., 1995; Ulrich Elling & Penninger, 2014). In 1999, Kotecki et al. reported the 
Figure 6: Derivation of parthenogenetic mhaESCs. Oocyte fertilization by the sperm sets the start 
point of embryonic development. However, this process can also be mimicked by the addition of 
strontium chloride to the oocyte, which induces blastocyst development in vitro. Mouse ESCs clonal 
lines can be isolated from the inner cell mass of these activated oocytes. Continuous cell sorting of the 
haploid fraction will establish over time mhaESCs. 
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isolation of a haploid subclone of the KBM7 cell line by serial subcloning events (Kotecki, Reddy, & 
Cochran, 1999). This near-haploid KBM7 subclone was haploid for all chromosomes except for the 
chromosome 8 (Figure 7A). Of note, the authors already suggested the unique potential of this cell 
line to enable forward genetic screens in mammalian cells. The first screening using KBM7 was 
reported ten years later and led to the identification of host factors used by pathogens for the 
infection (Carette et al., 2009). This pioneering work was followed by additional haploid mammalian 
screenings, which identified the receptors used by Ebola and Lassa viruses to infect human cells 
(Carette et al., 2011; Jae et al., 2014). Soon thereafter, a forward screening in KBM7 cells provided 
a genome-wide view of all genes that are essential for cell viability (Blomen et al., 2015; Wang et 
al., 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
While trying to generate induced pluripotent stem cells from KBM7 cells, which grow in 
suspension, the near-haploid adherently growing human HAP1 cell line was developed (Carette et 
al., 2011)(Figure 7B). Because the adherent growth facilitates their use in vitro, HAP1 cells 
became the cell line of choice and have been extensively used for forward genetic screenings. 
Recent examples include the discovery of regulators of tubulin detyrosination (Nieuwenhuis et al., 
Figure 7: Isolation of a haploid 
human cancer cell line KBM7 
subclone and generation of the 
HAP1 cell line. (A) Originally, it 
was described that the cancer cell 
line KBM7 suffered from a rapid 
diploidization in just 3 weeks of 
culture. Thus, subclones were 
generated from the heterogeneous 
KBM7 cell line and the P1-55 
subclone, now widely used within 
the research community, was 
isolated. Karyotyping of this clone 
revealed a near-haploid genome 
(only chromosome 8 was diploid) 
(Modified from Kotecki, Reddy and 
Cochran, 1999). (B) 16 years later, 
Carette et al. established, in an 
unsuccessful attempt of inducing 
pluripotency in KMB7, an adherent 
version of the KBM7 cell line, 
which was named HAP1. HAP1 
cells did not longer express 
haematopoietic markers and were 
haploid for all chromosomes. 
(Modified from Carette et al., 
2011.) 
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2017) or the identification of the essential enzyme PLA2G16 as a picornavirus host factor (Staring 
et al., 2017). In fact, due to the enormous potential of this cell line and the surrounding excitement, 
the company Haplogen, which generates and provides individual engineered HAP1 cell lines for 
research purposes, was founded. Unfortunately, and despite de usefulness of these cells, the 
haploid state of KBM7 and HAP1 is also unstable. 
 
 The availability of mammalian haploid cell lines has revolutionized forward genetic 
screenings in mammalian cells and provided a unique tool to perform these studies. However, 
researchers working with haploid cells invariably face the problem of “diploidization”. This is 
particularly acute in haploid ESC lines. In fact, the establishment and maintenance of mhaESCs 
requires continuous cell sorting in order to maintain a significant proportion of haploid cells (U 
Elling et al., 2011; Martin Leeb & Wutz, 2012). In any case, this phenomenon is not unique to 
mhaESCs and has been described in cell lines including frog, drosophila, rat and human ESC lines 
as well as KBM7 and HAP1 cell lines (Carette et al., 2011; Debec, 1984; Freed, 1962; Freed & 
Mezger-Freed, 1970; Kotecki et al., 1999; W. Li et al., 2014; Sagi et al., 2016; Yilmaz, Peretz, Sagi, 
& Benvenisty, 2016). Given the generality of this phenomenon, and the limitations it impinges to 
the use of mammalian haploid cells for biomedical research, we here sought to identify its causes, 
and tried to discover genetic and chemical ways to stabilize the haploid state in mammalian cells. 
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1. To identify the molecular mechanism behind the progressive loss of haploid mammalian 
cells in culture. 
 
 
2. To generate differentiated haploid mouse tissue in vivo. 
 
 
3. To identify chemicals capable of stabilizing the haploid state in mammalian cells. 
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Cell culture 
 The HAP1 cell line was a kind gift of Dr. Thijn Brummelkamp, NKI, Amsterdam and grown 
in IMDM (Invitrogen) supplemented with 15% FBS (Sigma), 1% P/S and 1% Glutamine (Carette et 
al., 2011). Mouse embryonic fibroblasts (MEFs) were obtained from 13.5 dpc embryos by standard 
methods and cultured in DMEM (Invitrogen), 15% FBS and 0.1 mM non-essential amino acids in 
low-oxygen conditions. To generate feeder layers, MEFs at early passages were growth arrested 
by ionizing irradiation (IR) with 80 Gy for 30 min. MEFs were immortalized by lentiviral expression 
of the SV40-T121 antigen following standard procedures. DLD1 cell lines were a kind gift of Erich 
Nigg (University of Basel, Switzerland) and Spiros Linardopouplos (ICR, London, UK) and cultured 
in RPMI, 10% FBS and 1% P/S. HEK293T (American Type Culture Collection) cells were grown in 
DMEM (Invitrogen), 10% FBS and 1% P/S. Mouse induced pluripotent stem (iPSCs) cell lines were 
a kind gift of Sagrario Ortega (Mouse Transgenic Unit, CNIO, Madrid) and cultured in DMEM, 20% 
KnockOut Serum Replacer (KSR), 0.1 mM non-essential amino acids, 1% P/S, 1% Glutamine plus 
1000 U/ml LIF. The CyclinB1-164-mCherry expressing U2OS cell line was a kind gift of Dr. Marcos 
Malumbres (Cell Division Cancer, CNIO, Madrid) and cultured in DMEM (Invitrogen), 10% FBS and 
1% P/S. When indicated the following compounds were used to treat the cells: Doxorubicin 
(D1515, Sigma), DAB (Deacetylbaccatin III, S2409, Selleckchem), Paclitaxel (T7402, Sigma), 
Nocodazole (M1404, Sigma). For clonogenic assays, 500 HAP1 cells were seeded per well on six-
well plates. After 5 days, cells were fixed, stained with methylene blue at 0.33% (w/v) in methanol 
followed by washes in water and air-dried. Colony size was measured and analyzed with the 
Image J software. P53-deficient HAP1 cells were generated by transfecting the CRISPR-based 
plasmids using the Amaxa® Nucleofector kit (Reactive L, X-001 program). A total of 5x105 cells 
were transfected with 10 μg of pX330-sgRNA-p53 plasmid. 
 
Derivation and culture of mhaESCs 
 mhaESCs were generated following a reported protocol (Martin Leeb & Wutz, 2012) but 
using oocytes isolated from p53+/- or p53+/-; Kathuska (KFP)T/+ female mice. mhaESCs were 
cultured on a feeder layer of MEFs in gelatin-coated plates at 37°C in N2B27-based medium plus 
1000 U/ml LIF, PD0325901 (1µM), CHIR99021 (3 µM) and supplemented with 15% knockout 
serum replacement (Invitrogen), 0.1 mM non-essential amino acids and 0.35% BSA fraction V. 
DNA was extracted from the cell clones using standard procedure.  
 
Plasmids 
 The plasmids pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene, 42230) and 
pLentiCRISPR-V2 (Addgene, 52961) were used in cells for gene editing. The sequences of the 
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sgRNAs used were designed and cloned as described by using the MIT CRISPR design tool 
(http://www.genome-engineering.org/crispr/). 
 
Oligonucleotides 
pX330-CRISPR-p53-F CACCGTGAAGCTCCCAGAATGCCAG 
pX330-CRISPR-p53-R:  AAACCTGGCATTCTGGAGCTTCAC 
pX330-CRISPR-V2-P21[1]-F CACCGACTGGAGGGTGACTTCGCCT 
pX330-CRISPR-V2-P21[1]-R AAACAGGCGAAGTCACCCTCCAGTC 
pX330-CRISPR-V2-P21[2]-F CACCGAGTCGAAGTTCCATCGCTCA 
pX330-CRISPR-V2-P21[2]-R AAACTGAGCGATGGAACTTCGACTC 
pX330-CRISPR-V2-USP28[1]-F CACCGACCCCAATCCCAATGACTGG 
pX330-CRISPR-V2-USP28[1]-R AAACCCAGTCATTGGGATTGGGGTC 
pX330-CRISPR-V2-USP28[2]-F CACCGCTCCAGTAGACTCAAAGCAA 
pX330-CRISPR-V2-USP28[2]-R AAACTTGCTTTGAGTCTCTGGAGC 
 
Only sgRNAs with the higher scores and lower probabilities of generating off-target effects were 
selected. pLenti-H2B-EGFP and pLenti-H2B-RFP were a kind gift from Dr. Marcos Malumbres 
(Cell Division and Cancer Group, CNIO, Madrid). The lentiviral plasmids pLVTHM (Addgene, 
12247), pHIV-tdTomato (Addgene, 21374), pKLV-U6gRNA(BbsI)-PGKpuro2ABFP (Addgene, 
50946) were used to express EGFP, tdTomato or BFP fluorescent proteins after infection, 
respectively. Down-regulation of human P53 was generated using the plasmid pLVTHM-
shRNAp53 as earlier described (Kawamura et al., 2009). All newly generated constructs were 
sequenced entirely to rule out the presence of mutations. 
 
Lentiviral production 
 Lentiviral vectors were individually co-transfected with 3rd generation packaging vectors in 
HEK293T cells using Lipofectamine 2000 (Invitrogen) to generate viral supernatants as described 
(Ruiz et al., 2011). 
 
Conditional P53 deletion 
 To generate cells with conditional expression of mouse P53, pSico (Addgene, 11578) and 
pSico-P53 (Addgene, 12089) plasmids were used. Cells infected with pSico-P53 express shRNAs 
targeting P53 from a Cre-dependent excisable gene cassette. To express Cre and restore P53 
expression, cells were infected with adenoviruses expressing Cre (Ad5CMVCre-EGFP; VVC-U of 
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Iowa-1174). In brief, 105 mhaESCs were infected in suspension with lentiviruses encoding for 
pSico (Addgene, 11578) or pSico-P53. Five days after, we sorted haploid cells based on DNA 
content and EGFP expression. Subsequently, we infected a total number of 2x105 haploid-sorted 
ESCs with Ad-Cre viruses in suspension. After infection, we grew the cells on feeder layers to 
evaluate DNA content and P53 expression levels by WB and flow cytometry at different time 
points, respectively. 
 
Flow Activated Cell Sorting (FACs) 
 HAP1, immortalized MEFs and mhaESCs were trypsinized followed by Hoechst staining 
(10 µg/ml Hoechst 33342, Thermo Fisher Scientific) for 30 minutes at 37°C. Sorting for specific 
haploid, diploid or tetraploid cell populations was based on FSC/SSC and/or expression of 
tdTomato, EGFP or BFP on a BD InfluxTM cell sorter (BD Biosciences). In brief, cells were 
trypsinized and a small sample was stained with Hoechst and analyzed on the cell sorter to identify 
the population of interest in the FSC/SSC dot plot through back gating. This was possible as 
haploid cells were considerably smaller in size and tetraploid cells were considerably bigger in 
size. Subsequently, HAP1 cells were then sorted for DNA content but based on the FSC/SSC 
parameters. In a mix culture of haploid/diploid cells, haploids were sorted based on the G1 haploid 
(1n) and diploids on the G2/M diploid (4n) peaks, respectively. In a mix culture of diploid/tetraploid 
cells, diploids were sorted based on the G1 diploid (2n) and G2/M tetraploid (8n) peak, 
respectively. Single cell sorting was conducted by collecting one cell per well on 96-well plates. 
The purity of the sorted cells was checked after each sort by flow cytometry analysis. 
 
Flow cytometry 
 We routinely analyzed the cell cycle profiles by flow cytometry. Briefly, trypsinized cells 
were stained with 10 µg/ml Hoechst 33342 for 30 minutes at 37°C or fixed with 70 % ethanol 
overnight at -20°C and subsequently stained with propidium iodide (PI) following a standard 
protocol. We recorded the analytic flow profiles of the DNA content on a BD FortessaTM (BD 
Biosciences). At the same time or independently, we monitored and recorded the tdTomato+, 
EGFP+ and BFP+ HAP1, DLD1 or immortalized MEF populations. Data was processed with the 
Flow Jo 10TM software. 
 
High-Throughput Chemical Screening 
HAP1 haploid cells expressing tdTomato+ and HAP1 diploid cells expressing EGFP+ were mixed in 
a ratio 4:1 and a total of 2500 cells were seeded per 96-well plate. Cells were treated individually in 
the wells with a FDA approved drug-screening library (Z145127, Selleckchem) containing 987 
MATERIAL AND METHODS	 	
 
52 
compounds (Table 2). Fresh compounds were added twice per week, cells passaged once per 
week and the screen was carried out in duplicates. After 3 weeks of treatment, cells were 
trypsinized, incubated with DAPI and analyzed the expression of tdTomato and EGFP by high 
throughput flow cytometry (BD FACS Canto IITM, BD Biosciences). Data was processed with the 
Flow Jo 10TM software. 
 
Western blot 
 Cell pellets were lysed in 50mM Tris, 150mM NaCl, 1% TritonX-100 or in 50mM Tris pH 
7.9/8M Urea/1%Chaps followed by 30 min of incubation time shaking at 4°C. 15-25 µg of 
supernatants were run on precast gels and transferred for protein detection by using the following 
antibodies: p53 (1:1000, Cell Signaling, #2524); p21 (1:500, Cell Signaling, #2947); USP28 
(1:1000, Abcam, #ab110744), CDK2 (1:2000; sc-163, Santa Cruz) and Tubulin (1:50000; Sigma, 
#T9026). 
 
Immunofluorescence 
 Cells were fixed with 4% PFA followed by permeabilization with 0.1% Triton-X100. Cells 
stained for detecting MAD2 expression were pre-extracted for 60 seconds in PEM buffer (100 mM 
PIPES, 10 mM EGTA, 1 mM MgCl and 0.1 % Triton X-100). Antibodies against 53BP1 (1:3500, 
Novus 100-304A2), γH2AX (1:1000, Millipore 05-636), γTubulin (1:1000, Sigma #T6557), αTubulin 
(1:1000, Sigma #T9026), pH3 (1:100, Millipore 06-570), MAD2 (1:100, Bethyl Laboratories A300-
301A) anti-centromeric antibody (ACA, 1:500, kind gift of Marco Malumbres, Cell Division and 
Cancer Group, CNIO, Madrid) were used. Images were aquired using a Leica TCS-SP5 equipped 
with a 0.7 NA 20x oil or 1.4 NA 63x oil (HCX plan Apo CS) objective and LAS AF 2.6 software. To 
generate the overlays of the spindles shown in Figure 18A, 25 metaphase spindles for each clone 
were acquired with the 2 poles visible in the same plane, followed by spindle centering leading to 
the same position for each spindle.  A 400x400 pxl cropped area was generated for each channel 
to create a stack of all the captures from the different conditions. Subsequently, the average 
projection of the 25 metaphases for each condition and channel was created and the overlay of the 
3 channels is displayed. HCS CellMask (Thermo Fisher Scientific) used to calculate mitotic cell 
size was obtained from Thermo Fisher. Images were analyzed and processed using imaging Leica 
Microsystems, Fiji softwares or Definiens Developer XDTM software. 
 
High-throughput microscopy 
 High-throughput microscopy analyses were carried out as previously described (Toledo, 
Murga, Gutierrez-Martinez, Soria, & Fernandez-Capetillo, 2008). Briefly, a total of 25000 ESCs per 
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well or 10000 HAP1 cells were seeded on µClear® bottom 96-well plates (Greiner Bio-One) pre-
treated with gelatin 0.1%. γH2AX (1:1000, Millipore, 05-636), H2AX (1:1500, Abcam ab11175) and 
pH3 (1:100, Millipore 06-570) immunofluorescence was performed as described above. Images 
from each well were automatically captured by an Opera High-Content Screening System (Perkin 
Elmer) at non-saturating settings. Images were segmented using the DAPI staining to generate 
masks matching cell nuclei from which the total nuclei intensity or number of foci was calculated 
and data was represented with the Prism software (GraphPad Software). For EdU incorporation 
analyses, EdU was added to the media at a final concentration of 20 µM for 30 minutes. EdU 
incorporation was detected using the Click-iTTM EdU Alexa Fluor® imaging kit (Invitrogen/Molecular 
probes). 
 
Cell viability assays 
 Cells were seeded at 25000 cells per well in a 96-tissue culture plate coated with gelatin 
0.1% and treated with the indicated compound and indicated time. Cell viability was measured 
using a luminescent system (CellTiter-Glo, Promega) according to the manufacturer’s protocol and 
the viability is plotted as percentage of viability compared to untreated control. 
 
Metaphase spreads 
 HAP1 cells were arrested at mitosis with overnight treatment with 100 ng/ml Colcemide 
(GIBCO/BRL). Cells were then collected, incubated in a hypotonic buffer (0.075 mM KCl) for 15 
min at 37°C and fixed with Carnoy’s buffer (methanol-glacial acetic acid, 3:1). To obtain metaphase 
spreads, cells were dropped on slides and stained with Giemsa solution. Images from metaphases 
were captured and a minimum of 19 metaphases were analyzed. 
 
Spectral karyotyping (SKY) analysis 
 For molecular cytogenetic analysis, ESCs were exposed to colchicine (0.5 µg/ml) for 4 h at 
37ºC, and harvested routinely. Metaphases were prepared following a conventional cytogenetic 
protocol for methanol-acetic acid (3:1)-fixed cells. Slides were prepared from the fixed material and 
hybridized using the SKY method, according to the manufacturer’s protocol (Applied Spectral 
Imaging, Migdal Ha’Emek, Israel). Images were acquired with an SD300 Spectra Cube (Applied 
Spectral Imaging) mounted on a Zeiss Axioplan microscope using a custom-designed optical filter, 
SKY-1 (Chroma Technology, Brattleboro, VT). At least 15 different metaphases were captured and 
analyzed in several single-cell sorted ESC clones. 
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Live cell imaging 
 To evaluate mitosis entry and duration, ESCs or HAP1 cells were infected with lentiviruses 
encoding the histone H2B-EGFP or H2B-RFP and seeded on 8 wells µ-Slide (Ibidi, 80826) pre-
treated with gelatin 0.1%. The day after, ESCs were imaged every 15 minutes for a total of 24h 
with a 20x objective in a Leica DMI 6000 B system. To quantify SAC-dependent time, HAP1 cells 
were treated with the indicated compounds and imaged every 4 minutes for a total of 16h with a 
20x objective in a Leica DMI 6000 B system. Overall mitotic duration was scored based on visual 
chromatin condensation/de-condensation. For a more careful evaluation of mitosis, SAC-
dependent time was defined as the time from NEBD until the observation of a metaphase plate and 
SAC-independent time from metaphase plate to chromosome decondensation. At least, 30 cells 
were followed to evaluate the time spent in mitosis and interphase as well as cell fate for each 
individual cell. 
 To evaluate the cyclin B degradation, U2OS cells expressing a CyclinB-mCherry fusion 
protein were seeded on 8 wells µ-Slide (Ibidi, 80826). The following day, cells were treated with the 
indicated compounds and imaged every 4 minutes for a total of 16h in a Leica DMI 6000 B system. 
Cyclin B degradation was evaluated in cells from the NEBD, with the maximum level of cyclin B 
expression, until the start of anaphase, where mCherry signal was lost entirely. 
 
Mice 
 P53+/- female mice (Jacks et al., 1994) were used to generate P53-deficient mhaESCs. 
P53-/- male mice (Jacks et al., 1994) were crossed with KFPT/+ female mice (Diéguez-Hurtado et 
al., 2011) to obtain P53+/-; KFPT/+ female mice to generate P53-; KFPT and mhaESCs. FAH-/-; 
Rag2+/+; II2rg+/+ female mice (Azuma et al., 2007) were used to generate FAH-/- blastocysts. FAH-/- 
animals were maintained with 2-(2-nitro-4-trifluoro-methyl-benzoyl)-1,3 cyclohexanedione (NTBC, 
CuRXTM Nitisinone, Yecuris Corporation; #104206-65-7)-containing drinking water at a 
concentration of 10 mg/l. In collaboration with the Transgenic Mice Unit of the CNIO, newly 
generated P53-; KFPT mhaESCs were microinjected into FAH-/- blastocysts and transplanted into 
female foster mice. NTBC was eliminated of the drinking water at E10.5. 
 
 Genotyping of the DNA from mouse-tails was performed following standard procedure. The 
following primers were used: FAH-F 5' TTGCCTCTGAACATAATGCCAAC 3’; FAH-RWT 5' 
TGAGAGGAGGGTACTGGCAGCTAC 3'; FAH-RMUT 5' GGATTGGGAAGACAATAGCAGGC 3'; 
Il2rg-F 5ʼ CTGCTCAGAATGCCTCCAATTCC 3ʼ; Il2rg-RWT 5ʼ ACCGTTCACTGTAGTCTGGCTGC 
3ʼ; Il2rg-RMUT 5ʼ GGTCGCTCGGTGTTCGAGGCCAC 3ʼ; Rag2-FWT 5ʼ GGGAGGACACTCACT 
TGCCAGTA 3ʼ; Rag2-FMUT 5ʼ CGGCCGGAGAACCTGCGTGCAA 3ʼ; Rag2-R 5ʼ AGTCAGGAG 
TCTCCATCTCACTGA 3ʼ; KFP-F 5’ AACGACCACCACTTCAAGTGC 3’; KFP-R 5’ 
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TAGCCAGAAGTCAGATGCTCAAGG 3’; p53 F1 5’ TGGTTTGTGCGTCTTAGAGACAGT 3’; p53-
F2 5’ CCAGCTCATTCCTCCCACTCA 3’; p53-R 5’ AAGGATAGGTCGGCGGTTCAT 3’. 
 Embryos or newborn pups were fixed in formalin, embedded in paraffin/formalin blocks and 
serial sections of 5 µM were cut. H&E staining was performed following a standard protocol. For 
immunohistochemistry analyses, the slides were treated with citrate buffer for antigen retrieval and 
stained with an antibody against Turbo-RFP (Katushka, Evrogen #AB233) following standard 
procedures. Immunohistochemistry slides were scanned and digitalized with a MIRAX system from 
Zeiss. Mouse work was performed in accordance with the Guidelines for Humane Endpoints for 
Animals Used in Biomedical Research and under the supervision of the Ethics Committee for 
Animal Research of the “Instituto de Salud Carlos III”. 
 
Immunofluorescence followed by FISH (Immuno-FISH) on embryo sections 
 Immunofluorescence was performed on deparaffinized embryo sections processed with 10 
mM sodium citrate (pH 6.5) cooked under pressure for 2 min for antigen retrieval. Tissues were 
permeabilized with 0.5% Triton X-100 in PBS for 1.5 h (3 x 30 min) at room temperature. Samples 
were blocked with PBS with 5% BSA for 3h and incubated overnight at 4 °C with an antibody 
against Turbo-RFP (Katushka, Evrogen #AB233) diluted 1:100 in PBS 5% BSA. Slides were 
washed three times for 15 min with 0.1% Tween 20 in PBS and incubated with an Alexa Fluor 488 
anti-rabbit (ThermoFisher Scientific A11008) secondary antibody for 1h at room temperature. 
Samples were washed three times for 15 min with PBS with 0.1% Triton X-100 and then fixed for 
20 min in 4% paraformaldehyde in PBS. Quantitative centromere fluorescence in situ hybridization 
(Q-FISH) was performed as described before (Gonzalo et al., 2006; Samper, Goytisolo, 
Slijepcevic, Van Buul, & Blasco, 2000) with some modifications: 1) Samples were not treated with 
pepsin and were subjected directly to dehydration steps. 2) Formamide concentration during 
incubation with the probe was reduced from 70% to 30%. 3) Samples were not subjected to 80ºC 
denaturation step. 4) Incubation time was reduced to 30 min. Samples were then washed with 
4xSSC 0.05% Tween for 15 min (3x5min). Centromere (major satellite) PNA probes labeled with 
CY3 (Panagene) were used. Nuclei were counterstained in a 4 µg/ml DAPI/PBS solution before 
mounting with Vectashield (Vector Laboratories H-1000). 
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As we have exposed in the introduction, there is the general notion in the field that haploid 
mammalian cells spontaneously “diploidize”, explaining the progressive loss of haploid cells in 
culture. This suggests that haploidy might be an unstable genetic state although the reasons for 
this phenomenon remained largely unknown. Here, we present our findings regarding the 
underlying cause of “diploidization” and reveal two independent strategies capable of stabilizing 
haploidy in culture.  
 
 
1. Haploid mammalian cells grow slower than diploids 
 Consistent with previous reports, while growing HAP1 cells we noticed a progressive loss of 
haploid cells (Figure 8A), eventually losing all haploid cells from the cultures if cell sorting was not 
performed on regular basis. To determine the basis of this phenomenon, we first explored whether 
haploid cells could have a growth disadvantage compared to diploid cells. To test this idea, haploid 
and diploid cell populations of HAP1 cells were sorted and cultured individually. In clonogenic 
assays, we observed that haploid cells formed smaller colonies compared to their diploid 
counterparts (Figure 8B, 8C). Moreover, in independent experiments the number of diploid cells 
after 6 days of culturing was almost five times higher when compared to the number of haploid 
cells (Figure 8D). These results indicated that haploid mammalian cells have a growth 
disadvantage compared to diploid cells existing in HAP1 cultures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Diploid cells show 
a better growth fitness than 
haploids. (A) DNA content 
analyses by flow cytometry 
illustrate the rapid loss of the 
haploid population in early 
passages of HAP1 cells. Cells 
were stained with Hoechst. 
The percentage of haploid 
cells in G1 is represented in 
red. (B) Representative image 
of a methylene blue stained 
clonogenic assay of a haploid 
and diploid cell culture 5 days 
after plating. (C) Colony size of 
the clonogenic assay as shown 
in (B). Data represent two 
independent experiments with 
three technical replicates each. 
*** P< 0.001. (D) Total number 
of haploid and diploid cells 6 
days after plating. As starting 
point, 5000 cells were seeded 
for each culture. Data 
represent two independent 
experiments with three 
technical replicates each. Error 
bars indicate SEM. *** P< 
0.001. 
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 We next asked whether the loss of haploid cells could be due to the better proliferation 
capacities of diploid cells, which would gradually take over the entire culture. To assess this 
possibility, sorted haploid HAP1 cells were infected with lentiviruses encoding for red fluorescent 
protein (RFP) and diploid cells with lentiviruses encoding for enhanced green fluorescent protein 
(EGFP). Subsequently, we mixed both populations at a 1:1 ratio and grew them for 36 days in 
culture. A time-course analysis by flow cytometry during the experiment revealed a gradual loss of 
the haploid population over time so that only 7% RFP positive cells remained at day 36, which 
were mostly haploid in DNA content (Figure 9A, 9B). Since the previous experiments indicated that 
haploid HAP1 cells were being out-competed by faster growing diploids, we speculated that 
cultures initiated from single-cell sorted haploid cells should remain haploid over time. 
Correspondingly, single-cell sorted HAP1 cell lines remained haploid even one month after the cell 
sorting (Figure 9C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: The loss of haploids in culture is due to the overgrowth of diploids. (A) Percentages of 
RFP-positive and EGFP-positive HAP1 cells measured by flow cytometry over a course of 36 days. 
The starting point of the culture was 50% for each population. (B) DNA content analysis from the two 
cell populations displayed in (A) at day 4 and 36. Red arrow points to the diploid 4n population found 
in RFP-positive HAP1 cells. (C) DNA content analysis by flow cytometry showing single-cell sorted 
clonal HAP1 cells at day 32 after cell sorting. In red is displayed the G1 peak of the haploid population. 
The yellow arrows point at the percentage of 4n population in each clone. 
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 Of note, DNA content staining revealed that a small fraction of the single-cell sorted 
haploids had become diploid after one month in culture (Figure 9C), indicating that bona-fide 
diploidization also occurs in HAP1 cells. Nevertheless, despite the fact that diploidization does take 
place at a very low frequency, our results reveal that loss of haploidy in HAP1 cells is mostly due to 
an outgrowth by diploids existing in these cultures. 
 
2. Loss of P53 stabilizes haploidy in HAP1 cells 
Besides haploidy, other alterations of ploidy in eukaryotes such as tetraploidy or aneuploidy 
have also been extensively documented to lead to reduced fitness (Ganem & Pellman, 2007; 
Santaguida & Amon, 2015), which in part is due to an activation of the tumor suppressor P53 
(Ganem et al., 2014). Consequently, P53 deficiency is able to rescue the proliferation impairment 
of aneuploid and tetraploid mammalian cells (Cross et al., 1995; Fujiwara et al., 2005; M. Li et al., 
2010; Thompson & Compton, 2010). Based on this, we first asked whether P53 levels were also 
altered in haploid cells. Indeed, P53 levels were higher in sorted haploid HAP1 cells compared to 
diploids (Figure 10A). Moreover, we detected a concomitant increase of the P53-target p21 in 
haploid cells indicative of an active P53-dependent transcriptional response. Consistently, P21 
levels were abrogated by the expression of a P53-targeting shRNA (Figure 10A). Importantly, we 
noticed that 43 days after starting a culture, P53-depleted HAP1 cells contained a higher 
percentage of haploidy compared to control cells (Figure 10B), suggesting that P53 activation 
could play an important role in the poor growth of haploid HAP1 cells. To address this hypothesis, 
haploid-sorted HAP1 cells were transfected with plasmids expressing the Cas9 nuclease and a 
P53-targeting short guide RNAs (sgRNAs). 45 antibiotic-resistant clones were subsequently 
isolated, from which 21 still expressed P53 (wild type, WT) and 24 had lost P53 expression 
(knockout, KO) (Figure 10C). Remarkably, although many of the WT clones had undergone 
diploidization to various extents, the majority of the P53-KO clones (87.5%) remarkably remained 
haploid (Figure 10D). Next, we cultured haploid WT and P53-KO HAP1 clones for 2 months and 
monitored their ploidy status over time. Consistent with all previous data, P53-deficient clones 
maintained their haploid status significantly better compared to WT clones (Figure 10E, 10F). 
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Figure 10: P53 depletion stabilizes haploidy. (A) P53 and P21 levels shown by Western blot in 
haploid and diploid cell populations infected with lentiviruses encoding for scramble or P53-specific 
shRNAs. Control cells were infected with empty vectors and expression of tubulin was used as a 
loading control. (B) DNA content analyses are displayed from the cell populations in (A) 43 days after 
infection and cell sorting. (C) A representative Western blot of the cell clones shown in (D) to illustrate 
P53-depletion by Cas9-gene editing in HAP1 clonal cell lines, CDK2 was used as loading control. (D) 
Graph displaying the number of isolated WT (n=21) and P53-deficient (n=24) clones obtained after the 
transfection of haploid HAP1 cells with a plasmid encoding for Cas9 and P53-targeting sgRNA. The 
DNA content was measured by flow cytometry and classified into haploid or diploid cell clones. (E) The 
percentage of haploid cells in G1 upon culture of the 11 WT and 21 P53-depleted HAP1 clones over 
55 days is displayed in the graph. Error bars indicate SEM. *** P < 0.001. (F) DNA content analyses 
from 3 different WT and 3 different P53-depleted HAP1 clones from E are displayed at day 0, 22 and 
55. The G1 haploid population is labeled in red. 
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Next, we assessed the relevance of two downstream targets of P53 in the maintenance of haploid 
phenotype; P21, a key mediator of P53-dependent cell cycle arrest (el-Deiry et al., 1993), and 
USP28, a deubiquitinase involved in the G1 arrest that follows a prolonged mitotic arrest (Meitinger 
et al., 2016). Both genes were deleted in HAP1 cells by CRISPR-mediated editing, and KO clones 
were followed in culture to evaluate their DNA content over time (Figure 11A, 11C). Interestingly, 
P21- or USP28-depleted cell pools lost the haploid cell fraction as fast as the WT clones (Figure 
11B, 11D), which suggested that P53-dependent apoptosis, rather than cell cycle arrest, was likely 
responsible for the reduced fitness of haploid HAP1 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Haploidy is not stabilized by the depletion of P21 or USP28. (A, C) P21 (A) and USP28 
(C) depletion in HAP1 cells after Cas9-dependent specific gene editing with 2 independent sgRNAs or 
empty control shown by Western blot. Tubulin serves as a loading control. (B) DNA content analyses from 
the samples described in (A) at day 0 and day 21; G1 haploid cells are labeled in red. (D) DNA content 
analyses from the samples described in (C) at day 0 and day 19; G1 haploid cells are labeled in red. 
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3. Absence of P53 facilitates the generation and maintenance of mhaESCs 
As described above, HAP1 cells derive from the human cancer cell line KBM7, which 
carries a high number of known and unknown mutations, which could in part contribute to P53 
activation. Thus, in order to rule out that the effects we observed were not a HAP1-cell specific 
phenomenon, we next evaluated the role of P53 in primary mouse haploid embryonic stem cells 
(mhaESCs). First, we determined the levels of endogenous P53 by high throughput microcopy in a 
haploid and diploid cell populations sorted from a mixed population of mhaESCs. Similar to HAP1 
cells, we observed a clear increase of P53 levels in mhaESCs compared to their diploid 
counterparts (Figure 12A).  
Next, we checked if P53 loss could facilitate the establishment and maintenance of newly 
generated mhaESC lines from activated oocytes. Thus, we derived WT and P53-deficient haploid 
ESC lines by inducing parthenogenesis with strontium chloride (U Elling et al., 2011; Martin Leeb & 
Wutz, 2012) on oocytes isolated from P53-/+ female mice (Figure 12B, 12C). As mentioned in the 
introduction, the generation of mhaESCs is quite inefficient due to the low amount of haploid cells 
existing after ICM isolation and the very rapid loss of haploid cells in culture. The first DNA content 
analysis we could perform was at passage 5, at which we had enough cells for the analysis. While, 
as expected, we detected a very low amount of haploids in all WT cell lines, there was a clear 
increase in the percentage of haploids in all P53-deficient cell lines (Figure 12D). Further 
enrichment of the haploid cell population in P53-deficient cell lines could be obtained at later 
passages and after only 2 rounds of cell sorting. This was in contrast to the percentage of haploids 
observed in the WT cell lines, where only a minor enrichment of the initial haploid cell population 
was achieved after 2 rounds of cell sorting (Figure 12E). The results above suggested that, similar 
to what occurs in HAP1 cells, the loss of haploidy in mhaESC cultures could be due to a P53-
dependent reduced fitness of haploid cells, which leads to the out-competition of the haploids by 
pre-existing diploids in these cultures. Consistently, single-cell sorting also facilitated the 
maintenance of WT mhaESCs (Figure 12F). Of note, spectral karyotype (SKY) analysis of these 
single-cell sorted clones confirmed a true haploid genome (Figure 12G). 
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 Finally, we tested if P53 re-activation would be particularly toxic for haploid cells in P53-
deficient mhaESC, or whether these cells had somehow adapted to the haploid state. In order to 
test this idea, we depleted P53 by expressing a Cre-dependent excisable P53-targeting shRNA 
cassette. Although, as expected, P53 depletion led to a better maintenance of haploidy in ESCs, 
Cre-dependent excision of the shRNA cassette restored P53 levels and led to a reduction of the 
haploid cells (Figure 13A, 13B). Thus, P53-deficient haploid ESCs do not “adapt” to the haploid 
Figure 12: Depletion of P53 facilitates the generation and maintenance of mhaESCs. (A) P53 
levels were measured by high throughput microscopy in individual haploid and diploid cell lines that 
were sorted from pools or single-sorted WT mhaESC clones. P53-depleted ESCs and ESCs treated 
with Doxorubicin to induce P53 expression served as a staining control. (B) Schematic representation 
of the protocol to generate mhaESCs from P53-/+ female mice. (C) Representative PCR analysis 
illustrating the P53 status in newly generated mhaESC lines. (D) and (E) Representative DNA content 
analysis from WT and P53-deficient mhaESC lines at passage 5 (D) and passage 15 including two cell 
sorts to select for haploidy (E). G1 haploid cells are labeled in red. (F) DNA content analysis from WT 
single-cell sorted mhaESC clones at day 17 after sorting. G1 haploid cells are labeled in red. (G) 
Representative SKY analysis from a WT haploid and a diploid ESC clone. 
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state, and remain sensitive to P53 activation. Taken all together, our data reveal that the rapid 
reduction of haploidy in mhaESC cultures is due to an overgrowth of diploid ESCs. In addition, and 
similar to what we observed in HAP1 cells, P53 depletion or single-cell sorting stabilizes the 
haploid state in mhaESC lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. P53-dependent cell death limits the expansion of mhaESCs in culture 
 We next explored the underlying cause of the poor growth of WT mhaESCs. We reasoned 
that because ESCs lack a P53-dependent G1/S checkpoint (Aladjem et al., 1998; Hong & 
Stambrook, 2004), a reduced S-phase entry might not explain the impaired growth of mhaESCs. 
Accordingly, when we compared the percentage of replicating cells by evaluating the incorporation 
of ethynyl dexoyuridine (EdU) we observed a similar percentage of EdU incorporation rates in 
haploid and diploid cultures (Figure 14). 
 
 
 
 
 
 
 
 
 
Figure 13: P53-depletion does not induce an adaptive response to maintain haploidy in ESCs. 
(A) DNA content analysis from 3 independent mhaESC cultures infected with a Cre-dependent 
excisable P53-targeting shRNA cassette and the subsequent restoration of P53 levels after infection 
with Adeno-Cre 2 days later. Uninfected cell cultures served as a control. G1 haploid cells are labeled 
in red and the numbers indicate its percentage. (B) Western blot showing the P53 levels in the 
different conditions from (A). 
Figure 14: Haploid and diploid ESCs display a similar 
number of replicating cells in culture. Percentage of EdU-
positive WT and P53-deficient haploid and diploid mESCs after a 
30 min EdU pulse. Three independent single-cell sorted haploid 
and diploid cell clones were evaluated in duplicates and 
averaged. Error bars indicate SEM. 
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To further determine the reasons behind the loss of haploid mhaESCs in culture, we 
infected P53 WT and KO single-cell sorted mhaESCs with lentiviruses expressing a fusion protein 
between EGFP and histone H2B (H2B-GFP) to record videos and monitor cell behavior for 24h 
(Figure 15A, 15B). This experiment revealed several interesting findings: First, we detected a 
similar amount of cells in mitosis, consistent with the previous observation that cell cycle 
progression was not grossly affected in haploid or diploid mhaESCs. Second, we observed a clear 
increase in cell death in the haploid WT cultures with up to 56.36% cells dying in 24h (compared to 
7% in the corresponding diploid WT cultures). Third, P53-deficiency significantly rescued the 
viability of haploid mhaESCs. Fourth, we noticed that WT haploid cells mostly died within or shortly 
after mitosis, suggesting that the cell death could be associated to problems during chromosome 
segregation. This observation is also supported by the fact that mitosis was longer in haploid cells 
compared to diploid cells (Figure 15B). Moreover, image analysis revealed that of up to 18 % of the 
haploid mitosis presented lagging chromosomes, anaphase bridges or micronuclei. While P53-
deficient haploid cells displayed a similar amount of segregation problems in mitosis, the absence 
of P53 limited their cell death. Taken together, these data indicated that haploid mhaESCs are lost 
in culture due to chromosome segregation problems that lead to the activation of P53-dependent 
cell death. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: P53-dependent death limits the expansion of mhaESCs. (A) Schematic representation of 
time spent in mitosis by individual, EGFP-H2B expressing, single-cell sorted WT haploid, P53-deficient 
haploid and WT diploid ESCs. Each scheme represents a single-cell sorted clonal cell line and 
horizontal bars depict the life of an individual cell showing in light blue the time in interphase and in dark 
blue the time in mitosis. Time in mitosis was defined as the time between chromosome condensation 
and cytokinesis. Cells were monitored every 15 min for a total of 24 h and a minimum of 40 cells per 
condition was analyzed. (B) Time spent in mitosis from the single-cell sorted clones shown in B. * P < 
0.05; ** P < 0.01; *** P < 0.001. 
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5. Chromosome segregation defects in mhaESCs 
Consistent with the hypothesis that the P53-dependent cell death observed in haploid ESCs 
was due to chromosome segregation problems, we observed a differential sensitivity to the 
microtubule poison Taxol in WT mhaESCs, which was abolished in the absence of P53 (Figure 
16A). To investigate the reasons that could underlie the segregation problems of mhaESCs, we 
first explored if these could arise from increased replication stress (RS), a type of DNA damage 
occurring during S-phase when fork progression is altered. Previous works had revealed that, upon 
the presence of RS, cells could enter into mitosis without a fully replicated genome and therefore 
lead to severe chromosome segregation problems (Mankouri, Huttner, & Hickson, 2013). To test 
whether mhaESCs suffered from higher levels of RS and consequently from higher levels of DNA 
damage, we measured the number of 53BP1 foci and the intensity of pan-nuclear histone H2AX 
phosphorylation in the nucleus (Figure 16B, 16C). While we could not detect a difference in any of 
the parameters, with these approaches we cannot exclude the possibility that specific regions of 
the haploid genome might suffer by RS and remain unreplicated before they reach mitosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: WT mhaESCs are sensitive to the spindle poison Taxol and do not suffer from RS. (A) 
WT and P53-deficient single-cell sorted haploid and diploid ESCs were treated with various doses of 
Taxol for 24h, when cell viability was measured. (B) 53BP1 foci were counted in haploid and diploid 
ESCs, percentage of cells with more than two foci are shown. (C) High throughput analysis of γH2AX 
intensity per nucleus normalized by the total levels of H2AX in WT haploid and diploid ESCs. Centerlines 
indicate mean values. 
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We next explored if the segregation defects observed in WT mhaESCs arise from problems 
directly occurring in mitosis. In this regard, we first tested if mhaESCs lacked centrosomes, since 
these cells derive from parthenogenic oocytes, and in nature centrosomes are provided by the 
sperm during fertilization (Simerly et al., 1995). Interestingly, immunofluorescence analysis of 
γTubulin expression, a centrosomal marker, revealed normal numbers of centrosomes in 
mhaESCs (Figure 17A, 17B), revealing that centrosomes are formed de novo in mhaESCs.  
 
 
 
 
 
 
 
 
 
 
 
 
Next, we tested whether imbalanced ratios between the spindle size and DNA content 
could underlie this phenomenon. In fact, an overlay of 25 spindles showed that while all spindles 
from diploid ESCs were perfectly aligned, the overlay from haploid spindles led to a blurry picture 
indicating a noisy distribution (Figure 18A). Moreover, although haploid cells contain half of the 
DNA than diploids (Figure 18B-D), the distribution of the DNA at the metaphase plate was wider 
and more heterogeneous in mhaESCs compared to the diploids (Figure 18E, 18F), further 
underscoring the intrinsic difficulties of haploid cells to arrange their chromosomes during mitosis 
(Figure 18A). 
 
 
 
 
 
 
 
 
 
 
Figure 17: Normal centrosome numbers in mhaESCs. (A) Representative 
immunofluorescence images of WT haploid and diploid ESCs in metaphase visualizing the 
centrosomes with γTubulin in green, DNA is stained with DAPI in blue. (B) Quantification of 
mitotic cells with 2, 3 or 4 centrosomes counted in WT haploid and diploid ESCs. 
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Figure 18: Heterogeneity in the alignment of the mitotic spindle in mhaESCs. (A) Representative 
images show an overlay of 25 different metaphases from WT haploid or diploid ESCs. Tubulin was 
stained in green to visualize the spindle, DNA in blue was stained with DAPI and the cytoplasm was 
stained in red with Cellmask. One single-cell sorted ESC clone each is shown but three different ones 
were analyzed per condition. (B-D) Transversal (B) and longitudinal (C) spindle diameter lengths, as well 
as mitotic cell size (D) was measured in 25 metaphases from WT haploid or diploid ESCs. Data from 
one single-cell sorted ESC clone each is shown but three different ones were analyzed in total per 
condition. (E) Representative images show the overlay of the average DAPI densitometry, hence the 
distribution of the DNA, from 25 different metaphases from WT haploid or diploid ESCs. One single-cell 
sorted ESC clone each is shown but three different ones were analyzed per condition. (F) DAPI area 
was measured in 25 metaphases from WT haploid or diploid mouse ESCs. Data from one single-cell 
sorted ESC clone each is shown but three different ones were in total analyzed per condition. 
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6. Generation of haploid mouse tissue 
A long-standing question regarding mhaESCs refers to whether they can contribute to the 
generation of haploid tissue. The current literature shows that although mhaESCs can contribute to 
the generation of mouse chimeras, the tissue obtained contained a diploid genome (U Elling et al., 
2011; M. Leeb et al., 2012; Martin Leeb & Wutz, 2012), reinforcing the idea that haploidy is also a 
very unstable genetic state in vivo. Nevertheless, based on our results presented above, we 
speculated that the use of P53-deficient mouse mhaESCs could help to stabilize haploidy during 
differentiation and perhaps allow the formation of haploid tissue. In collaboration with the 
Transgenic Mouse Unit at the CNIO, we conducted a wide variety of approaches (summarized in 
Table 1) to explore this possibility.  
 
#1 Microinjections of a pool of P53-deficient mhaESCs into EGFP+ blastocysts 
#2 Microinjections of single-cell sorted P53-deficient mhaESCs into EGFP+ blastocysts 
#3 Microinjections of single-cell sorted P53-deficient mhaESCs into KFPT blastocysts 
 
 
In order to easily identify the haploid derivatives, we microinjected P53-deficient mhaESCs 
into blastocysts obtained from fluorescently labeled mice. Unfortunately, we could not detect clear 
chimerism in the embryos obtained from any of these initial experiments. Next, we changed our 
initial experimental setup by fluorescently labeling the mhaESCs, as it could facilitate the detection 
of the haploid derived cells. To do so, P53-/- male mice were crossed with females expressing the 
fluorescent reporter Katushka (KFP+/T) (Diéguez-Hurtado et al., 2011). Subsequently, P53+/-/KFP+/T 
females were used as oocyte donors for the generation of parthenogenetic mhaESCs. To further 
increase our chances of developing haploid mammalian tissue, we speculated that focusing on 
organs that physiologically contain polyploidy cells, such as the liver (Gentric & Desdouets, 2014), 
could increase the probability of tolerating haploid differentiated cells. Hence, we took advantage of 
mice lacking the tyrosine catabolic enzyme fumarylacetoacetate hydrolase (FAH) and 
immunodeficient for T and B cells (Rag2-/-; Il2rg-/-), which are frequently used in transplantation 
studies (Azuma et al., 2007; Espejel et al., 2010). Mice lacking FAH develop severe hepatocyte 
damage and die from liver failure within the first weeks after birth, unless they are constantly 
supplemented with 2-(2-nitro-4-trifluoromethylbenzoyl)-1-3-cyclohexanodione (NTBC), a potent 
inhibitor of 4-hydroxyphenylpyruvate dioxygenase (Azuma et al., 2007; Espejel et al., 2010). 
Microinjecting wild type induced pluripotent stem (iPSCs) cells in FAH-depleted blastocysts leads 
to fully viable chimeric mice, where most of the liver is derived from fully functional hepatocytes 
differentiated from iPSCs cells (Espejel et al., 2010). Thus, we hypothesized that a similar 
Table 1: Different strategies performed trying to obtain haploid mouse tissue. 
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approach but performed with P53-; KFPT mhaESCs could lead to viable mice with livers made to a 
large extent from mhaESCs-derived cells (Figure 19A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Generation of P53-; KFP+ mhaESCs chimeras. (A) Schematic representation of the 
experimental procedure to obtain chimeras from P53-deficient; KFP+ mhaESCs. (B) Summary of the 
embryos/newborns obtained from several microinjection sessions. (C) Histopathology slides of the 
chimeric embryo obtain at E16.5 stained with H&E (left) and anti-KFP (right, brown cells), representative 
areas are magnified (face, backskin, liver). Most of the chimerism was found in the head area.  
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To reduce the initial selection pressure, we maintained the foster FAH-deficient mother on 
NTBC until E10.5, where the liver starts to develop (Swartley, Foley, Livingston, Cullen, & Elmore, 
2016). In collaboration with the Transgenic Mouse Unit we performed several microinjections with 
sorted P53-; KFPT mhaESCs into FAH-depleted blastocysts and obtained embryos at different 
developmental stages (Figure 19B). To evaluate the contribution of the P53-; KFPT mhaESCs we 
performed whole embryo immunohistochemistry analysis to detect KFP expression. While few 
embryos showed evidences of significant chimerism, at E16.5 presented an important contribution 
from the haploid cells in most tissues, including the liver (Figure 19C). 
 
Next, to determine whether cells arising from P53-; KFP+ mhaESCs remained haploid after 
embryonic development or had diploidized, we performed, in collaboration with Paula Martínez 
(Telomeres and Telomerase Group, CNIO), immunofluorescence against KFP followed by 
quantitative fluorescence in situ hybridization (Q-FISH) to detect centromeric major satellite 
repeats (Figure 20A). We then quantified the averaged intensity of the FISH signal from 
centromeric repeats in KFP positive and negative cells within the same tissue as an indirect 
readout of cell ploidy. Interestingly, these analyses revealed that in certain tissues such as the 
dermis, KFP positive cells showed significantly lower levels of centromere intensity than KFP 
negative cells (Figure 20B, 20C). While these experiments might indicate that we have succeeded 
in generating haploid mammalian tissue, a formal proof for the existence of haploid cells in mouse 
embryonic tissues demands additional experiments, which are currently underway. 
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Figure 20: Evidence for haploid differentiated cells in vivo. (A) Representative picture of the 
Immuno-Q-FISH in the dermis of the embryo from Figure 19C. Katushka (KFP) in green allows the 
detection of P53-deficient KFP+ differentiated cells. The centromeres were labeled in red and the nuclei 
with Dapi in blue. (B) Quantification of the centromere intensity in KFP+ and WT cells in the dermis area. 
Haploid cells are expected below the yellow bar. 57 cells are displayed per column. ***P< 0.001. (C) 
Histogram of KFP+ and WT cells in the dermis showing the cell distribution dependent on the centromere 
intensity. Haploid cells are expected on the left side from the yellow bar. 57 cells are displayed per 
curve. 
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Following our previous genetic work on the mechanisms that mediate the loss of haploid 
cells in culture, we next sought to conduct a chemical screening to identify compounds capable of 
stabilizing and/or favoring haploidy. Our original aim was to discover compounds that, when 
supplemented into the growth media, could facilitate the maintenance of haploid cells. In addition, 
this chemical biology approach could also help to understand better the underlying biology of 
haploid mammalian cells. In the following section, I present the results and what we learned from 
such screen. 
 
 
1. A chemical screen searching for compounds favoring haploid or diploid cells 
To identify chemical compounds that selectively favor either the haploid or the diploid 
genomic cell state, we first fluorescently labeled haploid HAP1 cells by expressing the red 
fluorescent protein tdTomato (TOM) and diploid HAP1 cells by expressing the enhanced green 
fluorescent protein (EGFP). HaploidTOM and diploidEGFP cells were then mixed in a 4:1 ratio, plated 
in duplicates in 96-well plates and treated individually for three weeks with a total number of 987 
compound (FDA-approved Drug Library, Selleckchem, Table 2). Due to the long duration of this 
experiment, cells were splitted once and fresh compounds were added twice per week. At the 
endpoint, cells were trypsinized and analyzed by high throughput flow cytometry to determine the 
final TOM/EGFP ratio. Consistent with our previous work, the amount of haploid cells in control 
(DMSO-treated) wells was reduced to more than half after 3 weeks, with the consequent increase 
in the diploid cell population (Figure 21A). Taking this into account, we considered a compound as 
a "haploid hit" when the deviation to the percentage of haploid cells in control wells was higher 
than 30 % and a diploid hit in the opposite situation (Figure 21A, 21B). In the primary screen we 
identified a total number of 19 compounds favoring haploidy and 18 favoring diploidy. However, 
since the readout used was based on tdTomato/EGFP ratios and not DNA content, we next 
performed a detailed evaluation of the initial hits using the DNA content dye Hoechst as a direct 
readout for ploidy. For this, we first used freshly cell-sorted haploid HAP1 cells and treated them 
with the 19 haploid and 18 diploid hits for up to four weeks. From two independent validation 
rounds, we could finally verify 6 compounds that consistently increased the fraction of haploid cells 
(Figure 21C) and 5 compounds favoring the diploid state (Figure 21D).  
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Figure 21: Chemical screening to identify compounds stabilizing haploidy or diploidy. (A) 
Schematic representation of the screening procedure. tdTomato-expressing haploid and EGFP-
expressing diploid HAP1 cells were mixed in a ratio of 4:1 and further cultured in media supplemented 
with 978 FDA-approved drugs during the course of 3 weeks. Screening evaluation was performed by 
high throughput flow cytometry. (B) Summary graph representing the percentage of deviation compared 
to DMSO-treated control cells for the 978 compounds evaluated. Every dot represents one compound 
and 0% deviation represents no change compared to the control. A compound was classified as haploid 
hit when a total deviation of 30% or higher of tdTomato-positive cells compared to the control was found 
at the end of the screening. A compound was classified as diploid hit when a total deviation of 30% or 
lower of tdTomato-positive cells compared to the control was found at the end of the screening. (C) 
Validation of haploid hits by DNA content staining in haploid HAP1 cells shown before and 26 days after 
drug treatment. G1 haploid cells are labeled in red. (D) Validation of diploid hits by DNA content 
staining in haploid HAP1 cells shown before and 19 days after drug treatment. G1 haploid cells are 
labeled in red.  
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Among the compounds stabilizing haploidy we found, in a ranked order: 1) DAB (10-
Deacetylbaccatin-III), a precursor of the chemotherapeutic drug Paclitaxel with unknown target 
(Guéritte-Voegelein, Sénilh, David, Guénard, & Potier, 1986; B. J. Li et al., 2017); 2) Regorafenib, 
a multikinase inhibitor used in several cancer treatments (Abou-Elkacem et al., 2013; Bruix et al., 
2017; Demetri et al., 2013; Grothey et al., 2013; Wilhelm et al., 2011); 3) Elvitegravir, an integrase 
inhibitor of the human immunodeficiency virus (HIV) (Shimura et al., 2008); 4) Nilotinib, a clinically 
approved inhibitor of the tyrosine kinase cAbl for the treatment of chronic myeloid leukemia (Wyse, 
Brundin, & Sherer, 2016); 5) Resveratrol, a compound originally thought to activate SIRT1, that 
has been explored to treat diseases affected by abnormal metabolic control, inflammation and cell 
cycle defects (Berman, Motechin, Wiesenfeld, & Holz, 2017); and 6) Diclazuril, an anticoccidial 
used in the prevention of bovine coccidiosis (Zechner et al., 2015). Remarkably, all 5 compounds 
favoring the diploid state (Mevastatin, Lovastatin, Fluvastatin, Atorvastatin and Simvastatin) target 
the same enzyme (Hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase) and belong to the 
class of statins. These compounds are in the clinic as one of the most commonly prescribed 
medications worldwide to reduce blood cholesterol levels (Ramkumar, Raghunath, & Raghunath, 
2016).  
 
 
2. DAB selects for cells with lower ploidy 
 Given that DAB was the compound showing the highest stabilization of haploidy in HAP1 
cells, we next investigated the resons behind this phenomenon. First, in order to further evaluate 
the potency of DAB as a stabilizer of haploidy, we mixed haploidTOM and diploidEGFP HAP1 cells in a 
1:4 ratio. This initial distribution led to a complete loss of the haploidTOM cell population in only few 
days. Remarkably, the DAB treatment not only maintained the haploidTOM cell population, but this 
actually increased to up to almost 50% (Figure 22A). This result suggested that diploid cells are 
preferentially affected by DAB and are lost during the course of our experiment. Given the previous 
experiments, we next investigated if the effects of DAB on mixed haploid/diploid cultures could 
reflect a more general role of this drug in selecting for cells with a lower ploidy. As mentioned in the 
introduction, the HAP1 line derives from KBM7 cells, which in the patient originally contained a mix 
of near haploid and hyperdiploid cell clones (Andersson et al., 1995; Carette et al., 2011; Kotecki et 
al., 1999). Similarly, cell sorting of early passage HAP1 cells allowed us to isolate, on top of the 
haploid and diploid cell populations, a tetraploid HAP1 cell population. To test our hypothesis, we 
first cultured haploid and tetraploid HAP1 cell populations with DAB for 20 days. Flow cytometry 
analysis revealed that while haploidy is clearly maintained upon DAB treatment, near-tetraploid 
cells were particularly sensitive to his compound. In fact, the few surviving cells from the tetraploid 
culture contained a diploid genome, likely representing cell contaminants from the cell sorter that 
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were enriched during the experiment (Figure 22B). To further test a potential ploidy-dependent 
toxicity of DAB, we infected tetraploid HAP1 cells with lentiviruses encoding for blue fluorescent 
protein (BFP) and mixed them with haploidTOM and diploidEGFP HAP1 at a ratio of 1:1:1. Consistent 
with the lower fitness of haploid and tetraploid cells (Andreassen, Lohez, Lacroix, & Margolis, 
2001; Ganem & Pellman, 2007; Olbrich et al., 2017), haploidTOM and tetraploidBFP HAP1 cells 
gradually disappeared from the mixed cultures while diploidEGFP HAP1 cells became enriched. In 
contrast, DAB treatment strongly favored the haploidTOM HAP1 cell population while decreasing the 
growth of diploidEGFP cells and more remarkably, led to the virtual disappearance of the 
tetraploidBFP HAP1 cell population (Figure 22C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We next explored if the effects of DAB in selecting for lower ploidy were conserved in other 
cell types. For this, sorted mhaESCs cultures were treated with DMSO or DAB for a total of 14 
days. Similar to HAP1 cells, a continuous DAB treatment in mhaESCs helped to maintain the 
haploid population (Figure 23A). Next, we took advantage of the spontaneous appearance of 
tetraploid mouse embryonic fibroblasts (MEFs) in SV40-transformed diploid cultures (Ganem & 
Figure 22: DAB selects for cells with lower ploidy. (A) tdTomato-expressing haploid and EGFP-
expressing diploid HAP1 cells were mixed in a ratio 1:4 and cultured untreated or treated with 10 µM 
DAB for 18 days. DNA content analyses were performed at day 0 and day 18. (B) DNA content analysis 
of haploid, diploid and tetraploid HAP1 cells untreated or treated with 20 µM DAB treatment for 20 days. 
G1 haploid cells are labeled in red, G2 tetraploid cells are labeled in dark blue. (C) tdTomato-expressing 
haploid, EGFP-expressing diploid and BFP-expressing tetraploid HAP1 cells were mixed in a ratio of 
1:1:1 and cultured untreated or treated with 10 µM DAB for 19 days. Percentage of cell population was 
evaluated by flow cytometry.  
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Pellman, 2007). Diploid MEFs expressing EGFP and tetraploid MEFs expressing tdTomato were 
mixed at a 1:4 ratio. In agreement with our previous results, DAB treatment of the mixed culture for 
a total of 13 days showed a dramatic decrease of the tetraploidTOM cell population (Figure 23B). 
Finally, we also tested DAB toxicity on diploid and tetraploid iPSCs. Similar to MEFs, we infected 
the diploid iPSCs with lentiviruses encoding for EGFP and the tetraploid iPSCs with lentiviruses 
encoding for tdTomato and mixed them in a 1:3 ratio. Once again, DAB treatment of the mixed 
culture for 6 days showed led to a decrease of the tetraploidTOM cell population (Figure 23C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Finally, and based on these results, we tested if DAB could also select for cells with lower 
ploidy in mixed population of cancer cells. To do this, we took advantage of recently generated 
diploid and tetraploid clones of the colon cancer cell line DLD1 (Viganó et al., 2018). As earlier 
Figure 23: DAB selects for cells with lower ploidy in cell types of different origin. (A) mhaESCs 
were cultured untreated or treated with 5 µM DAB over 14 days. DNA content staining was performed at 
day 0 and day 14. G1 haploid cells are labeled in red. Two independent experiments were performed. 
(B) tdTomato-expressing tetraploid and EGFP-expressing MEFs were mixed in a ratio of 4:1 and 
cultured untreated or treated with 10 µM DAB for 13 days. DNA content was evaluated by flow cytometry 
and numbers show the percentage of the individual populations. Three independent experiments were 
performed but one representative is shown. (C) tdTomato-expressing tetraploid and EGFP-expressing 
diploid iPSCs were mixed in a ratio of 3:1 and cultured untreated or treated with 1 µM DAB for 6 days. 
DNA content was evaluated by flow cytometry and numbers show the percentage of the individual 
populations. 
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described, we infected the diploid DLD1 cells with lentiviruses encoding for EGFP and the 
tetraploid DLD1 cells with lentiviruses encoding for tdTomato and mixed them in a 1:9 ratio. 
Remarkably, a 23-day treatment with DAB led to a dramatic decrease of the tetraploidTOM cell 
population (Figure 24). Collectively, these results indicate that DAB is able to select for cells with 
lower ploidy in mixed mammalian cell cultures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. DAB increases the time in mitosis by activating the SAC 
 We next sought to investigate the molecular mechanisms driving ploidy selection upon DAB 
treatment. We first investigated if DAB generated DNA damage, which would be more toxic on 
cells with more DNA or higher ploidy. To test this, we evaluated the levels of a phosphorylated 
H2AX (γH2AX), a widely used marker of DNA damage and replication stress, by high-throughput 
microscopy using the topoisomerase poison Doxorubicin as a positive control (Figure 25A). These 
experiments did not reveal a major genotoxicity of DAB. Next, we investigated if DAB could perturb 
DNA replication by measuring the incorporation of the nucleotide analog EdU (5-ethynyl-2’-
deoxyiridine) (Figure 25B). However, we also failed to see any significant impact of DAB in 
hampering DNA replication. Consistent with these results, karyotype analyses failed to reveal any 
obvious signs of genomic instability such as chromosomal breaks, gains or rearrangements, in 
mhaESCs treated with DAB for 21 days (Figure 25C, 25D). These results are important since they 
support the use of DAB as a chemical tool to stabilize the haploid state in mammalian cell cultures. 
 
 
 
Figure 24: DAB treatment selects for 
lower ploidy cells in the colon cancer 
cell line DLD1. tdTomato-expressing 
diploid and EGFP-expressing tetraploid 
DLD1 cells were mixed in a ratio 1:9 and 
cultured untreated or treated with 30 µM 
DAB for 23 days. DNA content analyses 
were performed at day 0 and day 23. 
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After ruling out potential effects of DAB on DNA replication and repair, we explored the 
potential link of this compound with mitosis. As mentioned above, DAB is a precursor of the 
microtubule targeting drug Paclitaxel. This, together with the fact that haploid cells suffer from 
chromosome segregation problems in mitosis, led us to explore if DAB could work somewhat 
similarly to Paclitaxel in its effects on haploid cells. Supporting our hypothesis, a low dose of 
Paclitaxel was also able to promote haploidy in a mixed (1:4) culture of haploid and diploid HAP1 
cells (Figure 26A). Paclitaxel stabilizes mitotic spindle microtubule polymers by binding to tubulin 
thus impairing the formation of a properly aligned metaphase plate. This leads to the activation of 
the spindle activation checkpoint (SAC) with the consequent mitotic lengthening and apoptosis. To 
assess whether DAB could also activate the SAC we used a U2OS cell line expressing a CyclinB-
Figure 25: DAB does not induce genomic instability. (A) High throughput microscopy analysis of 
γH2AX intensity per nucleus in haploid and diploid HAP1 cells treated with increasing doses of DAB 
for 24 h. Centerline indicates mean values. γH2AX-induction by Doxorubicin was used as control. One 
experiment is shown but three independent ones were performed. (B) High throughput microscopy 
analysis of EdU intensity in haploid and diploid HAP1 cells treated with increasing doses of DAB for 24 
h followed by 30 min EdU pulse. Centerlines indicate mean values. Three independent experiments 
were performed but one representative is shown. (C) Representative examples of metaphase spreads 
from haploid, diploid and tetraploid HAP1 cells at day 0 and day 21 untreated or treated with 10 µM 
DAB treatment. (D) Average number of chromosomes from the metaphase spreads obtained in (C). 19 
metaphases or more per condition were analyzed. Centerline indicates mean values. 
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mCherry fusion protein, and monitored the time required to degrade cyclin B after mitotic entry 
(Figure 26B). Cyclin B rises to maximum levels of expression at the nuclear envelope breakdown 
and is lowest at anaphase onset due to the silencing of the SAC and the consequent activation of 
APC (that degrades cyclin B). Similar to Nocodazol or Paclitaxel although to a lower extent, DAB 
increased the timed to achieve CyclinB-mCherry degradation upon mitotic entry, indicating that 
DAB also activates the SAC, extending the duration of mitosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. DAB activates the SAC in a ploidy-dependent manner 
We next asked whether activation of the SAC could explain the ploidy-dependent toxicity 
observed after treatment with DAB. To test this, we first measured the mitotic index (percentage of 
cells accumulated in mitosis) in HAP1 cells of different ploidy by analyzing the number of phospho-
histone H3 (pH3)-positive cells after DAB treatment (Figure 27A). While untreated haploid, diploid 
or tetraploid cells showed a similar percentage of mitotic cells, the treatment with DAB led to a 
ploidy-dependent accumulation of mitotic cells. This observation was recapitulated in mouse ESCs 
(Figure 27B). Further supporting this view, MAD2 intensity per kinetochore cells was increased in a 
ploidy-dependent manner in HAP1 cells and further increased upon DAB-treatment (Figure 27C). 
 
 
 
Figure 26: DAB mimics low-dose Paclitaxel treatment. (A) tdTomato-expressing haploid and EGFP-
expressing diploid HAP1 cells were mixed in a ratio of 1:4 and cultured untreated or treated with 15 nM 
Paclitaxel for 20 days. DNA content analyses were evaluated by flow cytometry and numbers indicate 
the percentage of the individual populations. (B) Graph showing the relative fluorescence levels of 
CyclinB-mCherry over time upon treatment of the stated compounds in a U2OS cell line expressing 
CyclinB-mCherry. Cyclin B degradation was monitored by live-cell imaging and levels evaluated from the 
nuclear envelope breakdown (NEBD) until anaphase. Only cells with apparent cell division were 
monitored and a minimum of 10 cell divisions was evaluated per condition.  
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 Finally, haploid, diploid and tetraploid HAP1 cells were infected with lentiviruses expressing 
a fusion protein between the Histone 2B and RFP (H2B-RFP) and used to perform live-cell video 
recording to monitor mitotic dynamics and overall cell cycle progression upon DAB treatment. This 
experiment allowed us to quantify the time spent by each cell in interphase and mitosis. In addition, 
we could estimate the SAC-dependent (red; from NEBD to metaphase plate formation) and SAC-
independent (green; from metaphase plate formation to cytokinesis) times of each mitosis. These 
analyses revealed several interesting observations: First, SAC-dependent, but not SAC-
independent times increase in a ploidy-dependent manner following DAB incubation (Figure 28A, 
B, C), further revealing that DAB activates the SAC. Second, the treatment with DAB was toxic in a 
ploidy-dependent manner. Third, upon DAB treatment most tetraploid cells (and some diploids) 
remain trapped in metaphase due to a constitutive activation of the SAC, ultimately leading to cell 
death. In contrast, most haploid cells can complete a successful mitosis even in the presence of 
DAB (Figure 28A). 
Figure 27: Ploidy-dependent activation of the SAC upon DAB treatment: (A) and (B) High 
throughput microscopy analysis showing the percentage of phospho-histone 3 (pH3)-positive 
haploid, diploid and tetraploid HAP1 cells (A) or haploid and diploid mouse ESCs (B) treated with 
increasing doses of DAB for 16 h (A) or 6 h (B). Two (B) and three (A) independent experiments 
were performed but one representative is shown. (C) Immunofluorescence staining of MAD2 
from HAP1 cells treated with 10 µM DAB o/n. MAD2 intensity on regions colocalizing with ACA 
(centromeric region) was analyzed in cells in prometaphase (n=5-19 cells).  
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Given that Paclitaxel is a microtubule-targeting drug, we asked if DAB also has an impact 
on spindle morphology. To evaluate this, haploid, diploid and tetraploid HAP1 cells were treated 
with DAB and mitosis were analyzed by confocal microscopy (Figure 29A). Consistent with the 
previous experiments, all tetraploid and most diploid HAP1 cells treated with DAB were trapped in 
prometaphase, whereas cells in anaphase/telophase could be easily observed in DAB-treated 
haploid HAP1 cells. Moreover, DAB treated diploid and tetraploid HAP1 cells showed a significant 
Figure 28: SAC-dependent time increased upon DAB treatment in a ploidy dependent-manner. (A) 
Schematic representation of time spent in mitosis by individual, RFP-H2B expressing, haploid, diploid 
and tetraploid HAP1 cells untreated or treated with 10 µM DAB. Light gray bars showed the time in 
interphase, red bars showed the SAC-dependent time in mitosis and green bars showed the SAC-
independent time in mitosis. SAC-dependent time was defined as the time between chromosome 
condensation and metaphase plate observation. SAC-independent time was defined as the time 
between metaphase plate observation and cytokinesis. Cells were monitored every 4 min for a total of 
16 h and a minimum of 30 cells per condition was analyzed. (B) and (C) Graphs showing SAC-
dependent (B) and SAC-independent time (C) in haploid, diploid and tetraploid HAP1 cells quantified 
from (A). 
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increase of spindle aberrancies in prometaphase compared to haploid HAP1 cells (Figure 29B, 
29C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Prometaphase spindle defects induced by DAB treatment. (A) Haploid, diploid and 
tetraploid HAP1 cells were treated with 10 µM DAB for 16 h and processed for immunofluorescence 
staining. Representative immunofluorescence staining is shown. DNA was stained with DAPI (grey), 
αTubulin in blue, anti-centromeric antibody staining in green and pH3 in red. Red arrows show a 
haploid cell in anaphase, white arrows indicating aberrant prometaphases in diploid and tetraploid 
cells. (B) Quantification of immunofluorescence staining from A shows the percentage of cells in the 
different phases of mitosis. A minimum of 20 mitosis per condition were evaluated. (C) Percentage of 
aberrant prometaphase spindles from the cells in (B). An aberrant prometaphase spindle was defined 
as spindle with lagging chromosomes and/or aberrant tubulin. 
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All taken together, our results indicate that DAB is a weak SAC activator, likely working by 
slightly perturbing microtubule function. Whereas haploid cells, due to their lower ploidy, might be 
able to complete the alignment of mitotic chromosomes in the metaphase plate even in the 
presence of DAB, diploid, and even more, tetraploid, cells show a significant impairment of mitotic 
progression by this drug ultimately leading to cell lethality. Moreover, the fact that our results are 
recapitulated with low-dose Paclitaxel reveal, for the first time, that a slight activation of the SAC 
can select for cells with lower ploidy in mixed populations of mammalian cells. 
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1. Evidences for a ploidy checkpoint in mammalian cells 
In one of the first manuscripts reporting the derivation of haploid cells from frogs, Freed 
described the phenomena of “diploidization” with the following words: “Study of the chromosomes 
of dividing cells in the cultures shows that a minority of diploid cells (five per cent or less) occur in 
the early subculture generations. These increase, with succeeding transfers, relative to the haploid 
population, until eventually they become the majority type. Such diploidized cultures of haploid 
origin do not, however, grow at the same rate as do the cultures of normal diploid origin. This is 
taken to suggest the origin of the diploidized cells by an endomitotic process” (Freed, 1962). 
Similar observations were further described in haploid cells derived from Drosophila, the near-
haploid human cancer cell line KBM7 and in haploid ESC lines isolated from different animals 
(Debec, 1984; Kotecki et al., 1999; Martin Leeb & Wutz, 2012; W. Li et al., 2014; Sagi et al., 2016; 
Yilmaz et al., 2016). In agreement with these published reports, we also observed a rapid increase 
of diploid cells in the human cancer cell line HAP1 as well as in newly generated mhaESCs upon 
culturing suggesting the existence of a true conversion of haploid into diploid cells. However, 
contrary to the established view of “diploidization”, we observed that this is a rare event. By 
performing competition assays between haploid and diploid cells, we detected a reduced fitness in 
the haploid population compared to their diploid counterparts (Figure 9A, 9B). The ability of diploid 
cells to outcompete the growth of the haploids seems to be a general phenomena among all 
reported haploid cell cultures (Debec, 1984; Kotecki et al., 1999; Martin Leeb & Wutz, 2012; W. Li 
et al., 2014; Sagi et al., 2016; Yilmaz et al., 2016). Yet, interestingly, this does not seem to be the 
case for haploid cells isolated from the fish Danio rerio or the monkey Macaca fascicularis (Yang et 
al., 2013; Yi et al., 2009). Haploid monkey and zebrafish ESC lines were stable without further 
manipulation in their haploid status for up to 140 days and 500 days of culture, respectively. 
However, the reasons that enable stable haploid ESCs in these animals remain unknown. 
Competition experiments led us to hypothesize that single-cell sorted haploid cells should 
remain haploid. Indeed, we have here demonstrated that this is the case, not only for HAP1 cells 
but also for the unstable mhaESCs (Figure 9C, 12F). Of note, in these haploid cultures we 
detected a small, but progressive, emergence of diploid cells, which could only be explained by 
real diploidization since these cell lines originate from a single haploid cell. Although diploidization 
is a very rare event, once diploid cells originate they progressively take over the culture due to their 
better proliferation capacities. While the underlying mechanism of diploidization in haploid 
mammalian cells is unknown, we speculate that it might be similar to what occurs during 
tetraploidization of diploid cells. In this regard, mitotic nondisjunction by furrow regression leads to 
cytokinesis failure and is a common mechanism to generate tetraploid cells. In fact, nondisjunction 
was previously suggested to explain the diploidization of KBM7 (Bürckstümmer et al., 2013), 
although there is no data to support this idea. Besides mitotic non-disjunction, endoreplication 
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(cells replicate the genome repeatedly skipping mitosis), endomitosis (skipping cytokinesis), cell 
fusion or mitotic slippage (a prolonged activation of the SAC leads to the exhaustion of cyclin B 
levels so that cells exit mitosis without anaphase or cytokinesis) have been reported as sources of 
tetraploidy. While formal proof is still lacking, based on our findings of prolonged mitosis and 
chromosome mis-segregation, mitotic slippage or non-disjunction seem as plausible candidates of 
the diploidization of mammalian haploid cells. 
 
In what regards to the reasons behind the reduced fitness of mammalian haploid cells, this 
is explained by the activation of a P53-dependent cytotoxic response that limits their viability. In 
turn, P53 activation is due to chromosome segregation defects including lagging chromosomes, 
anaphase bridges and micronuclei explaining. Consistent with the presence of a P53-dependent 
haplopidy checkpoint, P53 deletion rescued the viability of mhaESCs and helped to stabilize 
haploidy in culture (Figure 12D, 12E). Interestingly, numerous studies in tetraploid and aneuploid 
cells have revealed that these cells are also prone to accumulate chromosome segregation defects 
during mitosis, and their growth is also limited by the activation of P53 (Andreassen et al., 2001; 
Ganem et al., 2014; Ganem & Pellman, 2007; M. Li et al., 2010; Thompson & Compton, 2010). 
Given the similarity of these phenomena, we here wish to suggest the existence of a general 
"ploidy checkpoint", which limits the expansion of cells with an altered ploidy by P53-dependent 
cytotoxic or cytostatic responses (Figure 30).  
 
 
 
 
 
 
 
 
 
 
 
 How haploidy, or aneuploidy and tetraploidy for that matter, leads to P53 activation is not 
fully understood. In yeast, cell size is controlled by Pom1, a cell-division inhibitory factor is diluted 
as cells grow in size (Martin & Berthelot-Grosjean, 2009; Moseley, Mayeux, Paoletti, & Nurse, 
2009). While there seems to be no cell-size control in more complex pluricellular organisms (Leslie, 
2011), organ size is regulated by the Hippo pathway, which for instance regulates cell numbers in 
postnatal livers (Lloyd, 2013). Interestingly, the group of David Pellman showed that the Hippo 
Figure 30: A P53-dependent ploidy checkpoint in mammalian cells. A non-euploid mammalian cell 
detects by unknown mechanism the chromosome number aberrancies. These cells accumulate 
chromosome mis-segregation defects leading to a P53-dependent cytotoxic reponse.  
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pathway could be responsible for the activation of P53 in mammalian tetraploid cells, through a 
pathway involving the LATS2 kinase (Ganem et al., 2014). However, we could not detect activation 
of the Hippo pathway in mammalian haploid cells. While these results were not incorporated into 
this thesis, we also performed quantitative mass spectrometry and microarray in haploid and 
diploid mammalian cells, trying to identify imbalances that could explain the reduced fitness in 
haploid cells. Unfortunately, and consistent with previous transcriptomic data (Martin Leeb & Wutz, 
2012), none of these approached revealed major differences that could explain our observations. 
Nevertheless, given the above mentioned similarities between haploid, aneuploid and tetraploid 
cells, it could simply be that the mitotic spindle has evolved to deal with a specific amount of 
DNA/chromosomes, and that any deviation from the natural amount affects chromosome 
segregation, ultimately leading to genome instability and the activation of P53. Our data revealing 
chromosome segregation problems, and a noisy arrangement of chromosomes at the spindle in 
mammalian haploid cells supports this view (Figure 15, 18). 
In summary, we here propose the existence of a ploidy checkpoint that is responsible for 
the gradual loss of haploidy that is observed in mammalian haploid cell cultures. Based on our 
discovery, we have been able to define two strategies (P53-deficiency or single cell sorting), 
capable of stabilizing the haploid state in culture. Nevertheless, P53-deficiency will stabilize 
haploidy at the extent of genomic instability, so that we favor single-cell sorting. These simple 
procedures should significantly facilitate future work with mammalian haploid cells. 
 
 As mentioned above, while mammalian haploid cell lines have been generated, 
differentiation seems to significantly accelerate diploidization rates, and nobody has yet succeeded 
in generating mammalian haploid tissue. For instance, in the original study reporting the derivation 
of mhaESCs, it was shown that these could contribute to adult tissue when aggregated to WT 
diploid ESCs, but this tissue was made of diploid cells (Martin Leeb & Wutz, 2012). A follow-up 
study reported that a haploid karyotype was incompatible with postgastrulation in chimeric embryos 
with high contribution from the haploid cells (M. Leeb et al., 2012). Based on our finding that P53-
stabilizes haploidy in vitro, we immediately asked whether this genetic condition would also enable 
the generation of differentiated haploid mouse tissue. Previous work had shown that while 
tetraploid ESCs also activate P53-dependent apoptosis, P53-deletion enabled the generation of 
late-stage mouse tetraploid embryos (Horii et al., 2015). In addition, there have been reports of 
liveborn tetraploid human infants (Golbus, Bachman, Wiltse, & Hall, 1976; Horii et al., 2015; Pitt et 
al., 1981; Shiono, Azumi, Fujiwara, Yamazaki, & Kikuchi, 1988), such that it seemed plausible that 
the generation of a haploid mammal, or at least embryo, could be achieved. Besides its general 
interest in developmental biology, the access to mammalian haploid tissue could significantly 
facilitate forward genetic screenings in vivo. 
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 We initially started by trying to differentiate P53KO mhaESCs in vitro, with the aim to 
generate a primary differentiated haploid cell line that we could use for further studies such as 
genetic screens. However, while the cells differentiated normally, they invariably became diploid. 
Besides this in vitro work, we also tried to generate haploid mammalian tissue. To do so, and trying 
to maximize the contribution of haploid cells to a specific organ, we used mice carrying a mutation 
in the tyrosine catabolic enzyme fumarylacetoacetate hydrolase (FAH) that is deleterious for liver 
cells (Azuma et al., 2007; Espejel et al., 2010). The viability of these mice can be rescued by two 
means: 1) by the constant supply of the drug NTBC or 2) by microinjecting wild type stem cells 
(e.g. iPSCs) into FAH-depleted blastocysts, which leads to viable chimeric mice where most of the 
liver is derived from functional hepatocytes differentiated from the wild type cells (Espejel et al., 
2010). We hypothesized that the microinjection of P53-; KFPT mhaESCs into FAH-deficient 
blastocysts could lead to viable mice with livers made to a large extent from mhaESCs-derived 
cells. We also chose to focus on the liver since it is rather tolerant to genomic instability and/or 
ploidy alterations, as exemplified by the fact that polyploidy gradually increases with age in the 
mammalian liver (Gentric & Desdouets, 2014; Medvedev, 1986). While the embryos we obtained 
from these experiments did not show a preferential accumulation of the mhaESCs-derived cells in 
their livers, which we believe is due to the maternal contribution of FAH, we did obtain embryos 
with significant contribution of the P53-deficient mhaESCs in various organs, which we could 
identify on the basis of Katushka expression (Figure 19 B, 19C). We have promising preliminary 
data based on centromeric FISH intensities, which will be consistent with the presence of haploid 
cells in certain tissues such as the dermis or the brain in these embryos (Figure 20). While we are 
currently performing additional experiments to formally proof that these cells are indeed haploid, it 
might well be that we have indeed succeeded in making mammalian tissue containing haploid 
cells. 
 
 
2. Chemical stabilization of haploidy 
Given the poor stability of the haploid state in mammalian cell lines, it would be highly 
desirable to have compounds capable of overcoming this limitation. Under this premise, we here 
carried out a chemical screening to identify compounds that either select for haploid cells or diploid 
cells in a mixed culture. From a total of 978 compounds, six compounds were identified (and 
validated) to stabilize haploidy, and 5 to accelerate the loss of haploid cells from these cultures 
(Figure 21C, 21D). 
 The five compounds favoring the diploid condition identified in our screen belong to 
the group of statins, a widely used class of lipid-lowering drugs. Statins are inhibitors of the HMG-
CoA reductase, the rate-limiting step in the mevalonate pathway, playing a central role in 
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cholesterol synthesis. Thus, these compounds are generally used to decrease serum cholesterol 
levels and thus to prevent cardiovascular disease (Demierre, Higgins, Gruber, Hawk, & Lippman, 
2005). At the cellular level, the mevalonate pathway is crucial for maintaining the structure and 
function of cell membranes. Interestingly, statins have been recently identified to increase cell size 
in a drug screening aiming to find compounds regulating cell size control (Miettinen & Björklund, 
2015). In fact, it was shown that statins increase the overall duration of the cell cycle with the 
consequent slowdown in proliferation and increased cell size. In addition, statins also increase the 
cellular protein content through autophagy mediated by the mevalonate pathway. It is tempting to 
speculate that haploid cells could display a misbalance between cell size, membrane area and 
protein content compared to the diploid cells. Indeed, we observed that haploid cells do not have 
half of the size or half of the protein content compared to their corresponding diploid cells. Thus, 
additional interference into cell size control by using statins could lead to a selective disadvantage 
for the haploids upon cell culture. As an alternative possibility, the reduction of proliferation after 
statin treatment in cells, could selectively affect haploid cells to a greater extent as they have 
already intrinsic poor growth capabilities (as described above). Of note, HMG-CoA-reductase 
inhibition with statins has been shown to be rather pleiotropic, leading to anti-inflammatory, 
immunomodulatory, anti-angiogenetic and pro-apoptotic effects. Hence, we cannot rule out that the 
effect of statins on ploidy is independent of the HMG-CoA-reductase. However, and while we tried 
to address this experimentally, the essentiality of this enzyme precluded us to formally test this 
possibility by generating knockouts in haploid cells. 
 Of note, lipid metabolism might play a more general role in cells with an altered ploidy. In a 
recent study, the group of Angelika Amon performed an unbiased drug screening aiming for the 
discovery of drugs selectively killing aneuploid cells. In such a screen, they found that inhibition of 
the UDP glucose ceramide glycosyltransferase, an essential enzyme in the sphingolipid 
homeostasis, induces apoptosis in aneuploid cells via increased ceramide levels (Tang et al., 
2017). In addition, they report that aneuploid cells display elevated levels of ceramides and 
therefore harbor an intrinsically dysregulated sphingolipid metabolism. Although the sphingolipid 
pathway and the mevalonate pathway do not interplay directly with each other, they are tightly 
intertwined and cross talk between these pathway occurs (Gulati, Liu, Munkacsi, Wilcox, & Sturley, 
2010). Taken together with our work, we could speculate about the importance of lipid biosynthesis 
for mammalian cells with an altered ploidy such as haploid cells. 
 
 In regards to the six compounds that facilitate the maintenance of haploid cells, we focused 
on studying in detail the mechanism of action of DAB, the top hit of our screening. DAB is a 
chemical compound isolated from european yew trees and used as precursor in the synthesis of 
Paclitaxel (B. J. Li et al., 2017; Malik et al., 2011). Based on the chemical similarity between DAB 
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and Paclitaxel, we speculated that the mechanism by which DAB favors haploidy could resemble 
what Paclitaxel does on cells. In fact, we observed that a low-dose treatment of Paclitaxel also 
selects for haploid cells in a culture mix with diploids (Figure 26A). Moreover, either DAB also 
selected for cells with lower ploidy in mixed cultures of haploid/diploid/tetraploid mammalian cells, 
revealing that SAC activation provides one way to selectively kill cells with a higher number of 
chromosomes. Although we cannot be certain that the target of DAB is tubulin, we have clearly 
shown that DAB, similar to Paclitaxel, activates the SAC and elongates mitosis (Figure 26B, 27, 
28). These results demonstrated that interference with the mitotic process is an effective method to 
select haploid cells. Along these lines, recent studies have revealed that WEE1 (Takahashi et al., 
2014) or CDK1 inhibition (He et al., 2017) could facilitate the maintenance of haploid cells in vitro, 
which however is somewhat surprising given that these two enzymes have opposing roles in 
regulating mitotic entry. Moreover, we should mention that neither of these inhibitors had a 
significant effect on stabilizing haploidy in our hands, though we cannot rule out that different 
experimental conditions could influence the outcome of the experiments. 
 
Regardless of these differences, it seems clear that mitosis problems lie at the core of the 
reduced fitness of mammalian haploid cells and as such, treatments directed to alter mitosis might 
offer a solution to this problem. But, how would an activated SAC select for cells in a ploidy 
dependent manner? We speculate that cells with a higher ploidy need more time in mitosis to 
properly attach and bi-orientate all chromosomes to the kinetochores before proceeding to the 
anaphase. In other words, it is intuitive to think that the more chromosomes the longer time a cell 
needs to organize the metaphase plate and proceed through mitosis. If microtubules are 
challenged, this would further aggravate the situation and the effect would again be proportional to 
the number of chromosomes that need to be properly aligned. Accordingly, when cells are treated 
with DAB, the SAC-dependent time increases in a ploidy dependent manner (Figure 31). 
Supporting this general idea, the SAC is not essential in organisms carrying few chromosomes 
such as Drosophila melanogaster (4 chromosomes) or Caneorhabditis elegans (6 chromosomes), 
likely since they can arrange their chromosomes at the metaphase plate very fast (Kitagawa, 2009; 
Orr, Bousbaa, & Sunke, 2006). Moreover, and to our surprise, MAD2, an essential component of 
the SAC, is not essential in the HAP1 cell line (Blomen et al., 2015) (Raaijmakers et al., 2018). 
However, HAP1 cells derive from a cancer cell line and have been subjected to multiple selections, 
so that it is possible that they have selected for mutations that enable their growth in the haploid 
state.  
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In support to the concept that SAC-activating drugs can be preferentially toxic for cells with 
more chromosomes, the SAC has been shown to work as a rheostat rather than an all-or-nothing 
checkpoint (Collin et al., 2013). In fact, the strength of SAC activation depends on the number of 
signaling centers and critically on the amount of MAD2 recruited to kinetochores. Consistent with 
this, kinetochore-attached MAD2 levels correlated with the number of chromosomes in our 
experiments and were further increased upon DAB treatment in a ploidy-dependent manner 
(Figure 27C). This reinforced the idea that DAB allowed the survival of cells with lower ploidy due 
to their reduced time required to organize the metaphase plate. It remains to be tested whether 
other SAC-activating drugs, such as Nocodazole (inhibits reversibly the microtubule 
polymerization) or Monastrol (inhibits mitotic kinesin Eg5), can also select cells in a ploidy-
dependent manner. However, these compounds have a more profound impact on microtubules 
than Paclitaxel and they might indistinctly affect haploid or diploid cells.  
 
We are currently investigating whether the use of DAB can help the generation of mhaESCs, or the 
development of mammalian haploid tissue. Nevertheless, and besides its usefulness to stabilize 
Figure 31: Ploidy-dependent effect upon DAB treatment. DAB increases the SAC-dependent 
time in a ploidy-dependent manner. In haploid cells the SAC-dependent time is overall increased 
upon DAB treatment but short enough to allow most of the cells to exit from mitosis. However, 
with increasing ploidy, the SAC-dependent time under treatment increases and the exit of 
mitosis becomes precluded. 
 
DISCUSSION	 	
 
100 
the haploid state, the capacity of DAB to select for cells with lower ploidy in mixed cultures offers 
interesting possibilities. For instance, we are currently exploring if DAB can be used to selectively 
eliminate aneuploid cells containing 1 additional chromosome from mixed cultures. If this holds, it 
would be interesting to test if DAB could be in general used as a way to select for euploid cells in 
various cultures (e.g. ESCs). In addition, and while to our knowledge DAB has not been used 
medically, given the high prevalence of aneuploid or polypoid cells in cancer, DAB or lower doses 
of Paclitaxel could have potential in selectively killing these cells in vivo. 
In addition to DAB, we identified five more compounds that stabilize the haploid state. In contrast to 
the compounds that favor diploidy, which all belong to the class of statins, there was seemingly no 
common mechanism of action within this group. The two most potent compounds stabilizing 
haploidy besides DAB were Nilotinib, a kinase inhibitor that inhibits, among others, the cABL 
tyrosine kinase and which is used in the treatment of chronic myeloid leukemia (Wyse et al., 2016) 
and Diclazuril, an antibiotic used in the prevention of bovine coccidiosis for which no known target 
exists (Zechner et al., 2015). Regardless of their assumed mechanism of action, we cannot rule 
out that the effect of these compounds on haploid cells is not due to an unknown target. For this 
reason, we are currently investigating if, similarly to DAB, they also impact mitotic progression or 
can trigger the activation of the SAC. 
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PART I: Defining a novel (ha)ploidy checkpoint 
 
1. A competitive growth disadvantage, rather than diploidization, is responsible for the 
progressive loss of haploidy in mammalian cell lines. Consistently, single-cell sorting 
facilitates the long-term maintenance of haploidy in HAP1 cells and mhaESCs. 
 
2. While diploidization (e.g. the conversion of a haploid into a diploid cell) does happen in 
haploid mammalian cells, this is a rare event. However, once diploid cells emerge they 
progressively overgrow haploids. 
 
3. The reduced fitness of mhaESCs is associated to chromosomal segregation defects 
leading to cell death within or shortly after mitosis. 
 
4. A P53-dependent cytotoxic response limits the viability of haploid HAP1 cells and 
mhaESCs. 
 
5. We suggest the existence of a general "ploidy checkpoint", which integrates observations 
made in haploid, aneuploid and tetraploid mammalian cells, by which cells with an altered 
ploidy frequently suffer from chromosome mis-segregation, leading to genomic instability, 
P53 activation and ultimately cell cycle arrest or apoptosis. 
 
6. When aggregated to diploid WT ESCs, P53-deficient mhaESCs contribute to chimeric 
embryos. 
 
7. Preliminary evidence from these experiments supports that certain embryonic organs such 
as skin, might contain haploid P53-deficient cells. 
 
PART II: Chemical stabilization of haploidy in mammalian cells 
 
1. A chemical screen led to the identification of several compounds that favor either haploid or 
diploid cells in mixed cultures. 
 
2. All identified compounds that favor the growth of diploid cells belong to the group of statins, 
drugs used to lower cholesterol levels. 
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3. DAB, a precursor of Paclitaxel, was the top hit in the class of compounds favoring the 
growth of haploid cells. 
 
4. DAB increases the time in mitosis by activating the SAC. 
 
5. DAB facilitates the long-term maintenance of haploidy in HAP1 cells and mhaESCs.  
 
6. DAB and low-dose Paclitaxel, select for cells with a lower ploidy in mixed cultures of 
haploid, diploid and tetraploid cells. 
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PART I: Definiendo un nuevo “punto de control” basado en la (ha)ploidia cellular 
 
1. Una desventaja en el crecimiento competitivo, en lugar de diploidización, es la responsable 
de la pérdida progresiva de haploidía en líneas celulares de mamífero. De forma 
consistente, la separación celular mediante técnicas de citometría de flujo de células 
individuales facilita el mantenimiento a largo plazo de la haploidía en células HAP1 y 
mhaESCs.  
 
2. Mientras que la verdadera diploidización (es decir, la conversión de una célula haploide en 
una diploide) ocurre, es un evento raro. Sin embargo, una vez que las células diploides 
aparecen en el cultivo, crecen rápidamente y desplazan a las haploides. 
 
3. La viabilidad reducida de las mhaESCs está asociada a defectos de segregación 
cromosómica que llevan a la muerte durante o poco después de la mitosis. 
 
4. Una respuesta citotóxica dependiente de p53 limita la viabilidad de las células HAP1 y 
mhaESCs. 
 
5. Sugerimos la existencia de un "punto de control” basado en la ploidía celular, que integra 
observaciones realizadas en células de mamífero haploides, aneuploides y tetraploides, en 
el que las células con un estado de ploidía alterada sufren con frecuencia una mala 
segregación cromosómica que lleva a inestabilidad genómica, activación de P53 y, 
finalmente, parada del ciclo celular o apoptosis. 
 
6. Células mhaESCs deficientes en p53 contribuyen para formar embriones quiméricos 
cuando son agregadas junto a células ESCs salvajes diploides. 
 
7. Resultados preliminares de estos experimentos sugieren que ciertos órganos 
embrionarios, como la piel, pueden contener células haploides deficientes en p53. 
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PART II: Estabilización química de la haploidía en células de mamífero  
 
1. Un análisis masivo de compuestos químicos llevó a la identificación de varios compuestos 
que favorecen el crecimiento de células haploides o diploides en cultivos mixtos. 
 
2. Todos los compuestos identificados que favorecen el crecimiento de células diploides 
pertenecen al grupo de las estatinas, compuestos usados para disminuir los niveles de 
cholesterol. 
 
3. DAB, un precursor del Paclitaxel, es el mejor dentro de la clase de los compuestos que 
favorecen el crecimiento de células haploides. 
 
4. DAB aumenta el tiempo en mitosis mediante la activación del SAC 
 
5. DAB facilita el mantenimiento de la haploidía a largo plazo de las células HAP1 y 
mhaESCs. 
 
6. DAB, así como el tratamiento con bajas dosis de Paclitaxel, selecciona las células con 
menor ploidía in cultivos mixtos de células haploides, diploides y tetraploides. 
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ANNEX
Table 2: FDA approved drug-screening library (Z145127, Selleckchem) 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
(+,-)-Octopamine HCl Immunology Others 
Octopamine (OA), a biogenic monoamine structurally related to noradrenaline, acts as a neurohormone, a neuromodulator 
and a neurotransmitter in invertebrates. 
1-Hexadecanol   Others 1-Hexadecanol is a fatty alcohol used to make other chemicals. 
10-Deacetylbaccatin-III   Others 10-Deacetylbaccatin-III is an antineoplastic agent and an anti-cancer intermediate. 
2-Methoxyestradiol Cancer HIF 
2-methoxyestradiol (2ME2) is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 ± 0.11 
µM for the inhibition of BPAEC migration. 
2-Thiouracil Endocrinology Others 2-Thiouracil is a thiolated uracil derivative that is a known antihyperthyroid agent. 
5-Aminolevulinic acid 
hydrochloride 
Neurological 
Disease Others 5-Aminolevulinic acid is an intermediate in heme biosynthesis in the body and the universal precursor of tetrapyrroles. 
9-Aminoacridine   Others   
Abitrexate (Methotrexate) Cancer DHFR Abitrexate(Methotrexate) is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. 
Acadesine 
Cardiovascular 
Disease AMPK 
Acadesine is an AMP-activated protein kinase activator which is used for the treatment of acute lymphoblastic leukemia and 
may have applications in treating other disorders such as diabetes. 
Acarbose 
Metabolic 
Disease Others Acarbose is an anti-diabetic drug used to treat type 2 diabetes mellitus and, in some countries, prediabetes. 
Acebutolol HCl 
Neurological 
Disease Adrenergic Receptor 
Acebutolol is a β-adrenergic receptors antagonist used in the treatment of hypertension, angina pectoris and cardiac 
arrhythmias. 
Aceclidine HCl   Others   
Acemetacin (Emflex) Infection COX 
Acemetacin (Emflex) is a non-steroidal anti-inflammatory drug and a glycolic acid ester of indometacin that is a 
cyclooxygenase inhibitor. 
Acetanilide (Antifebrin) 
Neurological 
Disease Others Acetanilide is an aniline derivative and has possess analgesic. 
Acetarsone   Others   
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Acetylcholine chloride 
Neurological 
Disease AChR 
The chemical compound acetylcholine (ACh) is a neurotransmitter in both the peripheral nervous system (PNS) and central 
nervous system (CNS) in many organisms including humans.  
Acetylcysteine 
Respiratory 
Disease Others 
Acetylcysteine is a pharmaceutical drug and nutritional supplement used primarily as a mucolytic agent and in the 
management of paracetamol (acetaminophen) overdose. 
Acipimox 
Cardiovascular 
Disease Others Acipimox is a niacin derivative used as a hypolipidemic agent. 
Acitretin Infection Others Acitretin is a second generation retinoid used for psoriasis. 
Aclidinium Bromide 
Neurological 
Disease AChR 
Aclidinium Bromide inhibits human muscarinic AChR M1, M2, M3, M4 and M5 with Ki of 0.1 nM, 0.14 nM, 0.14 nM, 0.21 nM 
and 0.16 nM, respectively. 
Acyclovir (Aciclovir) Infection Others Acyclovir is a synthetic nucleoside analogue active against herpesviruses 
Adapalene Inflammation Retinoid Receptor Adapalene is a third-generation topical retinoid primarily used in the treatment of acne. 
Adefovir Dipivoxil 
(Preveon, Hepsera) Infection Reverse Transcriptase 
Adefovir Dipivoxil (Preveon, Hepsera) works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B 
virus (HBV) to reproduce in the body. 
Adenine hydrochloride Cancer DNA/RNA Synthesis 
Adenine hydrochloride is a hydrochloride salt form of adenine which is a purine derivative and a nucleobase with a variety of 
roles in biochemistry. 
Adenosine (Adenocard) 
Cardiovascular 
Disease Others 
Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via 
a β-N9-glycosidic bond. 
Adiphenine HCl 
Cardiovascular 
Disease Others Adiphenine is a nicotinic receptor inhibitor with IC50 of 15 µM, used as an antispasmodic drug. 
Adrenalone HCl 
Cardiovascular 
Disease Adrenergic Receptor 
Adrenalone is an adrenergic agonist used as a topical vasoconstrictor and hemostatic, mainly acts on alpha-1 adrenergic 
receptors. 
Adrucil (Fluorouracil) Cancer DNA/RNA Synthesis Adrucil (Fluorouracil) belongs to the family of drugs called antimetabolites. 
Afatinib (BIBW2992) Cancer EGFR,HER2 
Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 
with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M 
EGFR mutant. Phase 3. 
Agomelatine   5-HT Receptor Agomelatine is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor. 
Albendazole (Albenza) Vermifuge Microtubule Associated 
Albendazole (Albenza) is a member of the benzimidazole compounds used as a drug indicated for the treatment of a variety 
of worm infestations. 
Albendazole Oxide 
(Ricobendazole) Infection Others Albendazole Oxide is a tubulin polymerization or assembly inhibitor.  
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Alfacalcidol Endocrinology Others Alfacalcidol is a non-selective VDR activator medication. 
Alfuzosin hydrochloride 
(Uroxatral) 
Cardiovascular 
Disease Adrenergic Receptor Alfuzosin (Uroxatral) is an alpha1 receptor antagonist used to treat benign prostatic hyperplasia (BPH). 
Alibendol 
Neurological 
Disease Others Alibendol is an antispasmodic,chleretic, and cholekinetic. 
Aliskiren hemifumarate 
Cardiovascular 
Disease RAAS 
Aliskiren hemifumarate is a hemifumarate salt form of Aliskiren. Aliskiren is a novel orally effective direct renin inhibitor with an 
IC50 of 0.72 nM against renin. 
Allopurinol (Zyloprim) 
Neurological 
Disease Others Allopurinol (Zyloprim) is a clinically used xanthine oxidase (XO) inhibitor ,and its IC50 value is 0.78µM. 
Allylthiourea 
Metabolic 
Disease Others Allylthiourea is a metabolic inhibitor that selective inhibits ammonia oxidation. 
Almotriptan malate (Axert) 
Cardiovascular 
Disease 5-HT Receptor 
Almotriptan malate (Axert) is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, used for the treatment of 
Migraine attacks in adults. 
Alprostadil (Caverject) Endocrinology Others Alprostadil(Caverject) is used as a drug in the treatment of erectile dysfunction and has vasodilatory properties. 
Altrenogest 
Neurological 
Disease Estrogen/progestogen Receptor Altrenogest is a progestogen structurally related to veterinary steroid trenbolone. 
Altretamine (Hexalen) Cancer Others Altretamine (Hexalen) is an anti-neoplastic agent. 
Alverine Citrate 
Digestive 
system disease Others Alverine citrate is a drug used for functional gastrointestinal disorders. 
Amantadine hydrochloride 
(Symmetrel) 
Cardiovascular 
Disease Dopamine Receptor Amantadine hydrochloride (Symmetrel) is used to treat or prevent infections of the respiratory tract caused by a certain virus 
Ambrisentan 
Neurological 
Disease Endothelin Receptor 
Ambrisentan, a highly selective antagonist of the endothelin-1 type A receptor with IC50 of 18 nM, is indicated for the 
treatment of pulmonary arterial hypertension (PAH). 
Amfebutamone 
(Bupropion) Infection AChR,Dopamine Receptor 
Amfebutamone (Bupropion) is a selective norepinephrine-dopamine reuptake inhibitor with IC50 of 6.5 and 3.4µM for the 
reuptake of dopamine and norepinephrine, respectively. 
Amfenac Sodium 
(monohydrate) Inflammation COX Amfenac Sodium monohydrate is a non-steroidal analgesic anti-inflammatory drug with acetic acid moiety. 
AMG-073 HCl (Cinacalcet 
hydrochloride) Endocrinology CaSR AMG-073 (Cinacalcet hydrochloride) represents a new class of compounds for the treatment of hyperparathyroidism. 
Amidopyrine 
Neurological 
Disease Others Amidopyrine is white crystalline substance used as an analgesic and antipyretic. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Amiloride hydrochloride 
(Midamor) 
Metabolic 
Disease Sodium Channel 
Amiloride hydrochloride (Midamor), a pyrazine compound inhibiting sodium reabsorption through sodium channels in renal 
epithelial cells. 
Amiloride hydrochloride 
dihydrate 
Cardiovascular 
Disease Sodium Channel Amiloride hydrochloride dihydrate is a potent epithelial sodium channel blocker. 
Aminocaproic acid 
(Amicar) 
Cardiovascular 
Disease Others Aminocaproic acid (Amicar) is a derivative and analogue of the amino acid lysine. 
Aminoglutethimide 
(Cytadren) Endocrinology Aromatase Aminoglutethimide (AMG, Cytadren) is an aromatase inhibitor with IC50 of 10 µM. 
Aminophylline 
(Truphylline) 
Respiratory 
Disease PDE 
Aminophylline (Phyllocontin, Truphylline) is a competitive nonselective phosphodiesterase inhibitor with an IC50 of 0.12 mM 
and also a nonselective adenosine receptor antagonist. 
Aminosalicylate sodium 
Neurological 
Disease NF-κB Sodium 4-Aminosalicylate is an antibiotic used to treat tuberculosis via NF-ÎºB inhibition and free radical scavenging. 
Aminothiazole Infection Others Aminothiazole can be used as a thyroid inhibitor and it has antibacterial activity. 
Amiodarone HCl 
Cardiovascular 
Disease Potassium Channel,Autophagy Amiodarone HCl is an antiarrhythmic drug for inhibition of ATP-sensitive potassium channel with IC50 of 19.1 µM. 
Amisulpride 
Neurological 
Disease Dopamine Receptor Amisulpride is an atypical antipsychotic used to treat psychosis in schizophrenia and episodes of mania in bipolar disorder. 
Amitriptyline HCl Infection 5-HT Receptor 
Amitriptyline inhibits serotonin receptor, norepinephrine receptor, 5-HT4, 5-HT2 and sigma 1 receptor with IC50 of 3.45 nM, 
13.3 nM, 7.31 nM, 235 nM and 287 nM, respectively. 
Amlodipine (Norvasc) 
Cardiovascular 
Disease Calcium Channel Amlodipine(Norvasc) is a long-acting calcium channel blocker with an IC50 of 1.9 nM. 
Amlodipine besylate 
(Norvasc) 
Cardiovascular 
Disease Calcium Channel Amlodipine (Norvasc) is a long-acting calcium channel blocker with an IC50 of 1.9 nM. 
Ammonium Glycyrrhizinate   Dehydrogenase Ammonium Glycyrrhizinate inhibits growth and cytopathology of several unrelated DNA and RNA viruses. 
Amorolfine Hydrochloride Infection Others Amorolfine hydrochloride is a antifungal reagent. 
Amoxicillin (Amoxycillin) 
Neurological 
Disease Others 
Amoxicillin is a moderate-spectrum, bacteriolytic, β-lactam antibiotic used to treat bacterial infections caused by susceptible 
microorganisms. 
Amoxicillin sodium (Amox) Infection Others Amoxicillin (Amox) is a moderate- spectrum, bacteriolytic, β-lactam antibiotic. 
Amphotericin B    Others Amphotericin B (AmB) is an amphipathic polyene antibiotic which permeabilizes ergosterol-containing membranes. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Ampicillin sodium Infection Others Ampicillin is a beta-lactam antibiotic that is part of the aminopenicillin family. 
Ampicillin Trihydrate Infection Others 
Ampicillin Trihydrate is a β-lactam antibiotic, which inhibits bacterial cell-wall synthesis (peptidoglycan cross-linking) by 
inactivating transpeptidases on the inner surface of the bacterial cell membrane. 
Ampiroxicam 
Cardiovascular 
Disease COX Ampiroxicam is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug. 
Amprenavir (Agenerase) Infection HIV Protease 
Amprenavir is an human immunodeficiency virus (HIV) protease inhibitor with IC50 of 14.6 ¡À 12.5 ng/ml for wild-type HIV 
isolate 
Amprolium HCl 
Metabolic 
Disease Others Amprolium chloride is a thiamin antagonist, which prevents carbohydrate synthesis by blocking thiamine uptake.  
Anagrelide HCl Endocrinology PDE Anagrelide is a drug used for the treatment of essential thrombocytosis. 
Anastrozole Endocrinology Aromatase Inhibits the enzyme aromatase 
Aniracetam 
Neurological 
Disease 
AMPA Receptor-kainate Receptor-
NMDA Receptor Aniracetam is a nootropics and neuroprotective drug. 
Anisotropine 
Methylbromide  
Neurological 
Disease Others   
Antazoline HCl 
Neurological 
Disease Others 
Antazoline HCl is a first generation antihistamine, binding to the histamine H1 receptor and blocking the action of endogenous 
histamine. 
Antipyrine Infection Others Antipyrine is an analgesic and antipyretic agent. 
Apatinib (YN968D1) Cancer VEGFR 
Apatinib (YN968D1) is a small-molecule selective multitargeted tyrosine kinase inhibitor with an IC50 of 2.43 nM for the 
inhibition of VEGFR2. 
Apixaban 
Cardiovascular 
Disease Factor Xa 
Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, 
respectively. 
Aprepitant (MK-0869) 
Neurological 
Disease Substance P Substance P antagonists (SPA). 
Arbidol HCl 
Cardiovascular 
Disease Others Arbidol is an antiviral treatment for influenza infection. 
Arecoline Endocrinology AChR Arecoline is a muscarinic acetylcholine receptor agonist.  
Argatroban 
Cardiovascular 
Disease Thrombin Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Aripiprazole (Abilify) 
Neurological 
Disease 5-HT Receptor Aripiprazole is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM. 
Artemether (SM-224) Cancer Others Artemether is an antimalarial for the treatment of resistant strains of falciparum malaria. 
Artemisinin Infection Others Artemisinin is a drug used to treat multi-drug resistant strains of falciparum malaria. 
Articaine HCl 
Neurological 
Disease Others 
Articaine is a dental local anesthetic which contains an additional ester group that is metabolized by estearases in blood and 
tissue. 
Asenapine 
Neurological 
Disease 
Adrenergic Receptor,5-HT 
Receptor 
Asenapine (Saphris) is a new atypical antipsychotic used for the treatment of schizophrenia and acute mania associated with 
bipolar disorder . 
Aspartame 
Metabolic 
Disease Others Aspartame is an artificial, non-saccharide sweetener used as a sugar substitute in some foods and beverages. 
Aspirin (Acetylsalicylic 
acid) Cancer COX 
Aspirin is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, 
and as an anti-inflammatory medication. 
Atazanavir sulfate Cancer HIV Protease 
Atazanavir sulfate (BMS-232632-05) is a sulfate salt form of atazanavir (BMS-232632) that is an highly potent HIV protease 
inhibitor with EC50 and EC90 of 2.6~5.3 nM and 9~15 nM in cell culture. 
Atomoxetine HCl 
Neurological 
Disease 5-HT Receptor 
Atomoxetine is a selective norepinephrine (NE) transporter inhibitor with Ki of 5 nM, with 15- and 290-fold lower affinity for 
human 5-HT and DA transporters.Phase 4. 
Atorvastatin calcium 
(Lipitor) 
Cardiovascular 
Disease HMG-CoA Reductase 
Atorvastatin (Lipitor) is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the 
production of cholesterol. 
Atovaquone (Atavaquone) 
Neurological 
Disease Others Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia. 
Atracurium besylate 
Neurological 
Disease Others Atracurium besylate is a neuromuscular blocking agent with ED95 of 0.2 mg/kg. 
Atropine 
Respiratory 
Disease AChR Atropine sulfate monohydrate is a competitive muscarinic acetylcholine receptor antagonist with an IC50 of 2.5 nM. 
Avanafil 
Cardiovascular 
Disease PDE Avanafil is a highly selective PDE5 inhibitor with IC50 of 1 nM. 
Avobenzone (Parsol 1789)   Others 
Avobenzone(Parsol 1789) is an oil soluble ingredient used in sunscreen products to absorb the full spectrum of UVA rays and 
a dibenzoylmethane derivative. 
Axitinib Cancer c-Kit,PDGFR,VEGFR Axitinib blocked phosphorylation of VEGFR-2 and VEGFR-3 with average IC50s of 0.2 and 0.1 to 0.3 nM. 
Azacitidine (Vidaza) Cancer DNA Methyltransferase 
Azacitidine(Vidaza)and its deoxy derivative, decitabine (5-aza-2′deoxycytidine), are used in the treatment of myelodysplastic 
syndrome.  
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Azacyclonol 
Neurological 
Disease Others Azacyclonol, also known as γ-pipradol, is a drug used to diminish hallucinations in psychotic individuals. 
Azaguanine-8 Cancer Others Azaguanine-8 is a purine analogs showing antineoplastic activity by competing with guanine in the metabolism.  
Azaperone 
Neurological 
Disease Others 
Azaperone is a pyridinylpiperazine and butyrophenone neuroleptic drug with sedative and antiemetic effects, which is used 
mainly as a tranquilizer in veterinary medicine. 
Azatadine dimaleate Infection Histamine Receptor Azatadine is an histamine and cholinergic inhibitor with IC50 of 6.5 nM and 10 nM, respectively. 
Azathioprine (Azasan, 
Imuran) Immunology Rho 
Azathioprine(Azasan, Imuran) is a drug that suppresses the immune system and is used in organ transplantation and 
autoimmune disease.  
Azelastine hydrochloride 
(Astelin) 
Neurological 
Disease Histamine Receptor Azelastine is a potent, second-generation, selective, histamine antagonist.  
Azelnidipine 
Neurological 
Disease Calcium Channel Azelnidipine is a dihydropyridine calcium channel blocker. 
Azilsartan (TAK-536) 
Neurological 
Disease RAAS Azilsartan (TAK-536) is an angiotensin II type 1 (AT1) receptor antagonist with IC50 of 2.6 nM. 
Azilsartan Medoxomil 
(TAK-491) 
Cardiovascular 
Disease RAAS 
Azilsartan Medoxomil is a potent angiotensin II type 1 (AT1) receptor antagonist, inhibits the RAAS, with an IC50 of 2.6 nM, 
exhibits >10,000-fold selectivity over AT2. Phase 3. 
Azithromycin (Zithromax) Cancer Autophagy Azithromycin (Zithromax) is an antibiotic for inhibition of parasite growth with IC50 of 8.4 µM. 
Azithromycin Dihydrate Infection Others Azithromycin Dihydrate is an acid stable orally administered macrolide antimicrobial drug, structurally related to erythromycin. 
Azlocillin sodium salt 
Neurological 
Disease Others Azlocillin is an acylampicillin with a broad spectrum against bacteria. 
Aztreonam (Azactam, 
Cayston) Infection Others Aztreonam (Azactam, Cayston) is a synthetic monocyclic beta-lactam antibiotic. 
Bacitracin Infection Others 
Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var 
Tracy, which disrupts both gram positive and gram negative bacteria by interfering with cell wall and peptidoglycan synthesis. 
Balofloxacin 
Metabolic 
Disease Others Balofloxacin is quinolone antibiotic, inhibiting the synthesis of bacterial DNA by interference with the enqyme DNA gyrase. 
Bazedoxifene HCl 
Metabolic 
Disease Estrogen/progestogen Receptor 
Bazedoxifene HCl is a novel, non-steroidal, indole-based estrogen receptor modulator (SERM) binding to both ERα and ERβ 
with IC50 of 23 nM and 89 nM. 
Beclomethasone 
dipropionate Inflammation Glucocorticoid Receptor Beclomethasone dipropionate is a potent glucocorticoid steroid used for the treatment of rhinitis and sinusitis. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Bemegride   GABA Receptor Bemegride is a central nervous system stimulant and antidote for barbiturate poisoning. 
Benazepril hydrochloride 
Cardiovascular 
Disease RAAS Benazepril is a medication used to treat high blood pressure. 
Bendamustine HCL Cancer DNA/RNA Synthesis Bendamustine inhibits SU-DHL-1 cell proliferation with IC50 at 50 µm. 
Benidipine hydrochloride 
Cardiovascular 
Disease Calcium Channel Benidipine HCl is a hydrochloride salt form of benidipine which is a dihydropyridine calcium channel blocker. 
Benserazide 
Neurological 
Disease Others 
Benserazide hydrochloride (Serazide) is a peripherally-acting aromatic L-amino acid decarboxylase (AAAD) or DOPA 
decarboxylase inhibitor. 
Benzbromarone   P450 (e.g. CYP17) Benzbromarone is a CYP2C9 inhibitor, it binds to CYP2C9 with Ki value of 19.3 nM. 
Benzethonium chloride 
Neurological 
Disease AChR 
Benzethonium chloride is a potent inhibitor of nAChRs, it inhibits α4β2 nAChRs and α7 nAChRs with IC50 of 49 nM and 122 
nM, respectively. 
Benzocaine 
Respiratory 
Disease Sodium Channel 
Benzocaine is the ethyl ester of p-aminobenzoic acid (PABA), it is a local anesthetic commonly used as a topical pain reliever 
or in cough drops. 
Benzoic acid   Others Benzoic acid is a colorless crystalline solid and a simple aromatic carboxylic acid, used as a food preservative. 
Benzthiazide 
Cardiovascular 
Disease Others   
Benztropine mesylate Infection Dopamine Receptor Benztropine is a dopamine transporter (DAT) inhibitor with IC50 of 118 nM. 
Benzydamine 
Hydrochloride Inflammation Others 
Benzydamine hydrochloride is a topical nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, 
antipyretic and local anesthetic activity. 
Bephenium 
Hydroxynaphthoate Vermifuge Others   
Bepotastine Besilate Cancer Histamine Receptor Bepotastine is a non-sedating, selective antagonist of histamine 1 (H1) receptor with pIC50 of 5.7. 
Bergapten Cancer Others 
Bergapten is a psoralen that can be photoactivated and is capable of crossing-linking DNA, covalently modifying proteins and 
lipids, and consequently inhibiting cell replication. 
Beta Carotene   Others Beta Carotene is an organic compound and classified as a terpenoid. It is a precursor (inactive form) of vitamin A. 
Betahistine 2HCl   Histamine Receptor Betahistine is a <b>histamine H3</b> receptor inhibitor with <b>IC50</b> of 1.9 µM. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Betamethasone 
(Celestone) Inflammation Glucocorticoid Receptor Betamethasone is a glucocorticoid steroid with anti-inflammatory and immunosuppressive properties. 
Betamethasone 
Dipropionate   Glucocorticoid Receptor Betamethasone Dipropionate is a glucocorticoid steroid with anti-inflammatory and immunosuppressive abilities. 
Betamethasone valerate 
(Betnovate) Inflammation Glucocorticoid Receptor 
Betamethasone Valerate is a moderately potent glucocorticoid steroid with anti-inflammatory and immunosuppressive 
properties. 
Betamipron Infection Others 
Betamipron is a chemical compound which is used together with panipenem to inhibit panipenem uptake into the renal tubule 
and prevent nephrotoxicity.  
Betapar (Meprednisone) Inflammation Glucocorticoid Receptor Betapar (Meprednisone) is a glucocorticoid and a methylated derivative of prednisone. 
Betaxolol (Betoptic) 
Neurological 
Disease Adrenergic Receptor Betaxolol is a selective beta1 adrenergic receptor blocker used in the treatment of hypertension and glaucoma. 
Betaxolol hydrochloride 
(Betoptic) 
Cardiovascular 
Disease Adrenergic Receptor Betaxolol is a β1 adrenergic receptor blocker with IC50 of 6 µM. 
Bethanechol chloride 
Neurological 
Disease AChR 
Carbamyl-beta-methylcholine chloride (Bethanechol chloride) is a selective muscarinic receptor agonist without any effect on 
nicotinic receptors. 
Bexarotene 
Cardiovascular 
Disease Retinoid Receptor 
Bexarotene is a retinoid specifically selective for retinoid X receptors, used as an oral antineoplastic agent in the treatment of 
cutaneous T-cell lymphoma. 
Bextra (valdecoxib) 
Neurological 
Disease COX Valdecoxib is a potent and selective inhibitor of COX-2 with IC50 of 5 nM. 
Bezafibrate 
Metabolic 
Disease PPAR Bezafibrate is the first clinically tested dual and pan-PPAR co-agonism. 
BIBR-1048 (Dabigatran) Infection Thrombin Dabigatran etexilate (BIBR-1048) is an anticoagulant from the class of the direct thrombin inhibitors. 
Bicalutamide (Casodex) Endocrinology Androgen Receptor An oral non-steroidal anti-androgen. 
Bifonazole Infection Others Bifonazole is an antifungal agent and a prostatic aromatase activity inhibitor with IC50 of 1.6 µM. 
Bimatoprost 
Cardiovascular 
Disease Others 
Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the 
management of ocular hypertension. 
Bindarit Cancer Others Bindarit exhibits selective inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8. 
Biotin (Vitamin B7) Infection Others 
Biotin is a water-soluble B-vitamin and is necessary for cell growth, the production of fatty acids, and the metabolism of fats 
and amino acids. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Bisacodyl 
Cardiovascular 
Disease Others Bisacodyl (INN) is a stimulant laxative drug that works directly on the colon to produce a bowel movement. 
Bisoprolol fumarate   Adrenergic Receptor Bisoprolol fumarate is a selective type β1 adrenergic receptor blocker. 
Bleomycin sulfate Cancer DNA/RNA Synthesis A glycopeptide antibiotic produced by the bacterium Streptomyces verticillus. 
Bortezomib (Velcade) Cancer Proteasome 
Bortezomib also known as Velcade, MG-341, PS-341 is proteasome Inhibitor, effectively inhibits proteasome activity (Ki-0.6 
nM). 
Bosentan   Endothelin Receptor Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively. 
Bosutinib (SKI-606) Cancer Src Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively. 
Brinzolamide 
Neurological 
Disease Carbonic Anhydrase Brinzolamide is a potent carbonic anhydrase II inhibitor with IC50 of 3.19 nM. 
Bromhexine HCl 
Cardiovascular 
Disease Others Bromhexine hydrochloride is a medication prescribed for coughs which works by dissolving hard phlegm. 
Brompheniramine Infection Histamine Receptor Brompheniramine is a histamine H1 receptors antagonist. 
Broxyquinoline Vermifuge Others Broxyquinoline is an antiprotozoal agent and able to release oxygen free radicals from the water in mucous membranes.  
Brucine   Others   
Budesonide Endocrinology Glucocorticoid Receptor Budesonide is a glucocorticoid steroid for the treatment of asthma, non-infectious rhinitis. 
Bufexamac 
Metabolic 
Disease COX Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 µM. 
Buflomedil HCl 
Neurological 
Disease Others Buflomedil is a vasodilator used to treat claudication or the symptoms of peripheral arterial disease. 
Bumetanide 
Cardiovascular 
Disease Others Bumetanide (Bumex) is a loop diuretic of the sulfamyl category to treat heart failure. 
Bupivacaine hydrochloride 
(Marcain) 
Neurological 
Disease Sodium Channel Bupivacaine hydrochloride (Marcain) is a more potent cAMP production inhibitor with an IC50 of 2.3 µM. 
Busulfan (Myleran, 
Busulfex) 
Cardiovascular 
Disease Others Busulfan (Myleran, Busulfex) is a cell cycle non-specific alkylating antineoplastic agent. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Butenafine HCl 
Neurological 
Disease Others 
Butenafine HCl is a synthetic benzylamine antifungal, works by inhibiting the synthesis of sterols by inhibiting squalene 
epoxidase. 
Butoconazole nitrate Infection Others 
Butoconazole nitrate is an anti-fungal agent for IL-2, TNFα, IFN and GM-CSF with IC50 of 7.2 µg/mL, 14.4 µg/mL, 7.36 µg/mL 
and 7.6 µg/mL, respectively. 
Cabazitaxel (Jevtana) 
Neurological 
Disease Microtubule Associated Cabazitaxel (Jevtana, XRP6258) is a semi-synthetic derivative of a natural taxoid. 
Calcitriol (Rocaltrol) Endocrinology Others Calcitriol is the hormonally active form of vitamin D. 
Calcium Gluceptate    Others   
Camptothecin Cancer Topoisomerase 
Camptothecin (CPT) is a cytotoxic quinoline alkaloid which inhibits the DNA enzyme topoisomerase I (topo I) with an IC50 
and IC70 of 50 nM and 0. 225 µM . 
Camylofin Chlorhydrate 
Digestive 
system disease Others   
Candesartan (Atacand) 
Cardiovascular 
Disease RAAS Candesartan (Atacand) is an angiotensin II receptor antagonist with an IC50 of 15 µg/kg 
Candesartan cilexetil 
(Atacand) 
Cardiovascular 
Disease RAAS 
Candesartan Cilexetil is a specific nonpeptide Ang II receptor (ATR) antagonist and the prodrug of candesartan which is an 
ATR antagonist with an IC50 of 15 µg/kg 
Capecitabine (Xeloda) Cancer DNA/RNA Synthesis 
Capecitabine (Xeloda) is an orally-administered chemotherapeutic agent (IC50 = 0.7~5 mM) and prodrug of 5-fluorouracil 
which is a DNA synthesis inhibitor with an IC50 for 5.0 ± 1.8 µM. 
Captopril (Capoten) 
Metabolic 
Disease RAAS Captopril (Capoten) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 6 nM. 
Carbachol   Others   
Carbadox Infection Others   
Carbamazepine (Carbatrol) 
Neurological 
Disease Sodium Channel,Autophagy Carbamazepine is a sodium channel blocker with an IC50 of 140 µM. 
Carbazochrome sodium 
sulfonate Cancer Others Carbazochrome is an antihemorrhagic for use in the treatment of hemorrhoids. 
Carbenicillin disodium Infection Others 
Carbenicillin is a semi-synthetic penicillin antibiotic which interferes with cell wall synthesis of gram-negative bacteria while 
displaying low toxicity. 
Carbenoxolone Sodium Endocrinology Others   
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Carbidopa 
Neurological 
Disease Others Carbidopa is an aromatic-L-amino-acid decarboxylase inhibitor with an IC50 of 29 ± 2 µM. 
Carbimazole Infection Others Carbimazole is an imidazole antithyroid agent.  
Carfilzomib (PR-171) 
Cardiovascular 
Disease Proteasome 
Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM, displayed preferential in vitro inhibitory 
potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. 
Carmofur Cancer DNA/RNA Synthesis Carmofur (INN) is a pyrimidine analogue used as an antineoplastic agent. 
Carprofen Inflammation COX Carprofen inhibits canine COX2 with IC50 of 0.03 mM. 
Carvedilol 
Cardiovascular 
Disease Adrenergic Receptor Carvedilol is a non-selective beta blocker/alpha-1 blocker with an IC50 of 3.8 µM for inhibition of LDL oxidation. 
Caspofungin acetate Infection Others Caspofungin acetate is a lipopeptide antifungal drug. 
Catharanthine   Achr Catharanthine inhibits <b>nicotinic receptor</b> mediated diaphragm contractions with <b>IC50</b> of 59.6 µM. 
Cefdinir (Omnicef) Infection Others Cefdinir (Omnicef) is a bacteriocidal antibiotic. 
Cefditoren pivoxil Infection Others Cefditoren pivoxil is used to treat uncomplicated skin and skin structure infections, etc. 
Cefoperazone (Cefobid) Infection Others Cefoperazone is a cephalosporin antibiotic for inhibition of rMrp2-mediated [3H]E217βG uptake with IC50 of 199 µM. 
Ceftazidime Pentahydrate Infection Others   
Ceftiofur HCl   Others Ceftiofur HCl is a cephalosporin <b>antibiotic</b>, used to treat both Gram-positive and Gram-negative bacteria infection. 
Celecoxib Inflammation COX COX-2 inhibitor,IC50=0.04uM 
Cephalexin (Cefalexin) Infection Others Cefalexin is a cephalosporin antibiotic. 
Cephalomannine Cancer Others 
Cephalomannine is an active anti-cancer agent obtained from Taxus yunnanensis and has an antineoplastic effect on tumors 
found in mice. 
Cepharanthine 
Metabolic 
Disease Others 
Cepharanthine is a biscoclaurine alkaloid inhibiting tumor necrosis factor (TNF)-α-mediated NFκB stimulation, plasma 
membrane lipid peroxidation and platelet aggregation and suppressing cytokine production. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Cetirizine Dihydrochloride Inflammation Histamine Receptor Cetirizine is an antihistamine. 
Cetrimonium Bromide Infection Others 
Cetrimonium Bromide is a known component of the broad-spectrum antiseptic cetrimide, which is a mixture of different 
quaternary ammonium salts. 
Cetylpyridinium Chloride Infection Others Cetylpyridinium chloride is a cationic quaternary ammonium compound used as oropharyngeal antiseptic. 
Chenodeoxycholic acid Infection Others Chenodeoxycholic acid is a naturally occurring human bile acid. 
Chloramphenicol 
(Chloromycetin) Infection Others Chloramphenicol (Chloromycetin) is a bacteriostatic antimicrobial. 
Chlormezanone 
(Trancopal) 
Respiratory 
Disease Others 
Chlormezanone(Trancopal)，a non-benzodiazepine that is used in the management of anxiety. It has been suggested for use 
in the treatment of muscle spasm. 
Chlorocresol   Others Chlorocresol is an activator of ryanodine receptor 
Chlorothiazide 
Cardiovascular 
Disease Others Chlorothiazide is a diuretic and antihypertensive. (IC50=3.8 mM) 
Chloroxine Infection Others 
Chloroxine is a synthetic antibacterial compound that is effective in the treatment of dandruff and seborrheic dermatitis when 
incorporated in a shampoo. 
Chlorpheniramine Maleate 
Neurological 
Disease Histamine Receptor Chlorpheniramine (Chlorpheniramine maleate, Chlorphenamine) is an histamine H1 receptor antagonist with IC50 of 12 nM. 
Chlorpromazine (Sonazine) 
Neurological 
Disease 
Dopamine Receptor,Potassium 
Channel 
Chlorpromazine hydrochloride (Sonazine) is a dopamine and potassium channel inhibitor with IC50 of 6.1 and 16 µM for 
nward-rectifying K+ currents and time-independent outward currents. 
Chlorpropamide Infection Others Chlorpropamide is a sulfonylurea class drug for type 2 diabetes mellitus. 
Chlorprothixene 
Neurological 
Disease Dopamine Receptor Chlorprothixene is a typical antipsychotic drug of the thioxanthene class and was the first of the series to be synthesized. 
Chlorquinaldol Infection Others Chlorquinaldol is an antimicrobial agent used for local antisepsy. 
Chlorzoxazone 
Metabolic 
Disease Others Chlorzoxazone is a muscle-relaxing drug,and a probe for human liver cytochrome P-450IIE1. 
Choline Chloride   Others Choline chloride is a quaternary ammonium salt used as an additive for animal feed. 
Chromocarb 
Cardiovascular 
Disease Others Chromocarb is a vasoprotectant. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Ciclopirox (Penlac) 
Neurological 
Disease ATPase Ciclopirox (Penlac) is a synthetic antifungal agent. 
Ciclopirox ethanolamine Infection ATPase Ciclopirox ethanolamine (Ciclopirox olamine, HOE 296) is a broad-spectrum antifungal agent working as an iron chelator. 
Cilnidipine 
Cardiovascular 
Disease Calcium Channel Cilnidipine is a calcium channel blocker. 
Cilostazol 
Cardiovascular 
Disease PDE 
Cilostazol is a medication used in the alleviation of the symptom of intermittent claudication in individuals with peripheral 
vascular disease. 
Cimetidine (Tagamet) Inflammation Histamine Receptor Cimetidine (Tagamet), a histamine congener, competitively inhibits histamine binding to histamine H2 receptors. 
Cinchophen Immunology Others Cinchophen is an analgesic drug that is frequently used to treat gout. 
Cinepazide maleate Inflammation Calcium Channel Cinepazide maleate is a maleate salt form of cinepazide which is a vasodilator. 
Cisatracurium besylate 
(Nimbex) 
Neurological 
Disease Adrenergic Receptor 
Cisatracurium besylate is a nondepolarizing neuromuscular blocking agent, antagonizing the action of acetylcholine by 
inhibiting neuromuscular transmission. 
Cisplatin   DNA/RNA Synthesis 
Cisplatin is an inorganic platinum complex, which is able to inhibit <b>DNA synthesis</b> by conforming DNA adducts in 
tumor cells.  
Cladribine Cancer DNA/RNA Synthesis Cladribine (Leustatin) is an adenosine deaminase inhibitor with an IC50 of about 0.2 µM. 
Clarithromycin (Biaxin, 
Klacid) 
Neurological 
Disease P450 (e.g. CYP17) Clarithromycin is a macrolide antibiotic and a CYP3A4 substrate and inhibitor. 
Clemastine Fumarate Immunology Histamine Receptor 
Clemastine fumarate, a histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, 
and pruritus. 
Cleviprex (Clevidipine) 
Cardiovascular 
Disease Calcium Channel Cleviprex (Clevidipine) is a dihydropyridine calcium channel blocker use as agent for the reduction of blood pressure. 
Climbazole Infection Others Climbazole is a broad-spectrum imidazole antifungal agent that can provide anti-dandruff benefits.  
Clindamycin Infection Others Clindamycin inhibits protein synthesis by acting on the 50S ribosomal. 
Clindamycin hydrochloride 
(Dalacin) 
Neurological 
Disease Others Clindamycin hydrochloride (Dalacin) is the hydrated hydrochloride salt of clindamycin which is a semisynthetic antibiotic. 
Clindamycin palmitate HCl Infection Others 
Clindamycin palmitate HCl is a water soluble hydrochloride salt of the ester of clindamycin and palmitic acid and a 
lincosamide antibiotic. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Clobetasol propionate 
Neurological 
Disease Glucocorticoid Receptor Clobetasol propionate is a anti-inflammatory corticosteroid used to treat various skin disorders. 
Clofarabine Cancer DNA/RNA Synthesis Inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase 
Clofazimine Infection Phospholipase (e.g. PLA) 
Clofazimine is a rhimophenazine dye, originally developed for the treatment of tuberculosis, it has both antimicrobial and 
antiinflammatory activity, postulated mechanisms of action include intercalation of clofazimine with bacterial DNA and 
increasing levels of cellular phospholipase A2. 
Clofibric acid 
Metabolic 
Disease PPAR Clofibric acid is a PPARα agonist and hypolipidemic agent. 
Clofoctol Infection Others   
Clomifene citrate 
(Serophene) Cancer Estrogen/progestogen Receptor Clomifene citrate (Serophene) is a selective estrogen receptor modulator. 
Clomipramine HCl    5-HT Receptor 
Clomipramine HCl is a hydrochloride salt of clomipramine which is a serotonin transporter (SERT), norepinephrine transporter 
(NET) dopamine transporter (DAT) blocker with Ki of 0.14, 54 and 3 nM, respectively.  
Clonidine hydrochloride 
(Catapres) Infection Autophagy,Adrenergic Receptor 
Clonidine hydrochloride (Catapres) is a direct-acting α2 adrenergic agonist with an ED50 of 0.02±0.01 mg/kg. 
Clopidogrel (Plavix) 
Cardiovascular 
Disease P2 Receptor Clopidogrel is an oral, thienopyridine class antiplatelet agent. 
Clorprenaline HCL 
Cardiovascular 
Disease Adrenergic Receptor Clorprenaline HCl is a β2-receptor agonist, it has a significant expansion of the bronchial effect. 
Clorsulon Cancer Others Clorsulon is a competitive 8-phosphoglycerate kinase and phospho-glyceromutase inhibitor.  
Closantel Vermifuge Others Closantel is gram positive antibacterial activity inhibitor, inhibiting the KinA/Spo0F system with IC50 of 3.8 µM. 
Closantel Sodium Vermifuge Others Closantel is gram positive antibacterial activity inhibitor, inhibiting the KinA/Spo0F system with IC50 of 3.8 µM. 
Clotrimazole (Canesten) Infection Others Clotrimazole (Canesten) is a synthetic, antifungal and broad-spectrum derivate of imidazole. 
Cloxacillin sodium 
(Cloxacap) 
Cardiovascular 
Disease Others 
Cloxacillin sodium (Cloxacap) is a sodium salt of cloxacillin (Cloxapen, Cloxacap Orbenin) that is a penicillinase-resistant, 
acid resistant, semi-synthetic penicillin. 
Clozapine (Clozaril) 
Cardiovascular 
Disease 5-HT Receptor 
Clozapine (Clozaril) is a potent 5-HT1C receptor antagonist with an IC50 of 110 nM for 5-HT-stimulated phosphoinositide 
hydrolysis. 
Cobicistat (GS-9350) Cancer P450 (e.g. CYP17) Cobicistat (GS-9350) is a potent and selective inhibitor of CYP3A with IC50 of 30-285 nM.  
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Conivaptan HCl (Vaprisol) 
Cardiovascular 
Disease Vasopressin Receptor Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist). 
Cortisone acetate 
(Cortone) Cancer Glucocorticoid Receptor Cortisone acetate (Cortone) is an acetate salt form of cortisone that is a steroid hormone and a glucocorticoid. 
Coumarin   Others Coumarin is a secondary phytochemical with hepatotoxic and carcinogenic properties. 
Crizotinib (PF-02341066) Cancer ALK,c-Met PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nnM, respectivley. 
Crystal violet Infection Others Crystal violet is a triarylmethane dye. 
Curcumin   Others 
Curcumin is the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family 
(Zingiberaceae).  
Cyclamic  acid Inflammation Others Cyclamic acid in the form of its sodium or calcium salt is one of the most widely used artificial sweeteners. 
Cyclandelate 
Neurological 
Disease Others Cyclandelate is an effective inhibitor of rat hepatic acycloenzyme A: cholesterol acyltransferase (ACAT) with IC50 of 80 µM.  
Cyclophosphamide 
monohydrate Cancer Others Cyclophosphamide is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA.  
Cyclosporine (Neoral) Immunology Others Cyclosporine (Neoral) is an immunosuppressant drug. 
Cyproheptadine HCl 
(Periactin) 
Neurological 
Disease Histamine Receptor 
Cyproheptadine hydrochloride (Periactin) is a hydrochloride salt form of cyproheptadine which is a histamine receptor 
antagonist for 5-HT2 receptor with IC50 of 0.6 nM. 
Cyromazine Vermifuge Others Cyromazine is a triazine insect growth regulator used as an insecticide and an acaricide. 
Cysteamine HCl 
Metabolic 
Disease Others Cysteamine is an agent for the treatment of nephropathic cystinosis and an antioxidant. 
Cytidine 
Cardiovascular 
Disease Others Cytidine is a nucleoside molecule that is formed when cytosine is attached to a ribose ring, cytidine is a component of RNA. 
D-Mannitol (Osmitrol) 
Cardiovascular 
Disease Others D-Mannitol(Osmitrol) is an osmotic diuretic agent and a weak renal vasodilator. 
Dabrafenib (GSK2118436) Infection Raf 
Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM, with 4- and 6-fold less potency 
against B-Raf(wt) and c-Raf, respectively. Phase 3. 
Dacarbazine (DTIC-Dome) Cancer DNA/RNA Synthesis Dacarbazine (DTIC-Dome) is an antineoplastic chemotherapy drug used in the treatment of various cancers. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Daidzein 
Cardiovascular 
Disease Others Daidzein belongs to the group of isoflavones. 
Dapoxetine hydrochloride 
(Priligy) 
Neurological 
Disease 5-HT Receptor Dapoxetine hydrochloride is a short-acting novel selective serotonin reuptake inhibitor. 
DAPT (GSI-IX) Cancer Gamma-secretase,Beta Amyloid DAPT (GSI-IX) is a novel γ-secretase inhibitor, which inhibits Aβ production with IC50 of 20 nM in HEK 293 cells. 
Darifenacin HBr Infection AChR Darifenacin is a selective M3 muscarinic receptor antagonist with pKi of 8.9. 
Darunavir Ethanolate 
(Prezista) Infection HIV Protease Darunavir Ethanolate (Prezista) is an HIV protease inhibitor. 
Dasatinib (BMS-354825) Cancer Bcr-Abl,Src,c-Kit 
Dasatinib also known as BMS-354825, Sprycel, BMS354825 is ATP-competitive, dual SRC/ABL inhibitor. BMS-354825 
inhibits all members of the Src family, including c-Src, Lck, Fyn, and Yes (IC50 < 1.1nmol/L). 
Daunorubicin HCl 
(Daunomycin HCl) Cancer Topoisomerase Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 µM. 
Decamethonium bromide 
Neurological 
Disease AChR Decamethonium Bromide is a nicotinic AChR partial agonist and neuromuscular blocking agent. 
Decitabine 
Cardiovascular 
Disease DNA Methyltransferase 
Decitabine (NSC 127716, Dacogen, DAC) is an available nucleoside-based DNA methyltransferase (DNMT) inhibitor with 
IC50 of 490, 400 and 100 nM for A549, LoVo and LoVo-DX cell lines. 
Deferasirox (Exjade) Endocrinology Others Deferasirox(Exjade) is a rationally-designed oral iron chelator. 
Deflazacort (Calcort) Endocrinology Glucocorticoid Receptor Deflazacort (Calcort) is a glucocorticoid used as an anti-inflammatory and immunosuppressant. 
Dehydroepiandrosterone 
(DHEA) Endocrinology 
Estrogen/progestogen 
Receptor,Androgen Receptor Dehydroepiandrosterone(DHEA) is a 19-carbon endogenous natural steroid hormone. 
Deoxyarbutin 
Cardiovascular 
Disease Others DeoxyArbutin is a reversible tyrosinase inhibitor, inhibiting tyrosinase activity with IC50 of 50 nM. 
Deoxycorticosterone 
acetate Endocrinology Others 
Deoxycorticosterone acetate is a steroid hormone used for intramuscular injection for replacement therapy of the 
adrenocortical steroid. 
Desloratadine 
Cardiovascular 
Disease Histamine Receptor Desloratadine is a potent antagonist for human histamine H1 receptor with IC50 of 51 nM. 
Desonide Inflammation Glucocorticoid Receptor Desonide is a low potency topical corticosteroid. 
Detomidine HCl 
Cardiovascular 
Disease Adrenergic Receptor Detomidine produce dose-dependent sedative and analgesic effects, mediatated by activation of α2 catecholamine receptors. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Dexamethasone Inflammation IL Receptor,Autophagy Dexamethasone is an anti-inflammatory and immunosuppressant. 
Dexamethasone acetate Inflammation Autophagy,IL Receptor 
Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs used as an anti-inflammatory and 
immunosuppressant.  
Dexlansoprazole 
Cardiovascular 
Disease Proton Pump 
Dexlansoprazole, the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual 
delayed-release properties. 
Dexmedetomidine 
Neurological 
Disease Adrenergic Receptor Dexmedetomidine is a sedative medication used by intensive care units and anesthetists. 
Dexmedetomidine HCl 
(Precedex) 
Neurological 
Disease Adrenergic Receptor 
Dexmedetomidine is a highly selective and potent alpha-2 adrenoceptor agonist, which reduces anesthetic requirements for 
patients by providing significant sedation. 
Dexrazoxane 
Hydrochloride 
Cardiovascular 
Disease Others A cardioprotective agent 
Dextrose (D-glucose) Infection Others Dextrose (D-glucose), a simple sugar (monosaccharide), is an important carbohydrate in biology. 
Dibenzothiophene   Others Dibenzothiophene (DBT) is a model compound for organic sulfur in fossil fuels.  
Dibucaine HCL Endocrinology Sodium Channel Dibucaine (Cinchocaine) HCl is a local anesthetics. 
Diclazuril Infection Others Diclazuril is an anti-coccidial drug. 
Diclofenac 
Neurological 
Disease COX Diclofenac is a non-selective COX inhibitor with IC50 of 60 and 220 nM for ovine COX-1 and -2, respectively. 
Diclofenac Diethylamine 
Neurological 
Disease Others 
Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug taken to reduce inflammation and as an analgesic reducing 
pain in certain conditions. 
Diclofenac Potassium Infection Others 
Diclofenac potassium is a nonsteroidal anti-inflammatory drug taken to reduce inflammation and as an analgesic reducing 
pain in certain conditions. 
Dicloxacillin Sodium Infection Others 
Dicloxacillin is a β-lactamase resistant penicillin similar to oxacillin and it has activity against gram-positive/negative aerobic 
and anaerobic bacteria. 
Dicyclomine HCl 
Neurological 
Disease Others   
Didanosine (Videx) Infection Reverse Transcriptase Didanosine (Videx, Videx EC) is a reverse transcriptase inhibitor with an IC50 of 0.49 µM. 
Dienogest Endocrinology Estrogen/progestogen Receptor Dienogest is an orally active synthetic progesterone (or progestin).  
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Diethylstilbestrol 
(Stilbestrol) Cancer Estrogen/progestogen Receptor 
Diethylstilbestrol(Stilbestrol), a synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal 
disorders. 
Difloxacin HCl Infection Others   
Difluprednate Endocrinology Others 
Difluprednate (difluoroprednisolone butyrate acetate, or DFBA) is a synthetic difluorinated prednisolone derivative, it originally 
developed for dermatologic applications. 
Diltiazem HCl (Tiazac) 
Cardiovascular 
Disease Calcium Channel 
Diltiazem HCl (Tiazac) is a benzothiazepine derivative with vasodilating action due to its antagonism of the actions of the 
calcium ion in membrane functions. 
Dimethyl Fumarate Inflammation Others 
Dimethyl fumarate is a promising novel oral therapeutic option shown to reduce disease activity and progression in patients 
with relapsing-remitting multiple sclerosis. 
Diminazene Aceturate Vermifuge Others 
Diminazene is a di-amidine also known as 4,4-(1-Triazene–1,3–diyl)bis(benzenecarboximidamide), used as an effective 
trypanocidal agent. 
Diperodon HCl 
Neurological 
Disease Others   
Diphemanil methylsulfate 
Neurological 
Disease AChR Diphemanil Methylsulfate is a quaternary ammonium anticholinergic, it binds muscarinic acetycholine receptors (mAchR). 
Diphenhydramine HCl 
(Benadryl) Immunology Histamine Receptor 
Diphenhydramine hydrochloride (Benadryl), a histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and 
pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. 
Diphenylpyraline HCl  
Neurological 
Disease Others   
Dipyridamole (Persantine) 
Cardiovascular 
Disease PDE 
Dipyridamole (Permole, Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by 
erythrocytes and vascular endothelial cells. 
Dirithromycin Infection Others 
Dirithromycin is a macrolide glycopeptide antibiotic by binding to the 50S subunit of the 70S bacterial ribosome to inhibit the 
translocation of peptides. 
Disopyramide Phosphate  
Cardiovascular 
Disease Others   
Disulfiram (Antabuse) 
Neurological 
Disease Dehydrogenase 
Disulfiram (Antabuse) is a drug used to support the treatment of chronic alcoholism by producing an acute sensitivity to 
alcohol. 
Divalproex sodium 
Neurological 
Disease Autophagy 
Divalproex sodium consists of a compound of sodium valproate and valproic acid in a 1:1 molar relationship in an enteric 
coated form. 
DL-Carnitine hydrochloride 
Cardiovascular 
Disease Others DL-Carnitine hydrochloride is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine. 
Docetaxel (Taxotere) Cancer Microtubule Associated An microtubule disassembly inhibitor with IC50 of a range of 0.31–100 ηM. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Dofetilide (Tikosyn) 
Cardiovascular 
Disease Potassium Channel Dofetilide(Tikosyn) is a class III antiarrhythmic agent. 
Domiphen Bromide Infection Others Domiphen bromide is a quaternary ammonium antiseptic with actions as a cationic surfactant.  
Domperidone (Motilium) 
Neurological 
Disease Dopamine Receptor Domperidone (Motilium) is a dopamine blocker and an antidopaminergic reagent. 
Dopamine hydrochloride 
(Inotropin) Infection Dopamine Receptor 
Dopamine hydrochloride (Inotropin) is a catecholamine neurotransmitter present in a wide variety of animals,And a dopamine 
D1-5 receptors agonist. 
Doripenem Hydrate Infection Others Doripenem (doripenem monohydrate) is an ultra-broad spectrum injectable antibiotic. 
Doxapram HCl 
Neurological 
Disease Others 
Doxapram HCl inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 µM, 9 µM, 
respectively. 
Doxazosin mesylate 
Cardiovascular 
Disease Adrenergic Receptor Doxazosin mesylate (Cardura) is an alpha-1 adrenergic receptor blocker. 
Doxercalciferol (Hectorol) Endocrinology Others Doxercalciferol (Hectorol) is a synthetic analog of vitamin D. 
Doxifluridine Immunology Others Doxifluridine is a thymidine phosphorylase activator for PC9-DPE2 cells with IC50 of 0.62 µM. 
Doxofylline 
Metabolic 
Disease PDE Doxofylline is a phosphodiesterase inhibitor and a xanthine derivative drug for asthma. 
Doxorubicin (Adriamycin) Cancer Autophagy,Topoisomerase Doxorubicin is a topoisomerase II inhibitor with IC50 of 1 and 2 µM for the inhibition of MCF-7 and MDA-MB231. 
Doxylamine Succinate 
Neurological 
Disease Histamine Receptor Doxylamine succinate competitively inhibits histamine at H1 receptors with substantial sedative and anticholinergic effects. 
Dronedarone HCl (Multaq) 
Neurological 
Disease 
Potassium Channel,Sodium 
Channel,Calcium Channel Dronedarone is a therapy for the treatment of patients with paroxysmal and persistent atrial fibrillation or atrial flutter. 
Droperidol 
Neurological 
Disease Others Droperidol is a potent antagonist of dopamine subtype 2 receptors in the limbic system. 
Dropropizine 
Respiratory 
Disease Others Dropropizine is a racemic non-opiate antitussive agent, it is used as a cough suppressant. 
Drospirenone Endocrinology Estrogen/progestogen Receptor Drospirenone is a synthetic progestin that is an analog to spironolactone. 
Duloxetine HCl (Cymbalta) 
Neurological 
Disease 5-HT Receptor 
Duloxetine is a serotonin-norepinephrine reuptake inhibitor with Ki of 4.6 nM, used for treatment of major depressive disorder 
and generalized anxiety disorder (GAD). 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Dutasteride Endocrinology 5-alpha Reductase 5-alpha-reductase inhibitor 
Dyclonine HCl Inflammation Others Dyclonine hydrochloride is a hydrochloride salt form of dyclonine which is an oral anaesthetic. 
Dydrogesterone Endocrinology Estrogen/progestogen Receptor 
Dydrogesterone is an orally active progestogen which acts directly on the uterus, producing a complete secretory 
endometrium in an estrogen-primed uterus. 
Dyphylline (Dilor) 
Respiratory 
Disease PDE Dyphylline (Dilor, Lufyllin, diprophylline) is a xanthine derivative with bronchodilator and vasodilator effects. 
Econazole nitrate 
(Spectazole) 
Neurological 
Disease Calcium Channel Econazole nitrate (Spectazole) is an imidazole class antifungal medication. 
Edaravone (MCI-186) 
Cardiovascular 
Disease Others Edaravone(MCI-186), a strong novel free radical scavenger, is used for treatment of patients with acute brain infarction. 
Eltrombopag (SB-497115-
GR) Cancer Others 
Eltrombopag (SB-497115-GR, Promacta, Revolade) is a small molecule agonist of the c-mpl (TpoR) receptor with an IC50 of 
0.69 µM for the inhibition of hERG K+ channel tail current. 
Elvitegravir (GS-9137) Immunology Integrase 
Elvitegravir is a human immunodeficiency virus integrase inhibitor with EC50 of 0.7, 2.8 and 1.4 for HIV-1 IIIB, HIV-2 EHO 
and HIV-2 ROD. 
Emtricitabine (Emtriva) Infection Reverse Transcriptase Emtricitabine (Emtriva) is a nucleoside reverse transcriptase inhibitor with an IC50 of 27.7 µM. 
Enalapril maleate (Vasotec) 
Cardiovascular 
Disease RAAS 
Enalapril maleate (Vasotec ), the active metabolite of enalapril, competes with angiotensin I for binding at the angiotensin-
converting enzyme, blocking the conversion of angiotensin I to angiotensin II. 
Enalaprilat dihydrate 
Cardiovascular 
Disease RAAS Enalaprilat is the first dicarboxylate-containing ACE inhibitor with an IC50 of 4 nM. 
Enoxacin (Penetrex) Infection Topoisomerase 
Enoxacin(Penetrex)is an oral broad-spectrum fluoroquinolone antibacterial agent used in the treatment of urinary tract 
infections and gonorrhea. Insomnia is a common adverse effect. 
Entacapone 
Neurological 
Disease Histone Methyltransferase Entacapone inhibits catechol-O-methyltransferase(COMT) with IC50 of 151 nM. 
Entecavir hydrate Infection Reverse Transcriptase Entecavir hydrate belongs to the family of medicines called antivirals. 
Epalrestat Inflammation Others Epalrestat is an aldose reductase inhibitor with IC50 of 72 nM. 
Epinephrine bitartrate 
(Adrenalinium) Cancer Adrenergic Receptor Epinephrine bitartrate (D02149, Adrenalinium) is alpha- and beta-adrenergic receptor stimulator. 
Epirubicin HCl   Topoisomerase Epirubicin HCl, a semisynthetic L-arabino derivative of doxorubicin, is an antineoplastic agent by inhibiting Topoisomerase. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Eprosartan Mesylate 
Cardiovascular 
Disease RAAS 
Eprosartan is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM 
in rat vascular smooth muscle cells. 
Erdosteine 
Respiratory 
Disease Others Erdosteine is a mucolytic which is used in treatment of excessive viscous mucus. 
Erlotinib HCl Cancer EGFR,Autophagy Erlotinib also known as Tarceva, CP-358774, OSI-774, NSC-718781 is a HCL salt with IC50 of 2 nM for HER1/EGFR TK. 
Erythromycin (E-Mycin) Infection Others 
Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin 
(IC50=1.5 µg/ml). 
Erythromycin 
Ethylsuccinate Infection Others 
Erythromycin Ethylsuccinate, an oral macrolide antibiotic produced by Streptomyces erythreus, reversibly binds to the 50S 
ribosome of bacteria, and inhibits protein synthesis. 
Escitalopram oxalate Infection 5-HT Receptor 
Vitamin D3 (Cholecalciferol) is a form of vitamin D, binds and activates a H305F/H397Y mutant vitamin D receptor (VDR) with 
EC50 of 300 nM. 
Esmolol HCl 
Cardiovascular 
Disease Adrenergic Receptor Esmolol is a cardioselective b-blocker, used to control rapid heartbeats or abnormal heart rhythms. 
Esomeprazole magnesium 
(Nexium) 
Digestive 
system disease Proton Pump Esomeprazole magnesium is a proton pump inhibitor to reduce gastric acid secretion. 
Esomeprazole sodium 
(Nexium) Cancer ATPase 
Esomeprazole sodium (Nexium) is a sodium salt of esomeprazole that is a potent proton pump inhibitor with an IC50 of 0.076 
mg/kg. 
Estradiol Endocrinology Estrogen/progestogen Receptor Estradiol is the predominant sex hormone. 
Estradiol Cypionate   Estrogen/progestogen Receptor Estradiol cypionate is the 17 β-cyclopentylpropinate ester of estradiol, which inhibits ET-1 synthesis via estrogen receptor. 
Estradiol valerate Endocrinology Estrogen/progestogen Receptor Estradiol is a synthetic ester used to treat menopausal symptoms and hormone deficiencies. 
Estriol 
Neurological 
Disease Estrogen/progestogen Receptor Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast cancer cells. 
Estrone Endocrinology Estrogen/progestogen Receptor Estrone is an estrogenic hormone. 
Ethacridine lactate 
monohydrate Infection Others Ethacridine lactate monohydrate is an aromatic organic compound based on acridine used as an antiseptic agent. 
Ethambutol HCl 
Neurological 
Disease Others 
Ethambutol is a bacteriostatic antimycobacterial agent, which obstructs the formation of cell wall by inhibiting arabinosyl 
transferases. 
Ethamsylate 
Cardiovascular 
Disease Others 
Ethamsylate is a haemostatic drug, which inhibits biosynthesis and action of prostaglandins, and increases capillary 
endothelial resistance as and platelet adhesion. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Ethinyl Estradiol Endocrinology Estrogen/progestogen Receptor Ethynyl estradiol is an orally bio-active estrogen used in almost all modern formulations of combined oral contraceptive pills. 
Ethionamide Infection Others Ethionamide (2-ethylthioisonicotinamide) is an antibiotic used in the treatment of tuberculosis. 
Ethoxzolamide 
Neurological 
Disease Others   
Ethynodiol diacetate Endocrinology Estrogen/progestogen Receptor Ethynodiol diacetate is one of the first synthetic progestogens used in contraceptive pills. 
Etodolac (Lodine) Inflammation COX Etodolac is a nonsteroidal anti-inflammatory drug. 
Etomidate 
Neurological 
Disease GABA Receptor Etomidate is a GABAA receptors agonist at GABAA receptors. 
Etoposide (VP-16) Cancer Topoisomerase Etoposide (Etopophos) is a Topoisomerase II inhibitor (IC50 = 59.2 µM). 
Etravirine (TMC125) 
Neurological 
Disease Reverse Transcriptase Etravirine (TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. 
Everolimus (RAD001) Cancer mTOR Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM. 
Evista (Raloxifene 
Hydrochloride) Endocrinology Estrogen/progestogen Receptor 
A selective estrogen receptor modulator (SERM). raloxifene inhibited the proliferation of the human breast cancer cell line, 
MCF-7, with IC50=0.2 nM 
Exemestane Endocrinology Aromatase Exemestane was found to inhibit human placental aromatase with IC50 of 42 nM. 
Ezetimibe (Zetia) 
Cardiovascular 
Disease Others Ezetimibe (Zetia) is a drug that lowers cholesterol. 
Famciclovir (Famvir) Cancer Others Famciclovir(Famvir) is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections. 
Famotidine (Pepcid) 
Cardiovascular 
Disease Histamine Receptor 
Famotidine is a histamine H2–receptor antagonist with IC50 of 0.6 mM, commonly used to treat heartburn, GERD, ulcers, and 
other digestive conditions. 
Famprofazone Inflammation Others   
Febuxostat (Uloric) Inflammation Others Febuxostat is a non-purine selective xanthine oxidase inhibitor with IC50 of 114 -210 nM. 
Felbamate 
Neurological 
Disease Others Felbamate (Felbatol) is an anticonvulsant drug used in the treatment of epilepsy. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Felodipine (Plendil) 
Cardiovascular 
Disease Calcium Channel 
Felodipine (Plendil, Renedil) is a calcium channel blocker with an IC50 of 3 µM and 2 x 10 µM for the formyl-Met-Leu-Phe-
induced cytosolic calcium increase and H2O2 production, respectively. 
Fenbendazole    Others 
Fenbendazole is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites with an IC50 of about 
0.01 µg/mL. 
Fenofibrate (Tricor, 
Trilipix) 
Cardiovascular 
Disease PPAR Fenofibrate (Tricor, Trilipix) is a drug of the fibrate class and fibric acid derivative 
Fenoprofen calcium Inflammation Others Fenoprofen calcium is a nonsteroidal, anti-inflammatory antiarthritic agent. 
Fenoprofen calcium 
hydrate Immunology Others Fenoprofen calcium hydrate (Nalfon) is a non-steroidal anti-inflammatory drug (NSAID). 
Fenspiride HCl Inflammation PDE 
Fenspiride is a bronchodilator with anti-inflammatory properties, inhibiting phosphodiesterase 4 and phosphodiesterase 3 
activities with logIC50 values of 4.16 and 3.44, respectively, in human isolated bronchi. 
Fenticonazole nitrate 
Neurological 
Disease Others Fenticonazole nitrate is an azole antifungal agent. 
Fesoterodine fumarate 
(Toviaz) Immunology AChR 
Fesoterodine fumarate (Toviaz) is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl 
tolterodine that is a muscarinic receptor antagonist. 
Fexofenadine HCl 
Neurological 
Disease Histamine Receptor Fexofenadine inhibits histamine H1 receptor with IC50 of 246 nM. 
Fidaxomicin Infection DNA/RNA Synthesis Fidaxomicin is a narrow spectrum macrocyclic antibiotic that inhibits RNA polymerase sigma subunit. 
Finasteride Endocrinology 5-alpha Reductase Inhibitor of steroid Type II 5α-reductase 
FK-506 (Tacrolimus) Cancer mTOR An immunosuppressive agent and macrolide antibiotic. 
Flavoxate HCl 
Neurological 
Disease AChR Flavoxate is a muscarinic AChR antagonist with IC50 of 12.2 µM. 
Florfenicol Infection Others Florfenicol is a fluorinated synthetic analog of thiamphenicol with broad-spectrum, primarily bacteriostatic activity. 
Floxuridine Cancer DNA/RNA Synthesis 
Floxuridine (FUDR, FdUrd, Floxuridin) is a prodrugs of floxuridine and an oncology drug with an GI50 of 5.1 µM for the 
inhibition of MDCK/PEPT1. 
Fluconazole Infection P450 (e.g. CYP17) Fluconazole is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections. 
Flucytosine (Ancobon) Infection Others Flucytosine (Ancobon) is a fluorinated pyrimidine analogue and a synthetic antimycotic drug. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Fludarabine (Fludara) Cancer STAT,DNA/RNA Synthesis Fludarabine (Fludara) is a purine analog and a chemotherapy drug with IC50 < 3 µM. 
Fludarabine Phosphate 
(Fludara) Cancer DNA/RNA Synthesis 
Fludarabine Phosphate is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for 
incorporation into DNA and inhibit DNA synthesis. 
Flumazenil 
Neurological 
Disease GABA Receptor Flumazenil is a benzodiazepine antagonist. 
Flumequine 
Metabolic 
Disease Topoisomerase Flumequine is a synthetic chemotherapeutic antibiotic, inhibiting topoisomerase II with IC50 of 15 µM. 
Flumethasone Endocrinology Glucocorticoid Receptor 
Flumethasone is a glucocorticoid receptor agonist, this complex binds to the nucleus causing a variety of genetic activation 
and repressions. 
Flunarizine 2HCl Cancer Calcium Channel Flunarizine dihydrochloride is a dihydrochloride salt form which is a calcium channel blocker with a Ki of 68 nM. 
Flunixin meglumin Immunology COX 
Flunixin meglumine is a potent inhibitor of the enzyme cyclooxygenase used as analgesic agent with anti-inflammatory and 
antipyretic activity. 
Fluocinolone acetonide 
(Flucort-N) Infection Glucocorticoid Receptor Fluocinolone(Flucort-N) acetonide is a corticosteroid that binds to the cytosolic glucocorticoid receptor. 
Fluocinonide (Vanos) Endocrinology Glucocorticoid Receptor 
Fluocinonide (Vanos) is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin 
disorders such as eczema. 
Fluorometholone Acetate Inflammation Glucocorticoid Receptor 
Fluorometholone Acetate is a synthetic corticosteroid, used in the treatment of steroid responsive inflammatory conditions of 
the eye. 
Fluoxetine  HCl 
Neurological 
Disease 5-HT Receptor Fluoxetine (Prozac, Sarafem) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI)class. 
Flurbiprofen (Ansaid) Inflammation Others Flurbiprofen is a member of the phenylalkanoic acid derivative family of non-steroidal anti-inflammatory drugs (NSAIDs). 
Flutamide (Eulexin) Cancer Androgen Receptor Flutamide (Eulexin) is an oral nonsteroidal antiandrogen agent primarily used to treat prostate cancer. 
Fluticasone propionate 
(Flonase, Veramyst) Inflammation Glucocorticoid Receptor 
Fluticasone propionate (Flonase, Veramyst) is a synthetic corticosteroid which is derived from fluticasone used to treat 
asthma and allergic rhinitis (hay fever). 
Fluvastatin sodium 
(Lescol) 
Cardiovascular 
Disease HMG-CoA Reductase 
Fluvastatin Sodium (Lescol) is an orally active, potent and competitive HMG-CoA reductase inhibitor with an IC50 of 70 nM 
for vascular smooth muscle proliferation in vitro. 
Fluvoxamine maleate 
Neurological 
Disease 5-HT Receptor Fluvoxamine maleate is a selective serotonin (5-HT) reuptake inhibitor (SSRI) 
Formoterol hemifumarate 
Neurological 
Disease Adrenergic Receptor 
Formoterol hemifumarate is a potent, selective and long-acting β2-adrenoceptor agonist to β2 and β1 receptors with pKd of 
8.12 and 5.58, respectively. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Fosaprepitant 
dimeglumine 
Cardiovascular 
Disease Others Fosaprepitant (MK-0517, L-758,298) is a water-soluble phosphoryl prodrug for Aprepitant which is a NK1 antagonist. 
Fosfomycin Tromethamine   Others   
Ftorafur Cancer DNA/RNA Synthesis Ftorafur is a substance being used in the treatment of some types of cancer. 
Fulvestrant (Faslodex) Cancer Estrogen/progestogen Receptor Synthetic estrogen receptor antagonist (SERD) 
Furaltadone HCl Infection Others Furaltadone HCl is an antibacterial and has distinct curative effect in the treatment of coccidiosis. 
Furosemide (Lasix) 
Cardiovascular 
Disease Others Furosemide (Lasix) is a loop diuretic used in the treatment of congestive heart failure and edema. 
Gabexate mesylate 
Cardiovascular 
Disease Serine Protease 
Gabexate is a serine protease inhibitor with IC50 of 0.19 µM which is used therapeutically in the treatment of pancreatitis and 
disseminated intravascular coagulation. 
Gallamine triethiodide 
(Flaxedil) Inflammation AChR Gallamine triethiodide (Flaxedil) is a cholinergic receptor blocker with an IC50 of 68.0 ± 8.4 µM. 
Ganciclovir Infection Others Ganciclovir is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 µM. 
Gatifloxacin   Topoisomerase 
Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, and inhibits the bacterial enzymes <b>DNA 
gyrase</b> and </b>topoisomerase IV</b>. 
Gefitinib (Iressa) Cancer EGFR 
Gefitinib also known as ZD-1839 & Iressa is a novel potent EGFR tyrosine kinase & Akt phosphorylations inhibitor with IC50 
of 37, 26 and 57 nM. 
Gemcitabine (Gemzar) 
Metabolic 
Disease DNA/RNA Synthesis,Autophagy Gemcitabine(Gemzar) belongs to the group of medicines called antimetabolites. 
Gemfibrozil (Lopid) 
Cardiovascular 
Disease PPAR Gemfibrozil (Lopid) is an oral drug used to lower lipid levels. 
Genipin   Others 
Genipin is an active aglycone derived from an iridoid glycoside called geniposide, which is found in the fruit of Gardenia 
jasminoides Ellis.   
Geniposide   Others Geniposide is an iridoid glycoside isolated from the fruit of Gardenia jasminoides Ellis. 
Geniposidic acid   Others Geniposidic acid is an iridoid glucoside, used to treat inflammation, jaundice and hepatic disorders.  
Genistein Cancer EGFR,Topoisomerase Genistein is a soy-derived isoflavone and phytoestrogen with antineoplastic activity. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Gestodene Endocrinology Estrogen/progestogen Receptor Gestodene is a progestogen hormonal contraceptive. 
Gimeracil 
Neurological 
Disease Dehydrogenase 
Gimeracil is an inhibitor of dihydropyrimidine dehydrogenase, which inhibits the early step in homologous recombination for 
double strand breaks repair. 
Ginkgolide A 
Cardiovascular 
Disease GABA Receptor Ginkgolide A is an extract from in Ginkgo biloba and a g-aminobutyric acid (GABA) antagonist with a Ki of 14.5 µM. 
Glafenine HCl Inflammation Others   
Gliclazide (Diamicron) 
Neurological 
Disease Potassium Channel Gliclazide (Diamicron) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 ± 30 nM. 
Glimepiride 
Metabolic 
Disease Potassium Channel Glimepiride is a medium-to-long acting sulfonylurea anti-diabetic drug. 
Glipizide (Glucotrol) Endocrinology Others Glipizide (Glucotrol) is used to treat high blood sugar levels caused by a type of diabetes mellitus called type 2 diabetes. 
Gliquidone 
Metabolic 
Disease Potassium Channel Gliquidone is an ATP-sensitive K+ channel antagonist with IC50 of 27.2 nM. 
Glyburide (Diabeta) Endocrinology Potassium Channel Glyburide (Diabeta) is an anti-diabetic drug in a class of medications known as sulfonylureas, closely related to sulfa drugs. 
Guaifenesin 
(Guaiphenesin) 
Respiratory 
Disease Others Guaifenesin (Guaiphenesin) is thought to act as an expectorant. 
Guanabenz acetate Endocrinology Adrenergic Receptor 
Guanabenz Acetate is an selective agonist of α2a-adrenergic receptor, α2b-adrenergic receptor and α2c-adrenergic receptor 
with pEC50 of 8.25, 7.01 and ~5, respectively. 
Guanidine HCl Vermifuge Others 
Guanidine HCl, the crystalline compound of strong alkalinity formed by the oxidation of guanine, is a normal product of protein 
metabolism and a protein denaturant. 
Halobetasol Propionate Inflammation Phospholipase (e.g. PLA) Halobetasol Propionate is an anti-inflammatory and a dermatologic agent commonly used to treat psoriasis. 
Haloperidol (Haldol) 
Neurological 
Disease Others Haloperidol (Haldol)) is an antipsychotic and butyrophenone. 
Homatropine Bromide Infection AChR 
Homatropine Bromide is muscarinic AChR antagonist, inhibits endothelial and smooth muscle muscarinic receptors of WKY-E 
and SHR-E with IC50 of 162.5 nM and 170.3 nM, respectively. 
Homatropine 
Methylbromide   AChR 
Homatropine Methylbromide is muscarinic AChR antagonist, inhibits endothelial and smooth muscle muscarinic receptors of 
WKY-E and SHR-E with IC50 of 162.5 nM and 170.3 nM, respectively. 
Hydrochlorothiazide 
Cardiovascular 
Disease Others Hydrochlorothiazide is a first line diuretic drug of the thiazide class. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Hydrocortisone (Cortisol) Infection Glucocorticoid Receptor Hydrocortisone is a steroid hormone or glucocorticoid produced by the adrenal gland. 
Hydroxyurea (Cytodrox) Cancer DNA/RNA Synthesis 
Hydroxyurea (Cytodrox) is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside 
diphosphate reductase. 
Hydroxyzine 2HCl 
Neurological 
Disease Histamine Receptor 
Hydroxyzine is a histamine H1-receptor antagonist, inhibits binding of [3H]pyrilamine/[3H]desloratadine to human histamine 
H1 receptor with IC50 of 10 nM/19 nM. 
Hyoscyamine (Daturine) 
Neurological 
Disease AChR Hyoscyamine (Daturine) is an AChR inhibitor with IC50 of 7.5 nM. 
Ibuprofen (Advil) Inflammation COX Ibuprofen is a non-selective COX inhibitor with an IC50 of 3.3 x 10-4 M. 
Ibutilide fumarate 
Cardiovascular 
Disease Sodium Channel 
Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a 
recent onset to sinus rhythm by induction of slow inward sodium current, which prolongs action potential and refractory period 
of myocardial cells. 
Idarubicin HCl Cancer Topoisomerase 
Idarubicin is the anthracycline antibiotic and target DNA topoisomerase II (topo II). MCF-7 cells were sensitive to idarubicin, 
with an IC 50 value for growth inhibition of 0.01 µM 
Idebenone Inflammation Others Idebenone is a synthetic analog of coenzyme Q10 (CoQ10) and a brain stimulant. 
Idoxuridine Infection Others Idoxuridine is an antiviral agent for feline herpesvirus type-1 with IC50 of 4.3 µM. 
Ifosfamide Cancer DNA/RNA Synthesis Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer. 
Iloperidone (Fanapt) 
Neurological 
Disease 5-HT Receptor Iloperidone (Fanapt, Fanapta, Zomaril) is an atypical antipsychotic for the treatment of schizophrenia. 
Imatinib (Gleevec) 
Neurological 
Disease PDGFR Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 µM, 0.1 µM and 0.1 µM, respectively. 
Imatinib Mesylate Cancer c-Kit,Bcr-Abl,PDGFR 
Imatinib Mesylate is a multitargeted c-kit, PDGF-R and c-ABL inhibitor with IC50 of 3.9 and 2.9 µM for the inhibition of T-cell 
proliferation stimulated by DCs and PHA, respectively. 
Imidapril (Tanatril) HCl 
Cardiovascular 
Disease RAAS Imidapril HCl is a angiotensin-converting enzyme (ACE) inhibitor with IC50 of 2.6 nM, used for the treatment of hypertension.  
Imipramine HCl 
Neurological 
Disease Others   
Indacaterol Maleate Infection Adrenergic Receptor Indacaterol is an ultra-long-acting β-adrenoceptor agonist with pKi of 7.36. 
Indapamide (Lozol) 
Cardiovascular 
Disease Others 
Indapamide (Lozol) is a non-thiazide sulphonamide diuretic drug, generally used in the treatment of hypertension, as well as 
decompensated cardiac failure. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Indomethacin (Indocid, 
Indocin) Inflammation COX 
Indomethacin (Indocid, Indocin) is a non-steroidal anti-inflammatory drug commonly used to reduce fever, pain, stiffness, and 
swelling. 
Ipratropium bromide 
Respiratory 
Disease AChR Ipratropium bromide is a muscarinic antagonist, bronchodilator, N-Isopropyl salt of atropine. 
Irinotecan Cancer Topoisomerase 
Irinotecan (Camptosar, Campto, CPT-11) is a topoisomerase I inhibitor with an IC50 of 15.8 and 5.17 µM for LoVo cells and 
HT-29 cells, respectively. 
Irinotecan HCl Trihydrate 
(Campto) 
Neurological 
Disease Topoisomerase Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1. 
Irsogladine 
Neurological 
Disease AChR,PDE 
Irsogladine is an anti-gastric ulcer agent that facilitates gap-junctional intercellular communication through M1 muscarininc 
acetylcholine receptor binding. 
Isoconazole nitrate 
(Travogen) Infection Others Isoconazole nitrate (Travogen) is an azole antifungal reagent. 
Isoetharine Mesylate 
Cardiovascular 
Disease Others   
Isoniazid (Tubizid) Infection Others Isoniazid (Tubizid) is a prodrug and must be activated by bacterial catalase. 
Isoprenaline hydrochloride Infection Adrenergic Receptor Isoprenaline hydrochloride is a beta-adrenergic agonist. 
Isosorbide   Others Isosorbide is a heterocyclic compound that is derived from glucose, used as a diuretic. 
Isotretinoin 
Metabolic 
Disease Hydroxylase It was developed to be used as a chemotherapy medication for the treatment of brain cancer, pancreatic cancer and more. 
Isovaleramide 
Neurological 
Disease Dehydrogenase Isovaleramide is an anticonvulsant molecule isolated from Valeriana pavonii, it inhibits the liver alcohol dehydrogenases. 
Isoxicam Inflammation Others   
Isradipine (Dynacirc) 
Neurological 
Disease Calcium Channel Isradipine(Dynacirc) is a calcium channel blocker with an IC50 of 34±8 µM. 
Itraconazole (Sporanox) Cancer P450 (e.g. CYP17) Itraconazole (Sporanox) is a triazole antifungal agent. 
Ivabradine HCl 
(Procoralan) 
Neurological 
Disease Adrenergic Receptor 
Ivabradine, a new If inhibitor with IC 50 of 2.9 µM which acts specifically on the pacemaker activity of the sinoatrial node, is a 
pure heart rate lowering agent. 
Ivacaftor (VX-770) 
Respiratory 
disease CFTR 
Ivacaftor (VX-770, Kalydeco) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 
25 nM, respectively. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Ivermectin Vermifuge Others Ivermectin is a broad-spectrum antiparasitic medication. 
Ketoconazole Infection P450 (e.g. CYP17) Ketoconazole is a synthetic broad-spectrum antifungal agent. 
Ketoprofen (Actron) Inflammation COX 
Ketoprofen is a non-selective NSAID with IC50 of 0.5 µM and 2.33 µM for human recombinant COX-1 and COX-2, 
respectively. 
Ketorolac (Toradol) 
Neurological 
Disease COX 
Ketorolac tromethamine is a non-selective COX inhibitor with IC50 of 31.5 µM and 60.5 µM for human recombinant COX-1 
and COX-2, respectively. 
Ketotifen fumarate 
(Zaditor) 
Neurological 
Disease Histamine Receptor Ketotifen fumarate (Zaditor) is a fumaric acid salt of ketotifen which is a H1-antihistamine and mast cell stabilizer. 
L-Adrenaline (Epinephrine) 
Cardiovascular 
Disease Adrenergic Receptor L-Adrenaline (Epinephrine) belongs to a group of the compounds known as catecholamines. 
L-Thyroxine 
Neurological 
Disease Others L-Thyroxine is a synthetic form of thyroxine and a hormone replacement drug. 
Lacidipine (Lacipil, 
Motens) 
Cardiovascular 
Disease Calcium Channel Lacidipine (Lacipil, Motens) is a L-type calcium channel blocker.  
Lafutidine Infection Histamine Receptor Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion. 
Lamivudine (Epivir) Infection Reverse Transcriptase Lamivudine (Epivir) is a potent nucleoside analog reverse transcriptase inhibitor with an IC50 of 2.7 mM. 
Lamotrigine Cancer 5-HT Receptor,Sodium Channel 
Lamotrigine is a novel anticonvulsant drug for inhibition of 5-HT with IC50 of 240 µM and 474 µM in human platelets and rat 
brain synaptosomes, respectively. 
Lansoprazole Infection Proton Pump Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid. 
Lapatinib 
Neurological 
Disease HER2,EGFR 
Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, 
respectively. 
Lapatinib Ditosylate 
(Tykerb) Cancer EGFR,HER2 Lapatinib Ditosylate (GW572016, GW2016) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. 
Leflunomide Inflammation Dehydrogenase Immunosuppressant agent. Its active metabolite is A77 1726 (RS-61980). 
Lenalidomide 
Cardiovascular 
Disease TNF-alpha 
Lenalidomide also known as CC-5013 & Revlimid is TNF-alpha inhibitor. Revlimid with purity >99% & solubility DMSO is 
available. 
Letrozole Endocrinology Aromatase 
Aromatase inhibitor. CGS 20267 is a new non-steroidal compound which potently inhibits aromatase in vitro (IC50 of 11.5 nM) 
and in vivo (ED50 of 1–3 µg/kg p.o.) 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Levetiracetam 
Neurological 
Disease Calcium Channel Levetiracetam is an antiepileptic compound. 
Levobetaxolol HCl 
Cardiovascular 
Disease Adrenergic Receptor 
Levobetaxolol exhibits a higher affinity at cloned human β1 and β2 receptors with Ki value of 0.76 nM and 32.6 nM, 
respectively. 
Levofloxacin (Levaquin) Infection Topoisomerase Levofloxacin (Levaquin) is a synthetic fluoroquinolone (fluoroquinolones) antibacterial agent. 
Levonorgestrel (Levonelle) Endocrinology Estrogen/progestogen Receptor Levonorgestrel (Levonelle) is a synthetic progestogen used as an active ingredient in some hormonal contraceptives. 
Levosimendan 
Metabolic 
Disease Others 
Levosimendan is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC), provides 
treatment for heart failure. Phase 4. 
Levosulpiride 
(Levogastrol) 
Neurological 
Disease Dopamine Receptor Levosulpiride is a selective antagonist for D2 dopamine receptors used as an antipsychotic and prokinetic agent.  
Licofelone   COX Licofelone is a dual COX/LOX inhibitor being considered as a treatment for osteoarthritis. 
Lidocaine (Alphacaine) 
Neurological 
Disease Histamine Receptor Lidocaine is a common local anesthetic and antiarrhythmic drug. 
Linagliptin (BI-1356) Cancer DPP-4 Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM. 
Lincomycin hydrochloride 
(Lincocin) Cancer Others 
Lincomycin hydrochloride (Lincocin) is the monohydrated salt of lincomycin, a substance produced by the growth of a 
member of the lincolnensis group of Streptomyces lincolnensis. 
Linezolid (Zyvox) Infection Others Linezolid is a synthetic antibiotic used for the treatment of serious infections. 
Liothyronine Sodium Endocrinology Others 
Liothyronine Sodium is the most potent form of thyroid hormone acting on the body to increase the basal metabolic rate, 
affect protein synthesis.  
Lithocholic acid 
Neurological 
Disease FXR Lithocholic acid is a bile acid that acts as a detergent to solubilize fats for absorption. 
Lomerizine HCl 
Cardiovascular 
Disease Calcium Channel Lomerizine dihydrochloride is a relatively new L- and T-type calcium channel blocker used in the treatment of migraine. 
Lomustine (CeeNU) Cancer Others Lomustine (CeeNU) is an alkylating agent of value against both hematologic malignancies and solid tumors. 
Lonidamine 
Cardiovascular 
Disease Others Lonidamine is an orally administered small molecule hexokinase inactivator with an IC50 of 0.85 mM. 
Loperamide hydrochloride Infection Autophagy,Opioid Receptor Loperamide is an opioid-receptor agonist with an ED50 of 0.15 mg/kg. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Lopinavir (ABT-378) Infection HIV Protease Lopinavir is an inhibitor of the HIV protease. 
Loratadine Inflammation Histamine Receptor Loratadine (Claritin) is an antihistamine drug used to treat allergies. 
Lornoxicam (Xefo) Inflammation COX Lornoxicam (Xefo) is a COX-1 and COX-2 inhibitor with IC50 of 5 nM and 8 nM, respectively. 
Losartan potassium 
Cardiovascular 
Disease RAAS 
Losartan is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 
nM. 
Loteprednol etabonate   Glucocorticoid Receptor 
Loteprednol etabonate is a potent <b>glucocorticoid receptor</b> agonist, used in treatment of inflammation of the eye due to 
allergies. 
Lovastatin (Mevacor) 
Respiratory 
Disease HMG-CoA Reductase Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM, used for lowering cholesterol (hypolipidemic agent). 
Loxapine Succinate 
Neurological 
Disease 5-HT Receptor,Dopamine Receptor 
Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-
psychotic agent. 
Malotilate 
Metabolic 
Disease Others Malotilate is a liver protein metabolism improved compound. 
Manidipine (Manyper) 
Metabolic 
Disease Calcium Channel 
Manidipine (Manyper) is a lipophilic, third-generation, highly vasoselective dihydropyridine calcium antagonist with an IC50 of 
2.6 nM. 
Maprotiline hydrochloride 
Neurological 
Disease Adrenergic Receptor 
Maprotiline hydrochloride (Deprilept, Ludiomil, Psymion) is a selective noradrenalin re-uptake inhibitor and a tetracyclic 
antidepressant. 
Maraviroc Inflammation CCR Maraviroc is a selectiveantagonist of the CCR5co-receptorwith an in vitroIC50 of 0.1 to 4.5 nMand in vitro IC90 0.6to 13.4 nM. 
Marbofloxacin   Topoisomerase Marbofloxacin is a potent antibiotic inhibiting bacterial <b>DNA</b> replication. 
Masitinib (AB1010) 
Respiratory 
Disease PDGFR,c-Kit 
Masitinib also known as Masivet, AB1010 is a tyrosine kinase, c-Kit, PDGFR, FGFR3, the FAK pathway inhibitor with IC50 of 
150 ± 80, 200 ± 40 nM. 
MDV3100 (Enzalutamide) Cancer Androgen Receptor MDV3100 is an androgen-receptor (AR) antagonist with IC50 of 36 nM. 
Mecarbinate 
Metabolic 
Disease Others Mecarbinate is a antihypertensive agents through relaxing blood smooth muscle. 
Meclofenamate Sodium   COX 
Meclofenamate Sodium is a dual COX-1/COX-2 inhibitor with IC50 of 40 nM and 50 nM, respectively, used in the treatment of 
joint, muscular pain, arthritis and dysmenorrhea.  
Medetomidine HCl Infection Adrenergic Receptor Medetomidine is a selective α2-adrenoceptor agonist, with Ki of 1.08 nM, exhibts 1620-fold selectivity over α1-adrenoceptor. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Medroxyprogesterone 
acetate Infection Estrogen/progestogen Receptor 
Medroxyprogesterone acetate is a progestin, a synthetic variant of the human hormone progesterone and a potent 
progesterone receptor agonist. 
Mefenamic acid 
Cardiovascular 
Disease COX Mefenamic acid is a competitive inhibitor of COX-1 and COX-2. 
Megestrol Acetate Infection 
Androgen 
Receptor,Estrogen/progestogen 
Receptor Megestrol Acetate is a synthetic progesteronal agent with an IC50 of 260 µM for the inhibition of HegG2. 
Meglumine   Others Meglumine is an amino sugar derived from sorbitol for THP-1 cells with IC50 of 22 µg/mL. 
Melatonin Endocrinology MT Receptor Melatonin is a hormone produced in the brain by the pineal gland from the amino acid tryptophan.  
Meloxicam (Mobic) Inflammation COX Meloxicam (Mobic) is a nonsteroidal anti-inflammatory agent with analgesic and fever reducer effects. 
Memantine HCl (Namenda) 
Neurological 
Disease 
AMPA Receptor-kainate Receptor-
NMDA Receptor 
Memantine hydrochloride (Namenda) is a CYP2B6 and CYP2D6 inhibitor for recombinant CYP2B6 and CYP2D6 with Ki of 
0.51 nM and 94.9 µM, respectively.  
Menadione Endocrinology Others 
Menadione(Vitamin K3), a synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be 
converted to active vitamin K2, menaquinone, after alkylation in vivo. 
Mepenzolate Bromide   Others   
Mepiroxol   Others   
Mepivacaine HCl 
Metabolic 
Disease Others Mepivacaine is a tertiary amine used as a local anesthetic. 
Meptazinol HCl   Opioid Receptor 
Meptazinol is a unique centrally active <b>opioid analgesic</b>, which inhibits [<sup>3</sup>H]dihydromorphine binding with 
<b>IC50</b> of 58 nM. 
Mequinol Infection Others Mequinol (4-Methoxyphenol) is a depigmentation agent. 
Mercaptopurine Cancer DNA/RNA Synthesis Mercaptopurine is a drug used to treat leukemia. 
Meropenem Infection Others Meropenem is an ultra-broad spectrum injectable antibiotic. 
Mesalamine (Lialda) Inflammation IκB/IKK Mesalamine (Lialda, Apriso) is an anti-inflammatory drug. 
Mesna (Uromitexan, 
Mesnex) Cancer Others 
Mesna (Uromitexan, Mesnex), a sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated 
with certain chemotherapeutic agents. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Mesoridazine Besylate 
Neurological 
Disease Others   
Mestranol Endocrinology Estrogen/progestogen Receptor Mestranol is the 3-methyl ether of ethinylestradiol. It was the estrogen used in many of the first oral contraceptives. 
Metaproterenol Sulfate 
Respiratory 
Disease Others   
Metaraminol Bitartrate   Others   
Methacycline 
hydrochloride 
(Physiomycine) Cancer Others Methacycline hydrochloride (Physiomycine) is a tetracycline antibiotic. 
Methazolamide 
Neurological 
Disease Carbonic Anhydrase 
Methazolamide is a carbonic anhydrase inhibitor with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, 
respectively. 
Methazolastone Cancer Autophagy P.o. imidazotetrazine second-generation alkylating agent. 
Methenamine 
(Mandelamine) Inflammation Others Methenamine is an antibiotic used for the treatment of urinary tract infection. 
Methimazole (Tapazole, 
Northyx) Endocrinology Others Methimazole (Tapazole, Northyx) is an antithyroid medicine. 
Methocarbamol (Robaxin) 
Neurological 
Disease Carbonic Anhydrase Methocarbamol (Robaxin) is a central muscle relaxant used to treat skeletal muscle spasms. 
Methoxsalen (Oxsoralen) Inflammation Others 
Methoxsalen (Oxsoralen) a naturally occurring furocoumarin compound found in several species of plants, including Psoralea 
corylifolia, is a drug used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing 
the skin to sunlight. 
Methscopolamine (Pamine) 
Neurological 
Disease AChR Methscopolamine (Pamine) is a muscarinic acetylcholine receptor blocker.  
Methyclothiazide 
Cardiovascular 
Disease Others 
Methyclothiazide is a substituted benzothiadiazide, used to treat high blood pressure and fluid retention caused by various 
conditions including heart disease. 
Methylprednisolone Immunology Glucocorticoid Receptor Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. 
Methylthiouracil Infection Others Methylthiouracil is an antithyroid preparation. 
Meticrane 
Cardiovascular 
Disease Others   
Metolazone (Zaroxolyn) 
Cardiovascular 
Disease Others Metolazone (Zaroxolyn) is primarily used to treat congestive heart failure and high blood pressure. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Metoprolol tartrate 
Cardiovascular 
Disease Adrenergic Receptor Pefloxacin mesylate is a synthetic chemotherapeutic agent and an antibacterial agent with IC50 of 6.7 nM. 
Metronidazole (Flagyl) Infection DNA/RNA Synthesis Metronidazole(Flagyl)is a nitroimidazole antibiotic medication used particularly for anaerobic bacteria and protozoa. 
Mevastatin 
Cardiovascular 
Disease HMG-CoA Reductase 
Mevastatin is a competitive inhibitor of HMG-Coenzyme A (HMG-CoA) reductase with a binding affinity 10,000 times greater 
than the HMG-CoA substrate itself. 
Mexiletine HCl 
Cardiovascular 
Disease Sodium Channel 
Mexiletine HCl belongs to Class IB anti-arrhythmic group of medicines, inhibits sodium channels to reduce the inward sodium 
current. 
Mezlocillin Sodium Infection Others 
Mezlocillin sodium is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, 
usually gram-positive, organisms. 
Mianserin hydrochloride 
Neurological 
Disease Histamine Receptor Mianserin is a psychoactive drug of the tetracyclic antidepressant. 
Miconazole (Monistat) 
Neurological 
Disease Others Miconazole (Monistat) is an imidazole antifungal agent. 
Miconazole nitrate Infection Others Miconazole is an imidazole antifungal agent that is used topically and by intravenous infusion. 
Mifepristone (Mifeprex) 
Metabolic 
Disease Estrogen/progestogen Receptor 
Mifepristone (Mifeprex, RU-486, RU-38486, Mifegyne) is a remarkably active antagonist of progesterone receptor and 
glucocorticoid receptor with IC50 of 0.2 nM and 2.6 nM, respectively. 
Miglitol (Glyset) 
Neurological 
Disease Others Miglitol (Glyset) is an oral anti-diabetic drug. 
Milnacipran HCl Endocrinology Others 
Milnacipran inhibits both norepinephrine transporter (NET) and norepinephrine transporter (SERT) with IC50 of 77 nM and 
420 nM, respectively. 
Milrinone (Primacor) 
Cardiovascular 
Disease ATPase,PDE 
Milrinone (Primacor) is a a potent and selective phosphodiesterase 3 inhibitor with an IC50 of 0.42 µM for the inhibition of FIII 
PDE. 
Mirabegron (YM178) Cancer Adrenergic Receptor β3-adrenoceptor 
Mirtazapine (Remeron, 
Avanza) Immunology 5-HT Receptor Mirtazapine (Remeron, Avanza) is a potent tetracyclic antidepressant. 
Mitotane (Lysodren) Cancer Others Mitotane(Lysodren), is an antineoplastic medication used in the treatment of adrenocortical carcinoma. 
Mitoxantrone 
Hydrochloride 
Cardiovascular 
Disease Topoisomerase Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 µM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively. 
Moclobemide 
Neurological 
Disease MAO Moclobemide is MAO-A (5-HT) inhibitor with IC50 of 6.1 µM. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Moexipril HCl 
Digestive 
system disease RAAS 
Moexipril hydrochloride is a potent orally active non-sulfhydryl angiotensin converting enzyme inhibitor (ACE) with IC50 of 
0.041 µM, which is used for the treatment of hypertension and congestive heart failure. 
Moguisteine 
Respiratory 
Disease Others Moguisteine is a novel peripheral non-narcotic antitussive drug. 
Mometasone furoate Inflammation Glucocorticoid Receptor Mometasone furoate is a glucocorticosteroid used topically to reduce inflammation of the skin or in the airways. 
Monobenzone (Benoquin) 
Metabolic 
Disease Others Monobenzone (Benoquin) is a compound used as a topical drug for medical depigmentation. 
Montelukast Sodium 
Respiratory 
Disease Others 
Montelukast selectively antagonizes leukotriene D 4 (LTD4) by binding to it so that block the action of leukotriene D4 on the 
cysteinyl leukotriene receptor CysLT1. 
Moroxydine Cancer Others Moroxydine hydrochloride is a synthetic antiviral drug chemically belonging to the series of the  heterocyclic biguanidines. 
Mosapride citrate 
Neurological 
Disease 5-HT Receptor Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist. 
Moxalactam Disodium Infection Others   
Moxifloxacin hydrochloride Infection Topoisomerase Moxifloxacin (Avelox, Avalox) is a fourth generation synthetic fluoroquinolone antibacterial agent. 
Moxonidine 
Digestive 
system disease Others Moxonidine is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent. 
Mupirocin   DNA/RNA Synthesis Mupirocin is an isoleucyl t-RNA synthetase inhibitor, used of the treatment of bacterial skin infections. 
Mycophenolate mofetil 
(CellCept) Immunology Dehydrogenase Mycophenolate mofetil is a inhibitor of inosine monophosphate dehydrogenase and a immunosuppressant. 
Mycophenolic 
(Mycophenolate) Infection Dehydrogenase Mycophenolic acid (Mycophenolate) is an immunosuppressant drug used to prevent rejection in organ transplantation. 
Nabumetone Inflammation COX Nabumetone is a non-steroidal anti-inflammatory drug and its active metabolite inhibits the COX. 
Nadifloxacin 
Neurological 
Disease Others Nadifloxacin is a topical fluoroquinolone antibiotic for the treatment of acne vulgaris. 
Nafamostat mesylate 
Cardiovascular 
Disease Serine Protease Nafamostat is an anticoagulant. 
nafcillin sodium 
monohydrate Endocrinology Others Nafcillin sodium reversibly inhibits β-lactamase with Kd of 33 mM. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Naftopidil (Flivas) Endocrinology Adrenergic Receptor Naftopidil is a selective α1-adrenergic receptor antagonist or alpha blocker with a Ki of 58.3 nM. 
Nalidixic acid (NegGram) Infection Topoisomerase 
Nalidixic acid(NegGram) is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an 
inhibitor of the A subunit of bacterial DNA gyrase. 
Nalmefene HCl 
Neurological 
Disease Others   
Naloxone HCl Cancer Opioid Receptor Naloxone HCl is an opioid inverse agonist drug used to counter the effects of opiate overdose. 
Naltrexone HCl 
Neurological 
Disease Opioid Receptor 
Naltrexone is an opioid receptor antagonist with IC50 of 8 nM used primarily in the management of alcohol dependence and 
opioid dependence. 
Naphazoline hydrochloride 
(Naphcon) 
Neurological 
Disease Adrenergic Receptor Naphazoline hydrochloride (Naphcon) is an ocular vasoconstrictor and imidazoline derivative sympathomimetic amine. 
Naproxen (Aleve) Inflammation COX Naproxen (Aleve, Anaprox) is a COX inhibitor for COX-1 and COX-2 with IC50 of 2.2 µg/mL and 1.3 µg/mL, respectively. 
Naratriptan HCl 
Neurological 
Disease 5-HT Receptor Naratriptan (Amerge) is a triptan agent that is used for the treatment of migraine headaches. 
Natamycin (Pimaricin) Infection Others Natamycin (Pimaricin) is a naturally occurring antifungal agent. 
Nateglinide (Starlix) Immunology Potassium Channel 
Nateglinide (Starlix) is an insulin secretagog agent that lowers blood glucose levels by stimulating insulin secretion from the 
pancreas. 
Nebivolol (Bystolic) 
Cardiovascular 
Disease Adrenergic Receptor Nebivolol (Bystolic) is a β1 receptor blocker with an IC50 of 4.5 µM. 
Nefiracetam (Translon) 
Neurological 
Disease GABA Receptor Nefiracetam (Translon) is cognitive enhancer with an IC50 of approximately 150–200 µM for Ro 5-4864. 
Nelarabine (Arranon) Cancer DNA/RNA Synthesis Nelarabine (Arranon) performes growth inhibitory activity (IC50= 1.61 µM) against MOLT-4 cells. 
Nelfinavir Mesylate   HIV Protease Nelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM. 
Nepafenac Inflammation COX Nepafenac is a non-steroidal anti-inflammatory drug (NSAID). 
Nevirapine (Viramune) Infection Reverse Transcriptase Nevirapine (Viramune) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS. 
Niacin (Nicotinic acid) 
Metabolic 
Disease Others Niacin (Nicotinic acid) is a water-soluble vitamin belonging to the vitamin B family. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Nialamide 
Neurological 
Disease Others   
Nicardipine HCl 
Neurological 
Disease Calcium Channel Nicardipine is a dihydropyridine calcium-channel blocking agent used for the treatment of vascular disorders. 
Nicorandil (Ikorel) 
Cardiovascular 
Disease Potassium Channel Nicorandil (Ikorel) is potassium channel activator. 
Nicotinamide 
(Niacinamide) 
Neurological 
Disease Sirtuin Nicotinamide (Niacinamide) is a water-soluble vitamin and is part of the vitamin B group. 
Nicotine Ditartrate 
Neurological 
Disease Others   
Nifedipine (Adalat) 
Cardiovascular 
Disease Calcium Channel Nifedipine(Adalat), a potent vasodilator agent with calcium antagonistic action. 
Nifenazone Inflammation Others   
Niflumic acid Infection GABA Receptor,COX Niflumic acid is an inhibitor of cyclooxygenase-2 used for joint and muscular pain. 
Nifuroxazide Infection STAT 
Nifuroxazide is a cell-permeable and orally available nitrofuran-based antidiarrheal agent that effectively suppresses the 
activation of cellular STAT1/3/5 transcription activity with IC50 of 3 µM against IL-6-induced STAT3 activation in U3A cells 
Nilotinib (AMN-107) Cancer Bcr-Abl Inhibitor of BCR-ABL, IC50 < 30nM 
Nilvadipine (ARC029) Cancer Calcium Channel Nilvadipine (ARC029) is a potent calcium channel blocker with an IC50 of 0.03 nM. 
Nimesulide 
Cardiovascular 
Disease COX Nimesulide is a relatively COX-2 selective inhibitor with IC50 of 26 µM. 
Nimodipine (Nimotop) 
Cardiovascular 
Disease Autophagy,Calcium Channel 
Nimodipine (Nimotop) is a dihydropyridine derivative and an analogue of the calcium channel blocker nifedipine, with 
antihypertensive activity. 
Nisoldipine (Sular) 
Cardiovascular 
Disease Calcium Channel Nisoldipine (Sular) is a calcium channel blocker. 
Nitazoxanide (Alinia, 
Annita) Vermifuge Others 
Nitazoxanide (Alinia, Annita) is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent. (IC50 for canine 
influenza virus ranges from 0.17 to 0.21 µM) 
Nithiamide   Others Nithiamide is a non-5-nitroimidazole drugs. 
Nitrendipine 
Neurological 
Disease Calcium Channel,Autophagy Nitrendipine is a dihydropyridine calcium channel blocker with an IC50 of 95 nM. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Nitrofurazone (Nitrofural) Infection Others Nitrofurazone is a topical anti-infective agent with an IC50 of 22.83 ± 1.2 µM. (Rat LD50 = 590 mg/kg) 
Nizatidine 
Metabolic 
Disease Histamine Receptor Nizatidine (Axid) is a histamine H2-receptor antagonist with and IC50 of 6.7 nM for AChE. 
Noradrenaline bitartrate 
monohydrate (Levophed) 
Metabolic 
Disease Adrenergic Receptor Noradrenaline bitartrate monohydrate (Levophed) is a direct alpha-adrenergic receptors stimulator. 
norethindrone 
Neurological 
Disease Others 
Norethindrone (Norethisterone) is a synthetic progestin, which mimic the actions of the endogenous ovarian hormone 
progesterone. 
Noscapine HCl Cancer Others   
Novobiocin sodium 
(Albamycin) 
Cardiovascular 
Disease Topoisomerase 
Novobiocin (Albamycin) is a very potent bacterial DNA gyrase and human organic anion transporters with Ki of of 14.87 ± 
0.40 µM for hOAT1, 4.77 ± 1.12 µM for hOAT3, and 90.50 ± 7.50 µM for hOAT4 
Nystatin (Mycostatin) Infection Others Nystatin (Mycostatin) is a polyene antifungal drug to which many molds and yeasts are sensitive, including Candida spp. 
Olanzapine (Zyprexa) Infection 5-HT Receptor,Dopamine Receptor Olanzapine (Zyprexa) is a high affinity for 5-HT2 serotonin and D2 dopamine receptor antagonist. 
Olmesartan medoxomil 
(Benicar) 
Cardiovascular 
Disease RAAS 
Olmesartan medoxomil (Benicar) is a compound which is hydrolyzed to olmesartan that is a selective AT1 subtype 
angiotensin II receptor antagonist. 
Olopatadine hydrochloride 
(Opatanol) 
Neurological 
Disease Histamine Receptor 
Olopatadine hydrochloride (Opatanol) is a histamine blocker and mast cell stabilizer with an IC50 of 559 µM for the release of 
histamine. 
olsalazine sodium Inflammation Others Olsalazine Sodium is a anti-inflammatory prodrug, which consists of two 5-ASA moieties linked by an azo bond. 
Omeprazole (Prilosec) 
Metabolic 
Disease Autophagy,Proton Pump Omeprazole (Prilosec) is a proton pump inhibitor used in the treatment of dyspepsia. 
Ondansetron 
hydrochloride (Zofran) Infection 5-HT Receptor Ondansetron HCl is a serotonin 5-HT3 receptor antagonist.  
Orlistat (Alli, Xenical) 
Metabolic 
Disease Others Orlistat is a general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice. 
Ornidazole Endocrinology Others Ornidazole is a 5-nitroimidazole derivative with antiprotozoal and antibacterial properties against anaerobic bacteria. 
Orphenadrine citrate 
(Norflex) Infection AChR Orphenadrine citrate is a skeletal muscle relaxant, it acts in the central nervous system to produce its muscle relaxant effects. 
OSI-420 (Desmethyl 
Erlotinib) Cancer EGFR 
OSI-420 (Desmethyl Erlotinib,CP-473420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase 
inhibitor with IC50 of 2 and 20 nM for the inhibition of human EGFR and EGFR autophosphorylation in tumor cells. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Ospemifene   Estrogen/progestogen Receptor Ospemifene is a non-hormonal selective estrogen receptor modulator (SERM), used for the treatment of dyspareunia.  
Otilonium Bromide 
Cardiovascular 
Disease AChR Otilonium bromide is an antimuscarinic. 
Ouabain 
Neurological 
Disease Sodium Channel 
Ouabain is a selective Na+, K+-ATPase inhibitor, binds to α2 subunit and α3 subunit with Ki of 41 nM and 15 nM, 
respectively. 
Oxaliplatin (Eloxatin) Cancer DNA/RNA Synthesis 
Oxaliplatin (Eloxatin) is a 1,2-diaminocyclohexane (DACH) carrier ligand-based groups of platinum antitumor agent with IC50 
of median 1.3, 6.2 and 1.5 mM for SW480 DLD1, HT29, respectively. 
Oxaprozin Inflammation COX 
Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID) used to relieve the inflammation, swelling, 
stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. 
Oxcarbazepine 
Neurological 
Disease Sodium Channel Oxcarbazepine is an anticonvulsant and mood stabilizing drug. 
Oxeladin Citrate 
Respiratory 
Disease Others   
Oxethazaine 
Neurological 
Disease Others   
Oxfendazole Vermifuge Others Oxfendazole is the sulfoxide form of fenbendazole which is  a broad spectrum benzimidazole anthelmintic.  
Oxybuprocaine HCl 
Neurological 
Disease Others Oxybuprocaine HCl is a local anesthetic, which is used especially in ophthalmology and otolaryngology.  
Oxybutynin (Ditropan) 
Neurological 
Disease AChR Oxybutynin (Ditropan) is an anticholinergic medication used to relieve urinary and bladder difficulties. 
Oxybutynin chloride 
Neurological 
Disease AChR Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties. 
Oxymetazoline 
hydrochloride Immunology Adrenergic Receptor Oxymetazoline hydrochloride is an α1 and α2 adrenergic receptor agonist. 
Oxytetracycline 
(Terramycin) Infection Others Oxytetracycline (Terramycin) was the second of the broad-spectrum tetracycline group of antibiotics to be discovered. 
Oxytetracycline dihydrate Infection Others Oxytetracycline Dihydrate is a prescription antibiotic, iinterfering with the ability of bacteria to produce essential proteins.  
Ozagrel 
Cardiovascular 
Disease P450 (e.g. CYP17) Ozagrel is a potent and selective thromboxane A2 synthetase inhibitor with an IC50 of 4 nM. 
Ozagrel HCl 
Cardiovascular 
Disease P450 (e.g. CYP17) Ozagrel HCl is a selective thromboxane A2 synthetase enzyme inhibitors with IC50 of 11 nM, used as antiasthmatic agent.  
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Paclitaxel (Taxol) Cancer Autophagy,Microtubule Associated 
Paclitaxel also known as Taxol, Onxol, Nov-Onxol is a microtubule polymer stabilizer with an IC50 of 0.1 pM for human 
endothelial cells. 
Paeoniflorin   Others Paeoniflorin is a herbal constituent extracted from the root of Paeonia albiflora Pall. 
Pancuronium (Pavulon) 
Cardiovascular 
Disease AChR Pancuronium (Pavulon) is a competitive acetylcholine antagonist with an IC50 of 5.5 ± 0.5 nM. 
Paroxetine HCl Infection 5-HT Receptor,AChR Paroxetine is an antidepressant drug of the SSRI type. 
Pasiniazid Infection Others   
Pazopanib 
Cardiovascular 
Disease PDGFR,VEGFR,c-Kit 
Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, 
PDGFR-α/β, and c-Kit. 
Pazopanib HCl Cancer PDGFR,VEGFR,c-Kit 
Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms 
with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively. 
PCI-32765 (Ibrutinib) 
Neurological 
Disease BTK 
Ibrutinib is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK, 
less potent to EGFR, Yes, ErbB2, JAK3, etc. 
Pefloxacin mesylate Infection Others Pefloxacin mesylate is a synthetic chemotherapeutic agent and an antibacterial agent with IC50 of 6.7 nM. 
Penciclovir Infection Others Penciclovir is a purine acyclic nucleoside analogue with potent antiviral activity. 
Penfluridol 
Neurological 
Disease Dopamine Receptor Penfluridol is a highly potent, first generation diphenylbutylpiperidine antipsychotic. 
Penicillin G Sodium Infection Others Penicillin G Sodium is a β-lactam antibiotic produced by Penicillin spp 
Pentamidine Infection Others Pentamidine is an inhibitor of PRL Phosphatases and also inhibits synthesis of DNA, RNA and protein. 
Pentoxifylline   Others   
Pergolide mesylate 
Neurological 
Disease Dopamine Receptor Pergolide mesylate is an antiparkinsonian agent which functions as a dopaminergic agonist. 
Phenacetin Infection COX Phenacetin is a non-opioid analgesic without anti-inflammatory properties. 
Phenazopyridine HCl 
Cardiovascular 
Disease Others Phenazopyridine HCl a local analgesic that has been used in urinary tract disorders. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Phenformin hydrochloride 
Metabolic 
Disease AMPK Phenformin hydrochloride is a hydrochloride salt of phenformin that is an anti-diabetic drug from the biguanide class. 
Phenindione (Rectadione) 
Cardiovascular 
Disease Others Phenindione is an anticoagulant which functions as a Vitamin K antagonist. 
Pheniramine Maleate 
Neurological 
Disease Others 
Pheniramine Maleate is an antihistamine with anticholinergic properties used to treat allergic conditions such as hay fever or 
urticaria. 
Phenothrin   Others   
Phenoxybenzamine HCl Endocrinology Adrenergic Receptor Phenoxybenzamine HCl is a non-specific, irreversible alpha antagonist with an IC50 of 550 nM. 
Phentolamine mesilate 
Cardiovascular 
Disease Adrenergic Receptor Phentolamine mesilate is a nonselective alpha-adrenergic antagonist with IC50 of 0.1 µM. 
Phenylbutazone 
(Butazolidin, Butatron) Cancer Others 
Phenylbutazone (Butazolidin, Butatron) is used as a non-steroidal anti-inflammatory drug for the treatment of chronic pain, 
including the symptoms of arthritis. 
Phenylephrine HCl Endocrinology Adrenergic Receptor Phenylephrine hydrochloride is a selective α1-adrenergic receptor agonist. 
Phenytoin (Lepitoin) Endocrinology Sodium Channel 
Phenytoin (Lepitoin; NSC 8722; Phenytek; Phenytoine; Sodanton; Zentropi) is an inactive voltage-gated sodium channel 
stabilizer. 
Phenytoin sodium 
(Dilantin) 
Metabolic 
Disease Sodium Channel Phenytoin sodium is an inactive voltage-gated sodium channel stabilizer. 
Phthalylsulfacetamide   Others   
Pidotimod Immunology Others Pidotimod is an immunostimulant.  
Pilocarpine HCl 
Neurological 
Disease AChR 
Pilocarpine HCl is a nonselective muscarinic acetylcholine receptor agonist used to produce an experimental model of 
epilepsy. 
Pimecrolimus Cancer Others Inhibitor of inflammatory cytokine secretion 
Pimobendan (Vetmedin) 
Cardiovascular 
Disease PDE 
Pimobendan (Vetmedin) is a Ca(2+) sensitizer with an IC50 of 26 µM and a selective phosphodiesterase III inhibitor with an 
IC50 of <1 µM. 
Pimozide 
Neurological 
Disease Others   
Pioglitazone (Actos) Cancer PPAR Pioglitazone (Actos) is a selective peroxisome proliferator-activated receptor gamma stimulator. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Pioglitazone hydrochloride 
(Actos) 
Metabolic 
Disease P450 (e.g. CYP17) 
Pioglitazone HCl is a hydrochloride salt form of pioglitazone which is a cytochrome P450 (CYP)2C8 and CYP3A4 enzymes 
inhibitor for CYP2C8, CYP3A4 and CYP2C9 with Ki of 1.7 µM, 11.8 µM and 32.1 µM, respectively.  
Piperacillin Sodium Infection Others 
Piperacillin is a semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas 
infections. 
Piromidic Acid Infection Others   
Piroxicam (Feldene) Inflammation COX Piroxicam (Feldene, Roxam) is a non-selective COX inhibitor with an IC50 of 6 mM. 
Pitavastatin calcium 
(Livalo) 
Cardiovascular 
Disease Others Pitavastatin calcium (Livalo) is a novel member of the medication class of statins. 
Pizotifen malate Inflammation 5-HT Receptor  Pizotifen is a benzocycloheptane based agent used for recurrent migraine headaches. 
PMSF 
(Phenylmethylsulfonyl 
Fluoride) Inflammation Cysteine Protease,Serine Protease PMSF (Phenylmethyl sulfonyl fluoride) is an irreversible serine/cysteine protease inhibitor. 
Pomalidomide Cancer TNF-alpha Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM. 
Ponatinib (AP24534) Cancer Bcr-Abl,PDGFR,VEGFR,FGFR 
AP24534 is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 
nM, 2.2 nM and 5.4 nM, respectively. 
Posaconazole Infection Others Posaconazole is a triazole antifungal drug. 
Potassium iodide Endocrinology Others 
Potassium iodide is used to treat overactive thyroid and to protect the thyroid gland from the effects of radiation from inhaled 
or swallowed radioactive iodine. 
Pralatrexate (Folotyn) 
Metabolic 
Disease DHFR Pralatrexate(Folotyn) is an antifolate, and structurally a folate analog. Its IC50 is < 300 nM in some cell lines. 
Pramipexole (Mirapex) 
Neurological 
Disease Dopamine Receptor 
Pramipexole (Mirapex) is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, 
D3, D4 receptor, respectively. 
Pramipexole 
dihydrochloride 
monohydrate 
Neurological 
Disease Dopamine Receptor Pramipexole is a partial/full D2S, D2L, D3, D4, receptor agonist with a Ki of 3.9, 2.2, 0.5, 5.1 nM. 
Pramiracetam Endocrinology Others Pramiracetam is a more potent nootropic drug derived from piracetam. 
Pramoxine HCl 
Neurological 
Disease Others Pramoxine is a topical local anesthetic that has been shown to have antipruritic properties. 
Pranlukast Immunology Others Pranlukast is a selective cysteinyl leukotriene receptor antagonist. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Pranoprofen Inflammation COX Pranoprofen is a PGE2 inhibitor with IC50 of 7.5 µM. 
Prasugrel (Effient) 
Cardiovascular 
Disease P2 Receptor A novel platelet inhibitor 
Pravastatin sodium 
Metabolic 
Disease HMG-CoA Reductase Pravastatin sodium is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 µM. 
Praziquantel (Biltricide) Vermifuge Others Praziquantel(Biltricide, Droncit) is an anthelmintic effective against flatworms. 
Prednisolone 
(Hydroretrocortine) Infection Glucocorticoid Receptor Prednisolone (Hydroretrocortine) is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. 
Prednisolone acetate 
(Omnipred) Immunology Glucocorticoid Receptor Prednisolone Acetate is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant agent. 
Prednisone (Adasone) Immunology Glucocorticoid Receptor Prednisone (Adasone) is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. 
Pregnenolone 
Neurological 
Disease Estrogen/progestogen Receptor 
Pregnenolone is an endogenous steroid hormone for inhibition of M1 receptor- and M3 receptor-mediated currents with IC50 
of 11.4 µM and 6.0 µM, respectively.  
Pridinol Methanesulfonate   Others   
Prilocaine 
Neurological 
Disease Others Prilocaine is a local anesthetic of the amino amide type. 
Primaquine Diphosphate   Others 
Primaquine Diphosphate is a transmission-blocking anti-malarial clinically available, displaying a marked activity against 
gametocytes of all species of human malaria. 
Primidone (Mysoline) 
Neurological 
Disease Sodium Channel Primidone (Mysoline) is an anticonvulsant of the pyrimidinedione class. 
Proadifen HCl   Others   
Probenecid (Benemid) 
Metabolic 
Disease TRPV 
Probenecid (Benemid) is a classical competitive inhibitor of organic anion transport, which is also a TRPV2 agonist and an 
inhibitor of TAS2R16. 
Probucol 
Cardiovascular 
Disease Others 
Probucol is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL 
catabolism. 
Procaine (Novocaine) HCl 
Neurological 
Disease Sodium Channel 
Procaine (Novocaine) HCl is an inhibitor of sodium channel, NMDA receptor and nAChR with IC50 of 60 µM, 0.296 mM and 
45.5 µM, which is also an inhibitor of 5-HT3 with KD of 1.7 µM. 
Prochlorperazine 
Dimaleate 
Neurological 
Disease Others   
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Procodazole   Others   
Procyclidine HCl  
Neurological 
Disease Others   
Progesterone (Prometrium) Endocrinology Estrogen/progestogen Receptor Progesterone (Prometrium) is a C-21 steroid hormone. 
Propafenone (Rytmonorm) 
Cardiovascular 
Disease Sodium Channel 
Propafenone(Rytmonorm) is a classic anti-arrhythmic medication, which treats illnesses associated with rapid heartbeats 
such as atrial and ventricular arrhythmias. 
Proparacaine HCl 
Neurological 
Disease Sodium Channel Proparacaine HCl is a voltage-gated sodium channels antagonist with ED50 of 3.4 mM. 
Propranolol HCl 
Cardiovascular 
Disease Adrenergic Receptor Propranolol HCl is a competitive non-selective beta-adrenergic receptors inhibitor with IC50 of 12 nM. 
Propylthiouracil Endocrinology Others Propylthiouracil is a thyroperoxidase and 5'-deiodinase inhibitor.  
Protionamide 
(Prothionamide) Infection Others Protionamide (Prothionamide) is a drug used in the treatment of tuberculosis. 
Pyrazinamide (Pyrazinoic 
acid amide) Infection Others Pyrazinamide (Pyrazinoic acid amide) is a drug used to treat tuberculosis. 
Pyridostigmine Bromide 
(Mestinon) 
Cardiovascular 
Disease AChR Pyridostigmine Bromide (Mestinon) is a parasympathomimetic and a reversible cholinesterase inhibitor. 
Pyridoxine hydrochloride Endocrinology Others Pyridoxine HCl is a form of vitamin B6.  
Pyrilamine Maleate 
Neurological 
Disease Others   
Pyrimethamine Immunology DHFR Pyrimethamine is a dihydrofolate reductase(DHFR) inhibitor with an IC50 of 15.4 nM. 
Pyrithione zinc Infection Proton Pump Zinc pyrithione is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump. 
Quetiapine fumarate 
(Seroquel) 
Neurological 
Disease Dopamine Receptor 
Quetiapine fumarate(Seroquel) is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II 
depression, bipolar I depression. 
Quinapril HCl (Accupril) Inflammation RAAS 
Quinapril hydrochloride (Accupril) is the hydrochloride salt of quinapril that is an angiotensin-converting enzyme inhibitor with 
a Ki of 20 µM. 
Quinine hydrochloride 
dihydrate 
Cardiovascular 
Disease Potassium Channel 
Quinine hydrochloride dihydrate is a natural white crystalline alkaloid having antipyretic (fever-reducing), antimalarial, 
analgesic (painkilling), anti-inflammatory properties and a bitter taste. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Racecadotril (Acetorphan) Infection Opioid Receptor Racecadotril is a peripherally acting enkephalinase inhibitor with an IC50 of 4.5 µM. 
Ractopamine HCl 
Neurological 
Disease Others   
Raltegravir (MK-0518) Immunology Integrase Raltegravir (MK-0518) is anHIV integrase inhibitor, IC95 for HIV-1 in 50% normal human serum = 33 nM. 
Ramelteon (TAK-375) 
Neurological 
Disease MT Receptor 
Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 (IC50 =28.5 ± 8.55 pM)and MT2 (20.1 ± 
9.25 pM)receptors and selectivity over the MT3 receptor. 
Ramipril (Altace) 
Cardiovascular 
Disease RAAS Ramipril (Altace) is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 5 nM. 
Ranitidine (Zantac) 
Metabolic 
Disease Histamine Receptor Ranitidine hydrochloride (Zantac) is a histamine H2-receptor antagonist with IC50 of 3.3 ± 1.4 µM. 
Ranolazine (Ranexa) 
Cardiovascular 
Disease Calcium Channel Ranolazine (Ranexa) is an antianginal medication. 
Ranolazine 
dihydrochloride 
Cardiovascular 
Disease Calcium Channel Ranolazine 2HCl, is an antianginal medication. 
Rapamycin (Sirolimus) Immunology mTOR,Autophagy 
Rapamycin also known as Sirolimus & Rapamune is a mTOR inhibitor. Rapamycin Sirolimus inhibits cell motility by 
suppression of mTOR-mediated pathways. 
Rasagiline mesylate 
Cardiovascular 
Disease MAO Rasagiline mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. 
Rebamipide Infection Others Rebamipide is a cholecystokinin type 1 (CCK1) receptor inhibitor for inhibiting [125I]BH-CCK-8S with IC50 of 37.7 µM. 
Reboxetine mesylate 
Neurological 
Disease Others Reboxetine is a norepinephrine reuptake inhibitor with Ki of 8.2 nM. 
Regorafenib (BAY 73-4506) Cancer c-RET,VEGFR 
Regorafenib (BAY 73-4506, Fluoro-Sorafenib) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET 
and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. 
Repaglinide Endocrinology Potassium Channel Repaglinide is for the treatment of type II diabetes. 
Reserpine 
Cardiovascular 
Disease Others 
Reserpine is an indole alkaloid antipsychotic and antihypertensive drug that has been used for the control of high blood 
pressure and for the relief of psychotic symptoms. 
Resveratrol Infection Sirtuin,Autophagy 
Resveratrol is a phytoalexin produced naturally by several plants with anti-cancer, anti-inflammatory, blood-sugar-lowering 
and other beneficial cardiovascular effects . 
Retapamulin 
Neurological 
Disease Others Retapamulin is a topical antibiotic, which binds to both E. coli and S. aureus ribosomes with similar potencies with Kd of 3 nM. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Ribavirin (Copegus) 
Metabolic 
Disease Others Ribavirin is an anti-viral agent indicated for severe RSV infection (individually), hepatitis C infection and other viral infections. 
Rifabutin (Mycobutin) Infection Others Rifabutin (Mycobutin) is a semisynthetic ansamycin antibiotic with potent antimycobacterial properties. 
Rifampin (Rifadin, 
Rimactane) Infection DNA/RNA Synthesis Rifampin (Rifadin, Rimactane) is a bactericidal antibiotic agent of the rifamycin group. 
Rifapentine (Priftin) Infection Others Rifapentine (Priftin) is an antibiotic drug used in the treatment of tuberculosis. 
Rifaximin (Xifaxan) Infection DNA/RNA Synthesis 
Rifaximin (Xifaxan), an orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial 
activity. 
Riluzole (Rilutek) 
Neurological 
Disease Sodium Channel,GluR Riluzole (Rilutek) is a drug used to treat amyotrophic lateral sclerosis. 
Rimantadine (Flumadine) Infection Others Rimantadine (Flumadine) is an anti-influenza virus drug for T. brucei with IC50 of 7 µM. 
Rimonabant (SR141716) Inflammation Cannabinoid Receptor 
Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 
membrane. 
Risperidone (Risperdal) 
Neurological 
Disease 5-HT Receptor Risperidone (Risperdal) is an atypical antipsychotic used to treat schizophrenia. 
Ritodrine hydrochloride 
(Yutopar) Infection Adrenergic Receptor 
Ritodrine hydrochloride (DU 21220; Miolene; NSC 291565; Pre-Par) is a hydrochloride salt of ritodrine which is a β-2 
adrenergic receptor agonist. 
Ritonavir Infection HIV Protease Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS. 
Rivaroxaban (Xarelto) 
Metabolic 
Disease Factor Xa Rivaroxaban is a direct inhibitor of Factor Xa with Ki and IC50 of 0.4 nM and 0.7 nM, respectively. 
Rivastigmine tartrate 
(Exelon) 
Cardiovascular 
Disease AChR 
Rivastigmine, a cholinesterase inhibitor with IC50 of 5.5 µM, ues as a parasympathomimetic or cholinergic agent for the 
treatment of mild to moderate Alzheimer disease. 
Rizatriptan Benzoate    5-HT Receptor 
Rizatriptan Benzoate is an agonist at serotonin <b>5-HT1B</b> and <b>5-HT1D</b> receptors, used to treat acute migraine 
attacks. 
Rocuronium bromide 
Neurological 
Disease AChR Rocuronium is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant. 
Rofecoxib (Vioxx) 
Digestive 
system disease COX Rofecoxib (Vioxx) is a COX-2 inhibitor with IC50 of 18 nM. 
Roflumilast (Daxas) 
Neurological 
Disease PDE Roflumilast(Daxas) is a selective, long-acting the enzyme PDE-4 inhibitor with an IC50 of 0.8 nM. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Rolipram Inflammation PDE Rolipram is a PDE4-inhibitor and an anti-inflammatory agent. 
Ronidazole 
Neurological 
Disease Others Ronidazole is an antiprotozoal agent. 
Ropinirole HCl 
Neurological 
Disease Dopamine Receptor Ropinirole a selective dopamine D2 receptors inhibitor with IC50 of 29 nM. 
Ropivacaine HCl Infection Others 
Ropivacaine HCl is an anaesthetic agent and blocks impulse conduction in nerve fibres through inhibiting sodium ion influx 
reversibly. 
Rosiglitazone (Avandia) Cancer PPAR 
Rosiglitazone (Avandia) is a potent antihyperglycemic agent and a potent thiazolidinedione insulin sensitizer with IC50 of 12, 
4 and 9 nM for rat, 3T3-L1 and human adipocytes, respectively. 
Rosiglitazone HCl 
Cardiovascular 
Disease PPAR 
Rosiglitazone HCl is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the PPAR receptors in fat 
cells.  
Rosiglitazone maleate Infection PPAR 
Rosiglitazone, a member of the thiazolidinedione class of antihyperglycaemic agents, is a high-affinity selective agonist of the 
peroxisome proliferator-activated receptor-γ. 
Rosuvastatin calcium 
(Crestor) Infection HMG-CoA Reductase 
Rosuvastatin (Crestor) is a member of statins and used to treat high cholesterol and related conditions, and to prevent 
cardiovascular disease. 
Rotigotine   Dopamine Receptor Rotigotine is a dopamine receptor agonist, used in the treatment of Parkinson's disease and restless legs syndrome. 
Roxatidine acetate HCl 
Digestive 
system disease Histamine Receptor 
Roxatidine Acetate HCl is a specific and competitive histamin H2-receptor antagonist, with IC50 of 3.2 µM, inhibits gastric 
acid secretion and ulcer formation. 
Roxithromycin (Roxl-150) 
Metabolic 
Disease Others 
Roxithromycin(Roxl-150) is a semi-synthetic macrolide antibiotic. It is used to treat respiratory tract, urinary and soft tissue 
infections. 
Rufinamide (Banzel) 
Neurological 
Disease Sodium Channel Rufinamide, a triazole derivative, is an anticonvulsant medication. 
Ruxolitinib (INCB018424) Cancer JAK INCB018424 is a JAK family inhibitor for JAK1, JAK2 and JAK3 with IC50 of 2.7 nM, 4.5 nM and 322 nM, respectively. 
S-(+)-Rolipram 
Cardiovascular 
Disease PDE S-(+)-Rolipram is a less active enantiomer of the PDE4 inhibitor with an EC50 of 1.0 µM. 
Salicylanilide Infection Reverse Transcriptase 
Salicylanilides are a group of compounds with a wide range of biological activities including antiviral potency, antibacterial 
(including antimycobacterial) and antifungal activities. 
Sasapyrine Inflammation Others Sasapyrine (salsalate) is a nonsteroidal oral anti-inflammatory agent. 
Saxagliptin (BMS-
477118,Onglyza) Infection DPP-4 Saxagliptin (BMS-477118, Onglyza) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Scopine 
Metabolic 
Disease Adrenergic Receptor 
Scopine is the metabolite of anisodine, which is a α1-adrenergic receptor agonist and used in the treatment of acute 
circulatory shock. 
Scopolamine 
hydrobromide 
Respiratory 
Disease AChR Scopolamine is a competitive muscarinic acetylcholine receptor with an IC50 of 55.3 ± 4.3 nM. 
Secnidazole (Flagentyl) Infection Others Secnidazole (Flagentyl) is a nitroimidazole anti-infective. 
Serotonin HCl 
Neurological 
Disease 5-HT Receptor Serotonin HCl is a monoamine neurotransmitter and Endogenous 5-HT receptor agonist. 
Sertaconazole nitrate Infection Others 
Sertaconazole nitrate is a topical broad-spectrum antifungal that is developed to provide an additional agent for the treatment 
of superficial cutaneous and mucosal infections. 
Sertraline HCl Inflammation 5-HT Receptor Sertraline HCl is a 5-HT antagonist with Ki of 13 nM. 
Sildenafil citrate 
Cardiovascular 
Disease PDE Sildenafil citrate is a drug used to treat erectile dysfunction and pulmonary arterial hypertension (PAH). 
Silodosin (Rapaflo) 
Cardiovascular 
Disease Adrenergic Receptor Silodosin(Rapaflo) is an α1-adrenoceptor antagonist with high uroselectivity. 
Simvastatin (Zocor) 
Cardiovascular 
Disease HMG-CoA Reductase Simvastatin(Zocor) is a hypolipidemic drug belonging to the class of pharmaceuticals called "statins". 
Sitafloxacin Hydrate   Others Sitafloxacin Hydrate is a new-generation, broad-spectrum oral fluoroquinolone antibiotic. 
Sodium 4-aminohippurate 
Hydrate   Others   
Sodium ascorbate Endocrinology Others Sodium Ascorbate is a more bioavailable form of vitamin C that is an alternative to taking ascorbic acid as a supplement. 
Sodium nitrite 
Neurological 
Disease Others Sodium nitrite is a myeloperoxidase inhibitor with IC50 of 1.3 µM. 
Sodium Nitroprusside 
Cardiovascular 
Disease Others Sodium Nitroprusside is a potent vasodilator working through releasing NO spontaneously in blood. 
Sodium Picosulfate 
Metabolic 
Disease Others Sodium Picosulfate inhibits absorption of water and electrolytes, and increases their secretion. 
Sodium salicylate Infection NF-κB Sodium salicylate is used in medicine as an analgesic and antipyretic. 
Solifenacin succinate 
Cardiovascular 
Disease AChR Solifenacin succinate is a urinary antispasmodic of the antimuscarinic class. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Sorafenib (Nexavar) Cancer VEGFR,Raf,PDGFR 
Sorafenib Tosylate is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and 
RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. 
Sorbitol (Glucitol) 
Digestive 
system disease Others Sorbitol(Glucitol) is a sugar alcohol and a sugar substitute. 
Sotalol (Betapace) 
Neurological 
Disease Adrenergic Receptor Sotalol (Betapace) is a non-selective beta blocker and a potassium channel blocker with an IC50 of 43 µM. 
Sparfloxacin Infection Others Sparfloxacin is a fluoroquinolone antibiotic, shows broad and potent antibacterial activity. 
Spectinomycin  
hydrochloride 
Cardiovascular 
Disease Others Spectinomycin hydrochloride is a new parenteral antibiotic prepared from Streptomyces spectabilis. 
Spiramycin Infection Others Spiramycin is a 16-membered ring macrolide (antibiotic). 
Spironolactone Infection Androgen Receptor Spironolactone is a potent antagonist of the androgen receptor with IC50 of 77 nM. 
Stavudine Infection Reverse Transcriptase Stavudine is a nucleoside analog reverse transcriptase inhibitor (NARTI) active against HIV. 
Streptozotocin (Zanosar) Cancer Others 
Streptozotocin (Streptozocin, Zanosar, STZ) is a naturally occurring chemical used in cancer chemotherapy and Type 1 
diabetes treatment. 
Sucralose   Others Sucralose is an artificial and noncaloric sweetener, not broken down by the body. 
Sulbactam Infection Others Sulbactam is a beta-lactamase inhibitor with an average IC50 of 0.8 µM. 
Sulbactam sodium 
(Unasyn) Infection Others Sulbactam sodium (Unasyn) is an irreversible β-lactamase inhibitor. 
Sulconazole Nitrate Infection Others Sulconazole Nitrate is an imidazole derivative with broad-spectrum antifungal activity. 
sulfacetamide sodium 
Cardiovascular 
Disease Autophagy Sulfacetamide Sodium is an anti-biotic. 
Sulfadiazine Infection Others Sulfadiazine is a sulfonamide antibiotic. 
Sulfaguanidine Infection Others Sulfaguanidine is a sulfonamide used as an anti-infective agent. 
Sulfamerazine Infection Others Sulfamerazine is a sulfonamide antibacterial. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Sulfameter (Bayrena) Infection DHFR Sulfameter (Bayrena) is a long-acting sulfonamide antibacterial. 
Sulfamethazine Endocrinology Others Sulfamethazine is a sulfonamide antibacterial. 
Sulfamethizole (Proklar) Infection Others Sulfamethizole(Proklar) is a sulfathiazole antibacterial agent. 
Sulfamethoxazole Infection Others Sulfamethoxazole (Gantanol) is a sulfonamide bacteriostatic antibiotic with an IC50 of 2.7 µM. 
Sulfanilamide Infection Others Sulfanilamide is a sulfonamide antibacterial. 
Sulfasalazine (Azulfidine) Inflammation Others Sulfasalazine (Azulfidine) is a sulfa agent and a derivative of mesalazine used primarily as an anti-inflammatory agent. 
Sulfathiazole Infection Others Sulfathiazole is an organosulfur compound that has been used as a short-acting sulfa drug. 
Sulfisoxazole Infection Others Sulfisoxazole is a sulfonamide antibacterial with an oxazole substituent. 
Sulindac (Clinoril) Cancer COX Sulindac (Clinoril) is a non-steroidal anti-inflammatory drug of the arylalkanoic acid class. 
Sulphadimethoxine Infection Others Sulphadimethoxine is a non-reducing glucuronide. 
Sumatriptan succinate 
Neurological 
Disease 5-HT Receptor Sumatriptan succinate (Imitrex, Imigran) is a selective 5-hydroxytryptamine1 receptor subtype agonist. 
Sunitinib Malate (Sutent) Cancer VEGFR,PDGFR,c-Kit 
Sunitinib Malate (Sutent) is a multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase inhibitor with Ki of 0.009 and 0.008 µM 
for Flk-1 and PDGFR. 
Suplatast tosylate 
Cardiovascular 
Disease Others Suplatast tosylate is a Th2 cytokine inhibitor which is used as an anti-allergic agent. 
Suprofen (Profenal) Inflammation Others,COX Suprofen(Profenal) is an NSAID. 
Tacrine HCl 
Neurological 
Disease Others   
Tadalafil (Cialis) 
Cardiovascular 
Disease PDE Tadalafil (Cialis) is a PDE inhibitor. 
TAME Cancer APC,E3 Ligase  
Tosyl-L-Arginine Methyl Ester (TAME) inhibits an E3 ubiquitin ligase called "anaphase-promoting complex/cyclosome 
(APC/C)". 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Tamoxifen Citrate 
(Nolvadex) Endocrinology 
Autophagy,Estrogen/progestogen 
Receptor Tamoxifen (Nolvadex) is an estrogen receptor antagonist with an IC50 of 31 µM for the MCF-7 cells. 
Tazarotene (Avage) Inflammation Others Tazarotene is a prescription topical retinoid sold as a cream or gel. 
Tebipenem pivoxil (L-084) 
Cardiovascular 
Disease Others Tebipenem pivoxil(L-084) is a novel oral carbapenem antibiotic with an IC50 of 100 µg/ml for human CYP isoforms 
Telaprevir (VX-950) Infection HCV Protease Telaprevir (VX-950) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 µM. 
Telbivudine (Sebivo, 
Tyzeka) Infection Reverse Transcriptase Telbivudine (Tyzeka, Sebivo) is an antiviral drug used in the treatment of hepatitis B infection. 
Telmisartan (Micardis) 
Cardiovascular 
Disease RAAS Telmisartan (Micardis) is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. 
Temocapril HCl Cancer RAAS 
Temocapril HCl is the hydrochloride of Temocapril, which is a long-acting angiotensin-converting enzyme (ACE) inhibitor, 
used for the treatment of hypertension. 
Temsirolimus (Torisel) Cancer mTOR mTOR inhibitor. 
Teniposide (Vumon) Cancer Topoisomerase 
Teniposide (Vumon)is a chemotherapeutic medication mainly used in the treatment of childhood acute lymphocytic leukemia 
(ALL). 
Tenofovir    Reverse Transcriptase Tenofovir blocks <b>reverse transcriptase</b> and hepatitis B virus infections. 
Tenofovir Disoproxil 
Fumarate   Reverse Transcriptase 
Tenofovir Disoproxil Fumarate belongs to a class of antiretroviral drugs, it inhibits the activity of <b>HIV reverse 
transcriptase</b> by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, 
by DNA chain termination. 
Tenoxicam (Mobiflex) Infection Others Tenoxicam(Mobiflex) is a good HO. radicals scavenger with an IC50 of 56.7 µM 
Terazosin HCl (Hytrin) Infection Adrenergic Receptor Hytrin (terazosin) is an alpha-adrenergic blocker used to treat high blood pressure and enlarged prostate. 
Terbinafine (Lamisil, 
Terbinex) Infection Others 
Terbinafine (Lamisil, Terbinex) is used to treat infections caused by a fungus. It works by killing the fungus or preventing its 
growth. 
Terbinafine hydrochloride 
(Lamisil) Infection Others 
Terbinafine hydrochloride (Lamisil) is a hydrochloride salt of terbinafine that is a synthetic allylamine antifungal and a 
squalene epoxidase inhibitor with an IC50 of 30 nM for Candida albicans. 
Terfenadine 
Neurological 
Disease Others   
Teriflunomide Immunology Dehydrogenase 
Teriflunomide is the active metabolite of leflunomide, inhibiting pyrimidine de novo synthesis by blocking the enzyme 
dihydroorotate dehydrogenase, used as an immunomodulatory agent. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Tetracaine hydrochloride 
(Pontocaine) Endocrinology Calcium Channel 
Tetracaine hydrochloride (Pontocaine) is a hydrochloride salt form of tetracaine which is a potent local anaesthetic and a 
channel function allosteric inhibitor. 
Tetracycline HCl Infection Others Tetracycline hydrochloride is a hydrochloride salt of tetracycline that is a broad-spectrum polyketide antibiotic. 
tetrahydrozoline 
hydrochloride Inflammation Adrenergic Receptor Tetrahydrozoline HCl is an imidazoline derivative with alpha receptor agonist activity. 
Thalidomide Immunology E3 Ligase ,TNF-alpha 
Thalidomide was introduced as a sedative drug,immunomodulatory agent and also is investigated for treating symptoms of 
many cancers. 
Thiabendazole Vermifuge Others Thiabendazole inhibites the mitochondrial helminth-specific enzyme, fumarate reductase, with anthelminthic property.  
Thiamphenicol 
(Thiophenicol) 
Cardiovascular 
Disease Others Thiamphenicol (Thiophenicol) is an antimicrobial antibiotic and a methyl-sulfonyl analogue of chloramphenicol. 
Thioridazine HCl 
Neurological 
Disease Others   
Tianeptine sodium 
Neurological 
Disease 5-HT Receptor Tianeptine is a selective serotonin reuptake enhancer (SSRE) compound used for treating major depressive episodes. 
Ticagrelor 
Cardiovascular 
Disease P2 Receptor 
Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist, also inhibits CYP2C9 and 4-hydroxylation with IC50 of 
10.5 µM and 8.2 µM respectively. 
Tigecycline Infection Others Tigecycline is a glycylcycline antibiotic. 
Tilmicosin Infection Others Tilmicosin is a macrolide antibiotic. 
tinidazole Infection Others Tinidazole is an anti-parasitic drug. 
Tioconazole Infection Others Tioconazole is an antifungal medication with an average IC50 of 1.7 µM. 
Tiopronin (Thiola) 
Cardiovascular 
Disease Others 
Tiopronin is a US Food and Drug Administration (FDA)-approved drug for the treatment of cystinuria by controlling the rate of 
cystine precipitation and excretion. 
Tiotropium Bromide 
hydrate Infection AChR 
Tiotropium Bromide hydrate is a monohydrate of tiotropium bromide (Spiriva; Tiova; BA 679BR; tiopropium) that is an 
anticholinergic and bronchodilator and a muscarinic receptor antagonist. 
Tioxolone Endocrinology Carbonic Anhydrase Tioxolone is a metalloenzyme carbonic anhydrase I inhibitor with a Ki of 91 nM. 
Tiratricol Endocrinology Others Tiratricol (also known as TRIAC or triiodothyroacetic acid) is a thyroid hormone analogue. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Tizanidine HCl 
Neurological 
Disease Adrenergic Receptor Tizanidine is a drug that is used as a muscle relaxant. 
Tofacitinib citrate (CP-
690550 citrate) Cancer JAK 
Tofacitinib citrate (CP-690550 citrate) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 
and JAK1. Phase 3. 
Tolbutamide Cancer Potassium Channel Tolbutamide is an inhibitor of cAMP with IC50 of 4 mM. 
Tolcapone 
Metabolic 
Disease Transferase Tolcapone is a selective, potent and reversible of catechol-O-methyl transferase (COMT) inhibitor with Ki of 30 nM. 
Tolfenamic acid Inflammation COX Tolfenamic acid is a COX-2 inhibitor with IC50 of 0.2 µM. 
Tolmetin Sodium Inflammation Others   
Tolnaftate Cancer Others Tolnaftate is a synthetic thiocarbamate used as an anti-fungal agent. 
Tolperisone HCl 
Neurological 
Disease Sodium Channel Tolperisone HCl is an ion channel blocker and centrally-acting muscle relaxant.  
Tolterodine tartrate (Detrol 
LA) 
Neurological 
Disease AChR Tolterodine tartrate (Detrol LA) is a tartrate salt of tolterodine that is a competitive muscarinic receptor antagonist. 
toltrazuril Infection Others Toltrazuril is an antiprotozoal agent that acts upon Coccidia parasites. 
Tolvaptan (OPC-41061) 
Metabolic 
Disease Vasopressin Receptor 
Tolvaptan (OPC-41061) is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28¦ÌM for the 
inhibition of AVP-induced platelet aggregation. 
Topiramate 
Neurological 
Disease Carbonic Anhydrase Topiramate (Topamax) is an anticonvulsant drug. 
Topotecan HCl Cancer Topoisomerase 
Topotecan Hydrochloride (Hycamtin) is a topoisomerase I inhibitor with an IC50 of 13 and 2 nM for MCF-7 Luc cells and DU-
145 Luc cells. 
Toremifene Citrate 
(Fareston, Acapodene) Endocrinology Estrogen/progestogen Receptor 
Toremifene Citrate (Fareston, Acapodene) is an oral selective estrogen receptor modulator (SERM) which helps oppose the 
actions of estrogen in the body. 
Tranilast (SB 252218) 
Respiratory 
Disease Others Tranilast (Rizaben) is an antiallergic drug. 
Tretinoin (Aberela) Cancer Retinoid Receptor Tretinoin (Aberela) is a drug commonly used to treat acne vulgaris and keratosis pilaris. 
Triamcinolone (Aristocort) Inflammation Glucocorticoid Receptor 
Triamcinolone (Aristocort) is a glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local 
injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Triamcinolone Acetonide Inflammation Glucocorticoid Receptor Triamcinolone Acetonide is a more potent type of triamcinolone, being about 8 times as effective as prednisone. 
triamterene Inflammation Sodium Channel Triamterene blocks epithelial Na+ channel (ENaC) in a voltage-dependent manner with IC50 of 4.5 µM. 
Trichlormethiazide 
(Achletin) 
Cardiovascular 
Disease Others Trichlormethiazide(Achletin) is a diuretic with properties similar to those of hydrochlorothiazide. 
Triclabendazole Vermifuge Microtubule Associated 
Triclabendazole is a benzimidazole, it binds to tubulin impairing intracellular transport mechanisms and interferes with protein 
synthesis. 
Trifluoperazine 2HCl 
Neurological 
Disease Autophagy Trifluoperazine is a dopamine D2 receptor inhibitor with IC50 of 1.1 nM. 
Triflupromazine HCl 
Neurological 
Disease Others   
Trifluridine (Viroptic) Infection DNA/RNA Synthesis Trifluridine (Viroptic) is an anti-herpesvirus antiviral drug, used primarily on the eye. 
Triflusal Infection COX Triflusal irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1. 
Trilostane Endocrinology Dehydrogenase Trilostane is an inhibitor of 3 β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. 
Trimebutine 
Neurological 
Disease Opioid Receptor 
Trimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both 
acute and chronic abdominal pain. 
Trimethoprim Infection Others Trimethoprim is a bacteriostatic antibiotic mainly used in the prophylaxis and treatment of urinary tract infections. 
Trimipramine Maleate 
Neurological 
Disease Others   
Tripelennamine HCl 
Neurological 
Disease Histamine Receptor Tripelennamine is a widely used H1 antagonist, inhibiting PhIP glucuronidation with IC50 of 30 µM. 
Trometamol   Others Trometamol is a proton acceptor used to treat academia. 
Tropicamide 
Neurological 
Disease AChR Tropicamide is an anticholinergic and a muscarinic receptor subtype M4-preferring antagonist with IC50 of 8.0 nM. 
Tropisetron 
Neurological 
Disease 5-HT Receptor 
Tropisetron hydrochloride is a selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist with an IC50 of 70.1 ± 0.9 
nM for 5-HT3 receptor. 
Trospium chloride 
(Sanctura) 
Cardiovascular 
Disease AChR Trospium chloride (Sanctura) is a competitive muscarinic cholinergic receptor antagonist. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Troxipide 
Digestive 
system disease Others 
Troxipide is a novel systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus 
secreting properties irrespective of pH of stomach or duodenum. 
Tylosin tartrate 
Neurological 
Disease Others Tylosin tartrate is a macrolide antibiotic approved for the control of mycoplasmosis in poultry. 
Ulipristal Infection Estrogen/progestogen Receptor Ulipristal is a selective SPRM for emergency contraception after an unprotected intercourse or contraceptive failure. 
Uracil   Others Uracil is one of the four nucleobases in the nucleic acid of RNA can be used for drug delivery and as a pharmaceutical. 
Urapidil HCl 
Respiratory 
Disease 5-HT Receptor 
Urapidil hydrochloride is a hydrochloride salt form of urapidil which is α1-adrenoceptor antagonist and 5-HT1A receptor 
agonist with pIC50 of 6.13 and 6.4 respectively. 
Uridine Vermifuge DNA/RNA Synthesis Uridine is a nucleoside, contains a uracil attached to a ribose ring via a β-N1-glycosidic bond. 
Ursodiol (Actigal Urso) 
Metabolic 
Disease Others Ursodiol reduces cholesterol absorption and is used to dissolve (cholesterol) gallstones. (IC50=0.22 µM) 
Valaciclovir HCl Infection Others Valaciclovir hydrochloride is an antiviral drug used in the management of herpes simplex, herpes zoster, and herpes B. 
valganciclovir 
hydrochloride Endocrinology Others Valganciclovir HCl is a prodrug for ganciclovir with antiviral activity used to treat cytomegalovirus infections.  
Valnemulin HCl Infection Others 
Valnemulin HCl is a broad-spectrum bacteriostatic agent inhibiting protein synthesis in bacteria by binding to the peptidyl 
transferase component of the 50S subunit of ribosomes.  
Valproic acid sodium salt 
(Sodium valproate) 
Cardiovascular 
Disease GABA Receptor,HDAC,Autophagy 
Valproic acid sodium salt (Sodium valproate) is a HDAC inhibitor with IC50 of 0.4 mM and also inhibits GABA-transaminase 
or succinic 
 
semialdehyde dehydrogenase. 
Valsartan (Diovan) 
Cardiovascular 
Disease RAAS Valsartan (Diovan) is an angiotensin II receptor antagonist with IC50 of ranging from 39.5 to 116 µM. 
Vandetanib (Zactima) Cancer VEGFR 
Vandetanib is a VEGFR and EGFR antagonist and a tyrosine kinase inhibitor with IC50 of 60, 90, 40 nM for HUVEC 
proliferation, PC-9 cells and tyrosine kinase activity, respectively. 
Vardenafil (Vivanza) Infection PDE Vardenafil(Vivanza) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively. 
Vecuronium Bromide 
Neurological 
Disease Others Vecuronium (Norcuron) is a muscle relaxant in the category of non-depolarizing blocking agents. 
Vemurafenib (PLX4032) Cancer Raf PLX4032 (Vemurafenib, RG7204, Zelboraf, RO5185426) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Venlafaxine 
Neurological 
Disease 5-HT Receptor Venlafaxine (Effexor, Efexor) is an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI). 
Verteporfin (Visudyne) Endocrinology VDA Verteporfin(Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy. 
Vidarabine (Vira-A) Infection DNA/RNA Synthesis Vidarabine (Vira-A) is an antiviral drug which is active against herpes simplex and varicella zoster viruses. 
Vildagliptin (LAF-237) 
Metabolic 
Disease DPP-4 Vildagliptin (LAF-237) inhibits DPP−4 with IC50 of 2.3 nM. 
Vinblastine   Microtubule Associated 
Vinblastine inhibits microtubule formation and suppresses <b>nAChR</b> activity with <b>IC50</b> of 8.9 µM in a cell-free 
assay, used to treat certain kinds of cancer. 
Vincristine Cancer Autophagy,Microtubule Associated 
Vincristine Sulfate is a microtubule function inhibitor with IC50 of 10.4±1.1, 28.1±3.4, 22.4±2.1 µM for HL-60, Bel7402, HO-
8910, respectively. 
Vinorelbine Tartrate   Microtubule Associated Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin. 
Vismodegib (GDC-0449) Cancer Hedgehog/Smoothened 
GDC-0449 (Vismodegib, HhAntag691) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits 
P-gp with IC50 of 3.0 µM. 
Vitamin B12 
Metabolic 
Disease Others 
Vitamin b12 is a water soluble vitamin with a key role in the normal functioning of the brain and nervous system, and for the 
formation of blood. 
Vitamin C (Ascorbic acid) 
Respiratory 
Disease Others Ascorbic Acid (vitamin C) is a water-soluble vitamin indicated for the prevention and treatment of scurvy. 
Vitamin D2 Endocrinology Others Vitamin D2 is a selective inhibitors of mammalian DNA polymerase A (pol A) with IC50 of 123 mM. 
Vitamin D3 
(Cholecalciferol) 
Cardiovascular 
Disease Others 
Vitamin D3 (Cholecalciferol) is a form of vitamin D, binds and activates a H305F/H397Y mutant vitamin D receptor (VDR) with 
EC50 of 300 nM. 
Voglibose 
Metabolic 
Disease Others 
Voglibose is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action 
against hyperglycemia and various disorders caused by hyperglycemia. 
Voriconazole Infection P450 (e.g. CYP17) Voriconazole (VFEND) is a triazole antifungal medication that is generally used to treat serious, invasive fungal infections. 
Vorinostat (SAHA) Cancer HDAC,Autophagy 
Vorinostat also known as SAHA, Zolinza, MK-0683 is an HDAC inhibitor. Vorinostat CAS No 149647-78-9 with purity >99% & 
solubility DMSO is available. 
XL-184 (Cabozantinib) Cancer 
Tie-2,TAM 
Receptor,FLT3,VEGFR,c-Met,c-Kit 
XL184 (Cabozantinib) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and 
AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively. 
Xylazine HCl 
Cardiovascular 
Disease Adrenergic Receptor Xylazine HCl is α2 class of adrenergic receptor agonist. 
COMPOUND INDICATION TARGETS BRIEF DESCRIPTION 
Xylometazoline HCl Infection Adrenergic Receptor 
Xylometazoline is an α-adrenoceptor agonist commonly used as nasal decongestant, exhibits highest potency at α2B-
adrenoceptor subtype with EC50 of 99 µM. Phase 4. 
Xylose 
Metabolic 
Disease Others Xylose is a sugar first isolated from wood. 
Zafirlukast (Accolate) Inflammation Others Zafirlukast is a leukotriene receptor antagonist (LTRA). (IC50=0.6µM, IC50=7.0 µM for CYP2C9) 
Zalcitabine Infection Reverse Transcriptase Zalcitabine is a nucleoside analog HIV reverse transcriptase inhibitor (NARTI). 
Zaltoprofen Inflammation COX Zaltoprofen is an inhibitor of Cox-1 and Cox-2 for treatment of arthritis.  
Zanamivir   Others 
Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus and 
influenza B virus. 
Zidovudine (Retrovir) 
Cardiovascular 
Disease Reverse Transcriptase Zidovudine (Retrovir) is a reverse transcriptase inhibitor. 
Zileuton 
Respiratory 
Disease Others 
Zileuton (ZYFLO) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) 
formation. 
Ziprasidone hydrochloride 
Neurological 
Disease 5-HT Receptor,Dopamine Receptor Ziprasidone was the fifth atypical antipsychotic. 
Zolmitriptan (Zomig) 
Neurological 
Disease 5-HT Receptor Zolmitriptan (Zomig) is a selective serotonin receptor agonist. 
Zonisamide 
Neurological 
Disease Sodium Channel Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive. 
Zoxazolamine 
Neurological 
Disease Others Zoxazolamine is a centrally acting myorelaxant, which is formerly used as an antispasmodic and uricosuric.  
 
